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Objectives: To determine the best photographic surrogate markers for detecting sight-threatening
macular oedema (MO) in people with diabetes attending UK national screening programmes.
Design: A multicentre, prospective, observational cohort study of 3170 patients with photographic signs
of diabetic retinopathy visible within the macular region [exudates within two disc diameters,
microaneurysms/dot haemorrhages (M/DHs) and blot haemorrhages (BHs)] who were recruited from seven
study centres.
Setting: All patients were recruited and imaged at one of seven study centres in Aberdeen, Birmingham,
Dundee, Dunfermline, Edinburgh, Liverpool and Oxford.
Participants: Subjects with features of diabetic retinopathy visible within the macular region attending
one of seven diabetic retinal screening programmes.
Interventions: Alternative referral criteria for suspected MO based on photographic surrogate markers; an
optical coherence tomographic examination in addition to the standard digital retinal photograph.vii
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ABSTRACT
viiiMain outcome measures: (1) To determine the best method to detect sight-threatening MO in people
with diabetes using photographic surrogate markers. (2) Sensitivity and speciﬁcity estimates to assess the
costs and consequences of using alternative strategies. (3) Modelled long-term costs and quality-adjusted
life-years (QALYs).
Results: Prevalence of MO was strongly related to the presence of lesions and was roughly ﬁve times
higher in subjects with exudates or BHs or more than two M/DHs within one disc diameter. Having worse
visual acuity was associated with about a ﬁvefold higher prevalence of MO. Current manual screening
grading schemes that ignore visual acuity or the presence of M/DHs could be improved by taking these
into account. Health service costs increase substantially with more sensitive/less speciﬁc strategies. A fully
automated strategy, using the automated detection of patterns of photographic surrogate markers, is
superior to all current manual grading schemes for detecting MO in people with diabetes. The addition of
optical coherence tomography (OCT) to each strategy, prior to referral, results in a reduction in costs to the
health service with no decrement in the number of MO cases detected.
Conclusions: Compared with all current manual grading schemes, for the same sensitivity, a fully
automated strategy, using the automated detection of patterns of photographic surrogate markers,
achieves a higher speciﬁcity for detecting MO in people with diabetes, especially if visual acuity is included
in the automated strategy. Overall, costs to the health service are likely to increase if more sensitive referral
strategies are adopted over more speciﬁc screening strategies for MO, for only very small gains in QALYs.
The addition of OCT to each screening strategy, prior to referral, results in a reduction in costs to the
health service with no decrement in the number of MO cases detected.
Study registration: This study has been registered as REC/IRAS 07/S0801/107, UKCRN ID 9063 and
NIHR HTA 06/402/49.
Source of funding: This project was funded by the NIHR Health Technology Assessment programme and
will be published in full in Health Technology Assessment; Vol. 17, No. 51. See the HTA programme
website for further project information.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Contents© Queen
This issue
suitable a
Journals
SO16 7NList of abbreviations. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
Scientific summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xiii
Chapter 1 Introduction 1
Chapter 2 Study design and methods 3
Aims and objectives 3
Primary outcome measure 3
Other outcome measures 3
Study design 3
Recruitment and data collection 5
Image data analysis and grading 8Chapter 3 Comparison of optical coherence tomography scanner
thickness measurements 13
Subjects 13
Statistical analysis 13
Imaging protocols 14
Results 15
Conclusions 21
Chapter 4 Characteristics of study data 23
Introduction 23
Methods for demographics 23
Results 23
Conclusions 30
Chapter 5 Inferring the presence of macular oedema using retinal photographs 33
Introduction 33
Methods for statistical modelling 33
Results of statistical modelling 35
Strategies for detecting macular oedema 47
Classifiers 53
Results 54
Discussion and conclusions 58
Chapter 6 Health economic evaluation 61
Aims and objectives 61
Assessment of cost per case of macular oedema detected 61
Results 68
Assessing long-term cost-effectiveness 74
Results 82
Deterministic sensitivity analysis 82
Probabilistic sensitivity analysis 86
Discussion 86ix
's Printer and Controller of HMSO 2013. This work was produced by Olson et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
cknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
S, UK.
CONTENTS
x
NIHR JoChapter 7 Discussion 93
Reason for study 93
Aim of the study 93
Study design 94
Cost-effectiveness 96
Strengths 97
Limitations 98
Implications for health care 99
Recommendations for research 99
Acknowledgements 101
References 103
Appendix 1 Techniques for measuring retinal thickness 109Appendix 2 Cost estimates for optical coherence tomography and slit-lampurnals Library www.journalslibrary.nihr.ac.ukexamination within the screening programme 113
Appendix 3 Demographics and statistical modelling – additional data 117
Appendix 4 Protocol 125
LDOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51
© Q
This
suita
Jour
SO1ist of abbreviationsBH blot haemorrhage
CAH computer-assisted manual
annotation strategy
CI conﬁdence interval
CWS cotton wool spots
DD disc diameter radius
EQ-5D European Quality of Life-5
Dimensions
ETDRS Early Treatment Diabetic
Retinopathy Study
FA fully automated annotation
strategy
HRG Healthcare Resource Group
ICC intraclass correlation coefﬁcientueen's Printer and Controller of HMSO 2013. This work was produced by Olson et al. u
issue may be freely reproduced for the purposes of private research and study and extr
ble acknowledgement is made and the reproduction is not associated with any form of
nals Library, National Institute for Health Research, Evaluation, Trials and Studies Coord
6 7NS, UK.log-MAR logarithm of the minimum angle
of resolution
M/DH microaneurysm/dot haemorrhage
MO macular oedema
MVL moderate visual loss
QALY quality-adjusted life-year
OCT optical coherence tomography
OPCS Ofﬁce of Population Censuses
and Surveys
OR odds ratio
PbR payment by results
PSSRU Personal Social Services
Research Unit
SD standard deviationxi
nder the terms of a commissioning contract issued by the Secretary of State for Health.
acts (or indeed, the full report) may be included in professional journals provided that
advertising. Applications for commercial reproduction should be addressed to: NIHR
inating Centre, Alpha House, University of Southampton Science Park, Southampton

DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Scientiﬁc summaryBackground
Compared with more established screening programmes, such as cervical and breast screening, diabetic
retinopathy screening is still in its infancy: national screening programmes for diabetic retinopathy have
been running throughout the UK for less than a decade.
The risk of retinopathy increases with disease duration. Type 2 diabetes is often diagnosed several years
after onset (almost 40% of people with type 2 diabetes are found to have retinopathy at diagnosis). This is
potentially sight-threatening in between 4% and 8% of cases. Sixty per cent of people with type 2
diabetes will have retinopathy 20 years from onset.
There are two main mechanisms responsible for visual loss from diabetic retinopathy. The ﬁrst of these is
proliferative retinopathy and the development of new blood vessels. The second is macular oedema (MO),
the build-up of ﬂuid involving the area of the retina associated with best vision, the macula. Although
proliferative disease is most likely to lead to serious vision loss, MO is more common and is the leading
cause of moderate visual loss in people with diabetes. However, laser treatment is only moderately
effective, at best, for MO.
At the time of the introduction of national programmes for screening for diabetic retinopathy in the UK,
screening for diabetic MO was not deemed to meet strict World Health Organization guidelines for
screening. Diabetic retinopathy at the macula (maculopathy) is more common than proliferative diabetic
retinopathy so retinal screening programmes have had to develop pathways to address this, although it is
acknowledged that the evidence base for doing so is limited.
The current recommended method of retinal screening for diabetic retinopathy is digital fundus
photography, a two-dimensional technology which cannot detect MO directly. Current photographic
grading schemes rely on a combination of surrogate photographic markers, chosen by expert consensus,
to infer the presence of MO. These manual grading schemes use combinations of features of retinopathy
including microaneurysms/dot haemorrhages (M/DHs), blot haemorrhages (BHs), exudates and also visual
acuity. At present, there is no consensus among the four nations as to which, and how many, features
should be used to infer the presence of diabetic MO.
Clinical experience from the Grampian Retinal Screening Programme and Liverpool Screening Programme
suggests that only 12–14% of these patients have evidence of MO, when examined by ophthalmologists
using slit-lamp biomicroscopy.
Optical coherence tomography (OCT) is now recognised as the reference standard for measuring MO. It is
an optical analogue of ultrasound imaging. The test is rapid, non-invasive and well tolerated by subjects.
By acquiring a series of cross-sections it is possible to generate a thickness map of the macula. However,
the equipment is still expensive.
Retinal ischaemia acts as a stimulus for the production of vascular endothelial growth factor. Vascular
endothelial growth factor has very potent permeability-inducing properties, as well as stimulating
angiogenesis. Currently there is a great deal of interest in the use of a range of treatments to counteract
the action of vascular endothelial growth factor. Trials show, for the ﬁrst time, that visual loss in people
with diabetic MO can be reversed by intravitreal antivascular growth factor injection in approximately half
of all treated patients, introducing a new paradigm in the treatment of diabetic MO and also now
screening. It is probable that with these new treatments, screening for diabetic MO will meet thexiii
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SCIENTIFIC SUMMARY
xivWorld Health Organization's criteria. Identifying patients, who will beneﬁt most from these new therapies,
is now an important issue for all diabetic retinopathy-screening programmes.Objectives
The primary aim of the study was to determine the best photographic surrogate markers for detecting
potentially sight-threatening diabetic MO, within English and Scottish national screening programmes.
Speciﬁcally we wished to:
(a) investigate whether or not particular distributions and combinations of lesions (M/DHs, BHs and
exudates), assessed manually or automatically, were more speciﬁc photographic surrogate markers of
MO than current practice, using OCT as the reference standard
(b) assess the costs and consequences of using alternative distributions and combinations of these lesions
to screen for MO, using either automated or manual detection of lesions
(c) model the long-term cost and quality-of-life implications of using alternative distributions and
combinations of surrogate markers to screen for MO.
Once the study was under way, several screening programmes were found to be using OCT as part of the
screening process to reduce false-positive referrals to the hospital eye service. Consequently, we added a
further aim to assess the costs and consequences of using OCT within retinal screening programmes in
addition to photographic surrogate markers, as this would affect how photographic markers would be
used in future.Methods
A total of 3540 patients with photographic signs of diabetic retinopathy visible within the macular region
[exudates within two disc diameter radius (DD), M/DHs, BHs within one DD] were recruited from
seven study centres at Aberdeen, Birmingham, Dundee, Dunfermline, Edinburgh, Liverpool and Oxford.
Each subject had retinal photography and OCT on both eyes where possible.
Software was developed to assist the research nurse in the manual annotation of potential surrogate
markers for MO (M/DHs, BHs and exudates), visible in the colour photographs.
Separate software was developed to analyse the distribution of retinal lesions, either annotated manually
or automatically, to investigate whether or not particular distributions and combinations of lesions (M/DHs,
BHs and exudates) within one or two DD from the centre of the fovea are more speciﬁc photographic
surrogate markers of MO than current grading practice, using OCT as the reference standard.
The OCT images were analysed both quantitatively and qualitatively by the research nurse.
Statistical modelling was carried out to see if any of the manual grading schemes in England and Scotland
included everything that might be considered important if starting from de novo. This information was
used to inform the inclusion of various eye and subject characteristics within computer-assisted manual
grading strategies and full automated grading strategies for detecting MO.
The grading strategies utilising photographic surrogate markers for detecting MO can be categorised as:
l Manual grading strategies These use photographic features in a binary fashion, similar to existing
national criteria, which can be determined by visual inspection of retinal photographs by
trained graders.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51l Computer-assisted manual annotation grading strategies These use more detailed features obtained
by manual annotation of retinal photographs which are then combined by a software classiﬁer to
determine a likelihood that MO is present.
l Fully automated annotation grading strategies where no human intervention is required These use
features automatically annotated by image analysis software. As with computer-assisted manual
annotation grading strategies, these are combined by a software classiﬁer to determine a likelihood
that MO is present.
A study was then carried out to assess the cost-effectiveness of alternative pathways for screening for MO
using various combinations of photographic grading strategies, automation, visual acuity and OCT. An
initial analysis focussed on the cost per true case of MO appropriately detected and referred. However, in
most instances improvements in the sensitivity of the referral process come at the expense of decreased
speciﬁcity. Thus, a secondary analysis assessed whether or not the increased costs associated with more
sensitive screening strategies, resulting from more referrals to ophthalmology clinics (appropriate and
inappropriate), are worth incurring given the potential health beneﬁts. A Markov microsimulation model
was developed for this purpose.Results
The statistical analysis showed that the detection of MO in corresponding optical coherence tomograms
was strongly related to the presence of retinal lesions in retinal photographs, being roughly ﬁve times
more detectable among subjects with an exudate, a BH, or a M/DH present within one DD compared
with the same lesion being absent. Having more than two M/DHs within one DD in an eye was of
particular importance.
Subjects with worse visual acuity were about ﬁve times as likely to have MO in the relevant eye as those
with better visual acuity.
The best-performing photographic grading strategy was a computer-assisted manual annotation grading
strategy. This uses the results of manual annotation of the individual lesions in each image. Computer-
assisted manual annotation is, however, a time-consuming procedure and so is unlikely to be considered
for routine screening practice. Therefore, this strategy was not taken forward for economic analysis.
Grading strategies relying on the manual annotation of retinal images without computer assistance of all
retinal images were similarly not included.
The manual grading strategies chosen for comparison in the economic analysis included the current
English grading scheme (manual grading strategy 1) and the current Scottish grading scheme (manual
grading strategy 2). Manual grading strategy 2 is one of the higher-speciﬁcity, simple, manual grading
strategies (59.5% sensitivity; 79% speciﬁcity) whereas manual grading strategy 1 represents a moderate-
sensitivity, moderate-speciﬁcity, manual grading strategy (72.6% sensitivity; 66.8% speciﬁcity). A further
manual grading strategy (strategy 16) was also included as a potential alternative to grading strategy 1
(having similar sensitivity, 73.3%, and higher speciﬁcity, 70.9%). Furthermore, consideration was given to
the potential cost-effectiveness of utilising a fully automated annotation grading strategy which also
utilised visual acuity (denoted FA2), with slightly higher sensitivity (75.9%) and better speciﬁcity (73.7%)
than manual grading strategy 16. In addition, consideration was given to a grading strategy (grading
strategy 8) that had 100% sensitivity, albeit with only 1.7% speciﬁcity, coupled with OCT prior to referral.
The impact of a screening pathway combining the selected grading strategies with OCT (within the
screening programme prior to referral) to minimise false-positive referrals to eye clinics was also assessed.
The incremental costs per extra case of MO detected vary by grading strategy. Considering the more
sensitive grading strategy 16 compared with grading strategy 2, the additional cost per extra case detectedxv
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SCIENTIFIC SUMMARY
xviranges from £1579 (English costs) to £985 (Scottish costs). When the grading strategies are coupled with
OCT, in the screening pathway, these incremental costs fall to £636 and £528, respectively. Although the
fully automated annotation grading strategy dominates manual grading strategies 1 and 16 under the
base-case assumption of zero net increase in grading costs, it costs £897 per additional case detected and
referred in comparison with manual grading strategy 2 (applying English screening and referral costs).
This incremental screening cost drops to £405 when the grading strategies are coupled with OCT prior to
referral. The 100% sensitive screening strategy 8 costs an additional £1510 per extra case detected in
comparison with the most speciﬁc screening strategy (strategy 2 + OCT) when applying English referral
costs, and £1360 per extra case detected when applying Scottish referral costs. In comparison with manual
grading strategy 16 plus OCT, screening strategy 8 costs £1955 and £1784 per extra case detected and
referred when applying English and Scottish referral costs, respectively.
The longer-term cost-effectiveness results mirror the pattern observed in the short term, in that the
addition of OCT to the screening pathway results in cost-savings without reducing the health beneﬁts.
As with the short-term results, the fully automated annotation grading strategy also dominates manual
grading strategies 1 and 16, under the assumption of zero net increase in grading costs associated with
the introduction of automated grading. Furthermore, manual grading strategy 16 remains essentially
dominant over, or very cost-effective in comparison with, strategy 1.Conclusions
Compared with all current manual grading schemes, for the same sensitivity, a fully automated annotation
grading strategy, using the automated detection of patterns of photographic surrogate markers, achieves a
higher speciﬁcity for detecting OCT detectable MO in people with diabetes, especially if visual acuity is
included in the automated strategy.
Overall costs to the health service are likely to increase if more sensitive referral strategies are adopted over
more speciﬁc screening strategies for MO, for only very small gains in quality-adjusted life-years.
The addition of OCT to each grading strategy, as part of the screening pathway prior to referral, results in
a reduction in costs to the health service with no decrement in the number of MO cases detected.Study registration
This study has been registered as REC/IRAS 07/S0801/107, UKCRN ID 9063 and NIHR HTA 06/402/49.Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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Compared with more established screening programmes, such as cervical and breast screening, diabeticretinopathy screening is still in its infancy: national screening programmes for diabetic retinopathy have
been running throughout the UK for less than a decade.
The risk of retinopathy increases with disease duration.1 Type 2 diabetes is often diagnosed several years
after onset and consequently almost 40% of people with type 2 diabetes are found to have retinopathy at
diagnosis. This is potentially sight-threatening in between 4% and 8% of cases. Sixty per cent of people
with type 2 diabetes will have retinopathy 20 years from onset.
There are two main mechanisms responsible for visual loss from diabetic retinopathy. The ﬁrst of these is
proliferative retinopathy and the development of new blood vessels. The second is macular oedema (MO),
the build-up of ﬂuid involving the area of the retina associated with best vision, the macula. Although
proliferative disease is most likely to lead to serious vision loss, MO is more common and is the leading
cause of moderate visual loss (MVL) in people with diabetes. However, laser treatment is only moderately
effective, at best, for MO.
At the time of the introduction of national programmes for screening for diabetic retinopathy in the UK,
unlike screening for proliferative diabetic retinopathy, screening for diabetic MO was not deemed to meet
strict World Health Organization guidelines for screening.2 Diabetic retinopathy involving the macula
(maculopathy) is more common than proliferative diabetic retinopathy so retinal screening programmes
have had to develop pathways to address this, although it is acknowledged that the evidence base for
doing so is limited.
Diabetes can affect the integrity and increase the permeability of the blood–retinal barrier. This is caused
by a thickening of the basement membrane and fall in the number of supporting pericytes, making the
blood–retinal barrier leaky.3 This results in ﬂuid accumulation within the outer plexiform and inner nuclear
layers of the retina, and swelling of the cells within these layers. MO may be classiﬁed according to the
ﬂuid distribution: diffuse oedema is a general thickening of the central retina caused by either extensive
capillary dilatation or capillary closure, whereas focal oedema is centred on speciﬁc vascular abnormalities,
such as microaneurysms. Accumulated ﬂuid defocuses the image on the retina, reducing visual acuity. If
oedema persists, the increased pressure may lead to irreparable photoreceptor damage.
Retinal thickening is not visible directly on the retinal photographs used by screening programmes, so
people are referred to ophthalmology clinics on the basis of a range of surrogate photographic markers,
such as exudates within a certain distance of the foveal centre. A review of the evidence from the Early
Treatment Diabetic Retinopathy Study (ETDRS)4 suggests that exudates may be a sensitive marker of MO.5
However, as this study excluded patients with mild retinopathy in the absence of exudate, the results are
not directly applicable to screening programmes in the UK, where 60% of patients have no visible signs of
retinopathy and > 30% have only mild retinopathy. Evidence from the Grampian Retinal Screening
Programme suggests that only 12% of patients with surrogate markers referred to an ophthalmologist
have indications of MO when examined by slit-lamp biomicroscopy. Similarly, a retrospective analysis from
Liverpool, including 257 patients referred from the screening programme to the ophthalmology clinic
between December 2001 and June 2002, found that only 14% had evidence of MO (unpublished data).
Macular oedema has traditionally been assessed clinically using a combination of slit-lamp biomicroscopy,
stereoscopic photography and stereoscopic ﬂuorescein angiography. However, these techniques have a
number of limitations. Foremost is that they are only qualitative assessments, which are relatively
insensitive to thickness changes. Furthermore, slit-lamp examination does not provide a pictorial record
and, together with stereo photography, is known to be biased by the presence or absence of exudates.6
Although the angiogram is a sensitive test for leakage, an objective measurement of thickening is not1
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INTRODUCTION
2possible. Best corrected visual acuity has also been used as a surrogate indicator of thickening, but is
neither sensitive nor speciﬁc, being affected by several factors besides macular thickness.
Optical coherence tomography (OCT) is recognised as the reference standard for measuring MO.1,7 It is an
optical analogue of ultrasound imaging, and uses low-coherence interferometry to acquire cross-sectional
images of the retina. The resolution of the cross-sections is two orders of magnitude better than is
achievable using ultrasound, with the axial resolution (in the plane of the retina) being between 8 and
16 µm and the lateral resolution (depth) between 10 and 15 µm. The test is rapid, non-invasive and well
tolerated by subjects. By acquiring a series of cross-sections it is possible to generate a thickness map of
the macula. OCT was ﬁrst launched commercially by Carl Zeiss Meditec in 1996 and since then
improvements have been made to the signal-to-noise ratio and axial and lateral resolution, and the
acquisition time has been shortened.
Several investigators have compared OCT with slit-lamp biomicroscopy, concluding that OCT is the more
sensitive test for macular thickening. It has been reported that the agreement between the slit-lamp and
OCT is good for normal and extreme thicknesses, but equivocal between 200 and 325 µm.8 Good
agreement has also been found between thickening seen on stereo photographs and OCT.9 Similarly,
studies comparing OCT and ﬂuorescein angiography indicate OCT to be at least as sensitive as
angiography for detecting thickening.10
Since the ETDRS, focal and grid laser treatment have been the standard treatment for MO. A long-term
follow-up study by Chew et al.11 found that a median of 16.7 years after the original study, 42% of
patients had a visual acuity of 20/20 [logarithm of the minimum angle of resolution (log-MAR) 0] or better
in their best eye, and 84% had a visual acuity of 20/40 (log-MAR 0.3) or better in their best eye.
Nevertheless, laser treatment is not without risk and is not effective in all cases.
Retinal ischaemia acts as a stimulus for the production of vascular endothelial growth factor.12,13 Vascular
endothelial growth factor has very potent permeability-inducing properties, as well as stimulating
angiogenesis.12 Over the last few years there has been a great deal of interest in the use of a range of
adjunctive intravitreal treatments to counteract these pro-inﬂammatory and angiogenic stimuli, including
corticosteroids like triamcinolone (Kenalog®, Bristol-Myers Squibb)14,15 and antivascular endothelial growth
factor therapies like pegaptanib (Macugen®, Pﬁzer Ltd),16 bevacizumab (Avastin®, Roche Products Ltd)17,18
and ranibizumab (Lucentis®, Novartis Pharmaceuticals UK Ltd).19–22 These studies have shown signiﬁcant
visual and anatomic improvements in cases of diabetic MO using these novel treatments.
These trials show, for the ﬁrst time, that visual loss in people with diabetic MO can be reversed in
approximately half of all treated patients so introducing a new paradigm in the treatment of diabetic MO.
It is probable that with these new treatments, screening for diabetic MO will meet the World Health
Organization screening criteria.23 Identifying patients, who will beneﬁt most from these new therapies, is
now an important issue for all diabetic retinopathy-screening programmes.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Chapter 2 Study design and methodsAims and objectivesThe primary aim the study was to determine the best method for detecting potentially sight-threatening
MO in people with diabetes using photographic surrogate markers within the English and Scottish national
screening programmes. Speciﬁcally we wished to:
(a) investigate whether or not particular distributions and combinations of lesions [microaneurysms/dot
haemorrhages (M/DHs), blot haemorrhages (BHs) and exudates], assessed manually or automatically,
are more speciﬁc photographic surrogate markers of MO than current practice, using OCT as the
reference standard
(b) assess the costs and consequences of using alternative distributions and combinations of these lesions
to screen for MO, using either automated or manual detection of lesions
(c) model the long-term cost and quality-of-life implications of using alternative distributions and
combinations of surrogate markers to screen for MO.
Once the study was under way several screening programmes were found to be using OCT as part of the
screening pathway to reduce false-positive referrals to the hospital eye service. Consequently, we added a
further aim to assess the costs and consequences of using OCT within retinal screening programmes in
addition to improving the photographic surrogate markers, as this would affect how photographic markers
would be used in future.Primary outcome measureThe primary outcome was the sensitivity and speciﬁcity of manual grading, computer-assisted manual
annotation grading and fully automated annotation grading strategies, utilising photographic lesions to
infer the presence of diabetic MO, compared with a reference standard based on the detection of diabetic
MO using OCT.Other outcome measuresThe sensitivity and speciﬁcity estimates were used to assess the costs and consequences (i.e. the proportion
of appropriate ophthalmology referrals) of using the alternative grading strategies for the detection of MO.
The long-term costs and outcomes [visual loss and quality-adjusted life-years (QALYs)] of the alternative
grading strategies were modelled using data from the epidemiological literature and available cost
estimates. The effect of optionally including OCT within the screening pathway was also modelled.Study designThe study was a multicentre prospective observational cohort study. The cohort consisted of subjects with
features of diabetic retinopathy visible within the macular region attending one of seven diabetic retinal
screening programmes. The speciﬁc diabetic retinopathy features of interest as surrogate markers for MO
were M/DHs, BHs and exudates. All subjects were recruited and imaged at the participating centres in
Aberdeen, Birmingham, Dundee, Dunfermline, Edinburgh, Liverpool and Oxford.3
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4Inclusion criterial Aged ≥ 18 years.
l One or more of the following features present in at least one eye identiﬁed using retinal photography:
¢ M/DHs within one disc diameter radius (DD) of the centre of the macula.
¢ BHs within one DD of the centre of the macula.
¢ Exudates within two DD of the centre of the macula.
l Able and willing to provide signed informed consent.Main exclusion criterial Any macular or pan-retinal laser treatment in the study eye(s) or any intraocular injection, since these
interventions affect disease progression and characteristics.
l Intraocular surgery (e.g. cataract surgery) within 1 year of enrolment. Cystoid MO following cataract
surgery, also known as Irvine–Gass syndrome, is the most common cause of decreased vision following
cataract surgery.24
l Pregnancy. During pregnancy diabetic retinopathy can change much more rapidly.25–27
l An inadequate OCT image or two inadequate retinal photographs. Photographs are considered
inadequate if either (1) the clarity is insufﬁcient as the macular vessels are not clearly visible or (2) the
ﬁeld of view does not include a circular region with a radius of at least two disc diameters centred on
the fovea.
l Contraindications to pupillary dilatation should pupil dilatation be necessary. Pharmacological pupillary
dilatation is necessary where the pupil is too small to allow imaging, either retinal photography or
OCT. Typically the pupil diameter must exceed 4mm to allow imaging.Reference standard for macular oedema
Optical coherence tomography was chosen as the reference standard for identifying the presence of
diabetic MO.1 Although other technologies are available for measuring retinal thickness (see Appendix 1),
OCT has the highest resolution, good repeatability, and is the only method that provides detailed
anatomical cross-sections.Rationale for the macular oedema reference
The reference standard should identify all the cases with MO that would beneﬁt from assessment (though
not necessarily treatment) by an ophthalmologist in the eye clinic. The ﬁrst large study to investigate MO
(in the context of determining the efﬁcacy of laser treatment for potentially sight-threatening retinopathy)
was the ETDRS.28 Stereoscopic fundus photography was used to determine whether or not retinal
thickening was present and the following criteria were used to deﬁne clinically signiﬁcant MO.
l Thickening within 500 µm of the centre of the macula.
l Exudates within 500 µm of centre of macula with adjacent thickening.
l Thickening of one disc area or larger where any part is within one disc diameter of the centre of
the macula.
Optical coherence tomography now provides a more sensitive and speciﬁc test for MO than was available
for the ETDRS. The ETDRS deﬁned a circular grid consisting of nine regions4 (see Figure 29) where the
central region has a radius of 500 µm for the ETDRS central thickening region and the surrounding four
regions have a diameter of a DD for the non-central thickening region. All current OCT scanners generate
retinal thickness values for these regions of interest. Many studies have investigated the normal range of
retinal thickness in these regions of interest. Subjects with abnormally thickened retinas may be selected
based on a thickness threshold. For the Zeiss Stratus OCT™ (Carl Zeiss Meditec International, Jena,
Germany) studies have shown that biomicroscopy is able to reliably identify central thicknesses > 300 µm,NIHR Journals Library www.journalslibrary.nihr.ac.uk
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should therefore ensure that the majority of biomicroscopy-positive cases with central thickening will be
included in the study. A Diabetic Retinopathy Clinical Research Network study that used Zeiss Stratus OCT
selected eyes with previously untreated MO that were characterised by a central subﬁeld mean thickness
of at least 250 µm or an inner paracentral subﬁeld mean thickness of at least 300 µm:29 these thickness
thresholds were used in this study. However, as different OCT scanners were used at the various centres it
was necessary to correct for possible differences in thickness measurements, see Chapter 3.
Thickening seen on OCT, however, is not speciﬁc to diabetic retinopathy. When an abnormal thickness
measure was found within the inner ﬁve ETDRS regions the OCT cross-sections were examined for
intraretinal cysts or subretinal ﬂuid. This is similar to the grading protocol in the Diabetic Retinopathy
Clinical Research Network study29 which states: ‘Retinal morphology was assessed at baseline from OCT
images for cystoid abnormalities and subretinal ﬂuid’. Although the Diabetic Retinopathy Clinical Research
Network study29 used the selection criterion of a central ﬁeld thickness threshold of at least 275 µm rather
than the more common 250 µm. Other studies note that non-diabetic pathology is speciﬁcally excluded
from the study (e.g. the RESTORE study22 and the READ-2 study21).
In this study we used the Diabetic Retinopathy Clinical Research Network criteria for deﬁning MO.29 MO
was deemed to be present where the following two criteria were met:
l The central ETDRS region thickness was > 250 µm, or any of the inner ﬁve regions were > 300 µm.
l A visible intraretinal cyst or area of subretinal ﬂuid on the OCT cross-sections.Sample size
A previous study found a 14% prevalence of macular lesions within a screening programme,30 the subjects
making up the target cohort for this study. Of those with macular lesions, 10% are expected to have MO.
Thus, the majority of the study cohort will not have MO and hence the precision of the sensitivity
measurement will be the determining factor in the calculation of study power and sample size.
To detect a 3% difference in sensitivity between two diagnostic tests with 80% power using the McNemar
test requires a sample of 400 positive cases. Using the assumed prevalence of positive cases above of 10%
this would mean recruiting 4000 subjects.Regulatory approval
The study was approved by the North East Scotland Research Ethics Committee on 17 December 2007
(reference 07/S0801/107). Each participating centre obtained approval from their local ethics board. The
study was cosponsored by the University of Aberdeen and NHS Grampian. All participants provided signed
informed consent after reading the patient information sheet and following discussion with the local study
representative. A Trial Steering Committee oversaw the conduct of the study. The study was registered
with the United Kingdom Clinical Research Network (UKCRN reference 9063).Recruitment and data collectionAll patients were recruited at one of seven study centres in Aberdeen, Birmingham, Dundee, Dunfermline,
Edinburgh, Liverpool and Oxford.Visual acuity
Visual acuity was measured using either best corrected visual acuity or a pin hole (the method used was
noted). Visual acuity was recorded using the log-MAR scale. Where subjects could not resolve characters
on the vision chart they were asked if they could count ﬁngers, see hand movement or perceive light,
otherwise the eye was recorded as having no perception of light. Count ﬁngers was assigned a log-MAR5
© Queen's Printer and Controller of HMSO 2013. This work was produced by Olson et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
STUDY DESIGN AND METHODS
6value of 2, and hand movement a log-MAR value of 3.31 Where vision is worse than hand movement the
subject is unable to resolve any object and therefore the visual acuity is undeﬁned.Pupillary dilatation
In the English centres all patients received mydriasis, while Scottish centres only used mydriasis if
the pupil size was too small for imaging. Both retinal photograph and OCT scanning require a pupil
size of at least 4 mm. Studies have shown that the use of pupillary dilatation does not affect OCT
thickness measurements.32,33Retinal photograph acquisition
All photographs were acquired by ophthalmic photographers or retinal screeners and the name of the
photographer was noted for each image. A single retinal photograph was acquired for each eye meeting
the following criteria:
l 45 degrees ﬁeld of view
l macula centred
l colour digital photograph (between 3 and 8megapixels)
l JPEG image compression (if used) set for high quality
l adequate ﬁeld of view (the image should show a region having a radius of at least two disc diameters
around the fovea)
l adequate clarity (i.e. adequate to see macular microaneurysms, if present)
l the fundus camera small pupil facility was acceptable providing a region of at least two DD was still
visible around the fovea.Optical coherence tomography reference image acquisition
All OCT scans were acquired by operators who had been accredited for the study. There was a maximum
time limit of 4 weeks between the retinal photograph and OCT reference scan as the disease was unlikely
to progress signiﬁcantly during this period of time. Eighty-nine per cent of OCT scans were acquired on
the same day as the retinal photograph.Accreditation
As in other multicentre imaging studies, to avoid intercentre variation all OCT operators were required to
be accredited before submitting data for the study. Operators submitted a portfolio that included the
following images, collected using the OCT scanner they would be using for the study:
1. Normal eye Repeat macula maps of the same normal eye as per scanner model protocol.
2. MO eye Repeat macula maps of an eye showing obvious MO (i.e. central thickness of at least 300 µm).
The images were uploaded using the same website as the study data. Images were checked for:
1. Foveal position (where visible) The foveal minimum should be within 250 µm of the centre of the
thickness map.
2. Adequate image quality Image quality was assessed by visual inspection as well as quantitative
parameters such as signal strength and standard deviation (SD) in the central measurement,
where present.
3. Repeatability Repeatability was assessed for each region as the absolute percentage difference
between the repeat scans. These should be < 10% in all regions.Optical coherence tomography data description
Although the precise OCT acquisition protocol depended on the model of scanner used, every scanner was
set up to provide the following data.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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l A horizontal cross-sectional view through the centre of the macula.
l (Optional.) If the cross-sectional view through the centre of the macula did not contain the region of
greatest thickening then a second cross-section that included the region of greatest thickening
was taken.Other recorded patient information
No patient-identiﬁable information left the recruiting centre. Patient identiﬁers were removed from images
and data such as subject age were recorded with insufﬁcient granularity to be of help in identiﬁcation.
In addition to the retinal photograph, OCT scan and visual acuity assessment the following subject
information was collected:
l age (rounded to the nearest year)
l gender
l amblyopia.
Amblyopia is an uncorrectable decrease in vision in one eye with no apparent structural abnormality seen
to explain it. It is a diagnosis of exclusion, meaning that when a decrease in vision is detected, other
causes must be ruled out. There is wide variation in reported estimates for its prevalence. A review of UK
amblyopia studies in children aged ≤ 5 years assumed a prevalence of 4.8%.34 A cohort study at an
English retinal screening programme recorded a 10% amblyopia prevalence.35 Since visual acuity is used as
an indicator of MO in some screening programmes, amblyopia represents a confounding factor in the
detection of MO. Other non-diabetic factors affecting visual acuity, such as lenticular opacities and macular
degeneration, were not recorded separately as, unlike amblyopia, they directly affect the appearance or
quality of the retinal photograph:
l type of diabetes (the type of diabetes was recorded as type 1, type 2, secondary or other)
l ethnicity (the ethnicity categories were Asian, Black, Caucasian, Chinese, mixed, other, unknown)
l ﬁrst half of postcode
l glitazone use within the previous 6 months.
Glitazones, or thiazolidinediones, are a group of drugs that are prescribed to increase sensitivity to insulin
in people with type 2 diabetes. The most common forms are rosiglitazone and pioglitazone. Rosiglitazone
had its marketing authorisation suspended during the study in September 2010 by the European
Medicines Agency because of concerns regarding an increased cardiovascular risk. Oedema is a known
risk factor when using glitazones and studies have suggested they are associated with an increased risk
of MO,34–36 although another study found no association.37 The recording of the use of glitazones was
added to the study protocol in June 2009 because of the uncertainty surrounding their role in the
development of MO.Web submission and data validation
A website was developed to enable the transfer of both subject information and image data from each
recruiting centre to the database in Aberdeen. The website also allocated the unique study identiﬁer for
each subject and printed out a reference sheet for the local study folder.
The website was designed to reduce data entry errors. Tick boxes, menus and calendar entry tools were
used in preference to plain text entry (Figure 1). Checks were performed on the entered data, for instance
that the subject was aged ≥18 years and therefore eligible for the study. Checks were also performed on
the image data that were uploaded to ensure that the images were the expected size and format for the
OCT scanner used at that centre.7
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IGURE 1 Web form used to upload study data.
STUDY DESIGN AND METHODS
8FCheck sums were calculated for all images when they were uploaded. This served two purposes: ﬁrst, it
allowed the continuing integrity of the image data to be veriﬁed and, second, it enabled attempted
duplicate image uploads to be rejected.Image data analysis and grading
Retinal photographs
All the retinal photographs were graded and annotated by the same research nurse, who had
3 years' experience working as a retinal grader. A screenshot of the software used for grading is
shown in Figure 2.
Image grading
All of the images were graded for image quality and severity of retinopathy and maculopathy following
the Scottish Diabetic Retinopathy Grading Scheme.38NIHR Journals Library www.journalslibrary.nihr.ac.uk
IGURE 2 Screenshot of the software used to grade images.
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Software was developed to enable the research nurse to annotate the retinal images, indicating the size
and position of the optic disc, the position of the fovea, and the location, shape and size of individual
lesions within two DD of the fovea (Figure 3). All the lesions associated with maculopathy (M/DHs, BHs
and exudates) were annotated, as well as non-diabetic features with similar appearance which could
confound the analysis [ﬂame haemorrhages, drusen and cotton wool spots (CWS)].
Optical coherence tomography reference standardOptical coherence tomography scans
The OCT scan was the study reference standard for determining whether or not oedema was present. The
reference was based on the nine region thickness map and visual inspection of the cross-sectional images.Thickness map
Each OCT scanner in the study displays the thickness map on a graphical report. Optical character
recognition software was used to automatically store the thickness values in the database.
The retinal thickness was considered abnormal if the centre region thickness was > 250 µm or > 300 µm in
any of the surrounding four regions (the outer four regions outside a 3mm radius were not used). These
thickness thresholds were taken from studies that used the Zeiss Stratus OCT, and were adjusted to
account for the scanners used in the study (see Chapter 3). Images with abnormal thickening were then
visually inspected for the presence of oedema.9
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FIGURE 3 Screenshot of software used to annotate features on the retinal photographs.
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10Cross-sectional images
The cross-sectional images were visually assessed for the presence of oedema because several pathologies,
besides diabetic MO, could affect retinal thickness. Confounding features include vitreo-macular traction,
epiretinal membranes, macular holes, drusen, subretinal haemorrhage, pigment epithelial detachment and
choroidal neovascular membrane. Example OCT thickness map and cross-sections are shown in Figure 4.NIHR Journals Library www.journalslibrary.nihr.ac.uk
IGURE 4 Example of OCT cross-sections and thickness map (report from Zeiss Cirrus OCT).
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tomography scanner thickness measurements
When the study was originally planned the OCT market was dominated by a single device, the ZeissStratus OCT, which had been available since 2001. Subsequently, a number of new scanners came
on the market offering faster acquisition, lower image noise and higher resolution.
As a result it was decided not to limit the study to one scanner. Furthermore, the advantages offered by
the newer scanners meant that the Stratus OCT would rapidly become obsolete and so patient recruitment
would become difﬁcult.
In order to include results from different OCT scanners, experiments were undertaken before the study
began to estimate the differences in thickness between the new scanners and the Stratus OCT, and so
allow corrections to be made.
This study was considered a service evaluation by the North East of Scotland Research Ethics Committee
on 20 August 2007. All subjects gave informed consent after the intent of the evaluation was explained
to them.SubjectsForty-two volunteers aged ≥ 18 years took part. Sixteen of the volunteers were male and the median age
was 37 years (interquartile range 28–43 years). None of the subjects had a history of eye disease or
diabetes. Each subject had both eyes scanned twice by the same operator on at least one of the four OCT
scanners used in the study. Fifteen subjects were scanned on a single scanner, 17 on two scanners and
10 on more than two scanners. Pharmacological pupillary dilatation was not used as other studies have
shown it has no effect on thickness measurements.32,33 There was no signiﬁcant difference in the age
(Wilcoxon signed-rank test) or male/female ratio (chi-squared test) between the subjects imaged on
each scanner.
Measurements from left eyes were reﬂected left to right such that the nasal region was to the right and
the temporal region to the left in both left and right eyes.Statistical analysisBoth eyes were included in the analysis since no correlation was expected between repeat measurements
in left and right eyes. This reduced the number of subjects required and also allowed investigation of
temporal/nasal asymmetry. Repeatability was calculated as:
Repeatability ¼ 1.96 stdðDÞ; ð1Þ
where std(D) is the SD of the repeat measurement differences.39 Conﬁdence intervals (CIs) were calculated
for repeatability as ± (tn− 1,0.05/√(2(n− 1))) × 1.96 × std(D), where n is the number of eyes and tn− 1,0.05 is the
inverse cumulative t-distribution for a 5% probability.40 The intraclass correlation coefﬁcient (ICC) was also
calculated as described by Shrout and Fleiss.41 Interscanner agreement was calculated as for intrascanner
repeatability using the equation above. Repeatability and ICC values were obtained from SPSS (version 17;
SPSS Inc., Chicago, IL, USA). The difference between scanner measurements was plotted against the mean
of the scanner measurements to detect any thickness dependence on the difference between scanners.13
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14As not all subjects were measured on all four scanners a mixed-effects model was used in preference to
a standard analysis of variance.42 It was implemented using the PROC MIXED procedure within SAS
(version 9.1; SAS Institute Inc., Cary, NC, USA). The scanners were treated as ﬁxed effects, using the Zeiss
Stratus OCT as the reference scanner. Differences between volunteers' left and right eyes were also
treated as a ﬁxed effect, while the differences between volunteers were considered a random effect. The
size of the differences between scanners could thus be estimated while allowing for differences between
volunteers and between eyes within volunteers. Analyses were also carried out on the means of the
annular inner four and outer four ETDRS regions.
Two schemes were compared for converting values between different scanners. The ﬁrst applied a single
additive constant, calculated as the mean difference between scanners, to all nine regions. The second
used three separate additive constants for the central (region 1), inner regions (2, 3, 4 and 5) and outer
regions (6, 7, 8 and 9). The mixed-model analysis was repeated in each case using the adjusted values to
test whether or not the differences between the scanners remained signiﬁcant.Imaging protocols
Zeiss Stratus OCT
The ‘fast macular protocol’ was used on the Stratus OCT. It acquires six intersecting 6 mm radial
cross-sections centred on the fovea. Each cross-section includes 128 A-scans of 1024 axial samples over a
2 mm depth range. The total acquisition takes 1.9 seconds. The scans were considered acceptable if (1) the
SD of the central foveal measurements was < 10% of the mean central measurement, (2) the recorded
signal strength was at least 4 out of a possible maximum of 10, (3) there were no warnings from the
instrument regarding ‘low analysis conﬁdence’, ‘missing data’ or ‘high variance’, (4) there were no visible
boundary tracking errors and (5) the ﬁxation point was within approximately 250 µm of the centre of the
foveal pit. The scanner software version was 4.0.7.Zeiss Cirrus OCT™ (Carl Zeiss Meditec International, Jena, Germany)
The Cirrus OCT (Carl Zeiss Meditec International, Jena, Germany) acquires A-scan data almost 70 times
faster than the Stratus OCT. Scans were collected covering a 6 × 6mm square area with a 512 × 128 raster
pattern. Each A-scan consisted of 1024 samples over a 2 mm depth range. The total acquisition time was
2.4 seconds. A faster protocol is available, using a 200 × 200 raster pattern, which covers the same area in
1.5 seconds. The scans were considered acceptable if (1) the signal strength was at least 6 out of 10,
(2) there were no obvious signs of movement, (3) there were no visible boundary tracing errors and
(4) the ﬁxation point was within 250 µm of the centre of the foveal pit. The scanner software version
was 2.0.0.54.Topcon 3D OCT-1000™ (Topcon Corporation, Tokyo, Japan)
Scans were acquired covering a 6 × 6mm square area to a depth of 1.68 mm using a 256 × 128 raster
pattern of A-scans. Each acquisition took approximately 2 seconds. The scans were considered acceptable
if (1) there were no visible boundary tracing errors, (2) there were no obvious signs of movement,
(3) < 10% of B-scan lines were missing in any ETDRS region and (4) the ﬁxation point was within 250 µm
of the centre of the foveal pit. The scanner software version was 2.11.Heidelberg Spectralis™ (Heidelberg Engineering, Heidelberg, Germany)
The Spectralis A-scan rate of 40,000 A-scans/second is the fastest in this group. Its acquisition also differs
from the other scanners in two signiﬁcant respects. First, it includes an eye tracking facility which pauses
the acquisition whenever the subject moves or blinks (consequently, the scan time can vary depending on
subject movement). Second, each B-scan cross-section is acquired several times and combined to improve
the signal-to-noise ratio and reduce speckle artefacts.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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B-scan cross-section acquired ﬁve times. Each A-scan consisted of 512 samples covering a 1.8 mm depth
range. The scans were considered acceptable if (1) the 6mm ETDRS region ﬁtted within the acquired
region and (2) there were no boundary tracking errors. Software allowed the regions to be translated to
correct for minor ﬁxation errors. Boundary tracings were not available for all images and so the exclusion
criteria were less stringent than for the other scanners. The software version used was 3.0.Results
Boundary measurements
Differences in how boundaries are identiﬁed by the various scanners were a signiﬁcant problem. Boundary
A (Figure 5) indicates reﬂections from the nerve ﬁbre layer on the top surface of the retina; all the scanners
begin their thickness measurements at this layer. However, there is disagreement about where to place the
lower limit of the thickness measurement. Boundary B, probably reﬂections from the external limiting
membrane, tends to be fainter than the three lower boundaries C, D and E. The Zeiss Stratus OCT takes
the top of the bright reﬂective band (approximately layer C above) as the posterior limit (measurement
M1). In contrast, the Heidelberg Spectralis takes the bottom of the bright reﬂective band (layer E,
measurement M3). The Zeiss Cirrus OCT and Topcon 3D OCT-1000 use a limit between these two
extremes, with the Topcon 3D OCT-1000 tending to ﬁnd the lower edge of layer C and the Zeiss Cirrus
OCT the top edge of layer D (measurement M2).
Scans meeting inclusion criteria
Eyes were excluded if either of the repeat scans failed to meet the inclusion criteria. The number of eyes
included from each scanner were: the Zeiss Stratus OCT (45/60), the Zeiss Cirrus OCT (55/66), the Topcon
3D OCT-1000 (17/26) and the Heidelberg Spectralis (27/28).
Four Zeiss Stratus OCT scans had visible boundary errors (Figure 6), two had low analysis conﬁdence
warnings, one had a ﬁxation error, one had missing data and two had high variance warnings. On the
Zeiss Cirrus OCT, ﬁxation errors affected 10 scans and one was excluded because of movement. On
the Topcon 3D OCT-1000, 13 scans showed missing data, which in nine cases was serious enough for the
scans to be excluded. One Heidelberg Spectralis scan was excluded owing to a missing thickness value in
one region, probably because of a boundary tracing error.
Repeatability
Both eyes were included in the repeatability analysis since the repeat measurement differences are
expected to be random and uncorrelated. In this study the correlation between thickness measurements in
left and right eyes was strong (Pearson correlation coefﬁcient 0.780), but there was no signiﬁcant
correlation in the repeat measurement differences in left and right eyes (Pearson correlation coefﬁcient
0.014; p = 0.9).
Table 1 lists the repeatability and ICCs for the nine ETDRS regions. In general, repeatability was poorest in
the smallest, central region (1) and best in the inner regions (2, 3, 4 and 5). The Zeiss Stratus OCT shows
the poorest repeatability, with all regions being equal to, or worse than, the newer scanners.
Interscanner agreement
Box and whisker plots of the macular thickness in each of the nine regions are shown in Figure 7. By
inspection it is clear that there were differences between all the scanners and that the sizes of these
differences were similar for all regions.
The mean central thickness in volunteers was greatest on the Heidelberg Spectralis (277 µm, SD 15 µm)
and least on the Zeiss Stratus OCT (201 µm, SD 19 µm). The Topcon 3D OCT-1000 (230 µm, SD 22 µm)
and Zeiss Cirrus OCT (258 µm, SD 21 µm) were between these two extremes. In all scanners the average15
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FIGURE 6 Example of an automatic boundary detection failure. Left, Topcon 3D OCT-1000 example from a patient
with MO; right, a Zeiss Stratus OCT scan from a volunteer.
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51thickness in the superior region was greater than in the inferior region, and likewise greater in the nasal
compared with the temporal region.
Table 2 lists the results of the mixed-model analysis. It shows the estimated differences between scanners
calculated using scans from both eyes meeting the inclusion criteria. There were signiﬁcant differences in
thickness between all of the scanners in all nine regions (p < 0.001). In the central region the
measurements were greater on the Zeiss Cirrus OCT, Topcon 3D OCT-1000 and Heidelberg Spectralis
scanners than the Zeiss Stratus OCT by 58 µm, 28 µm and 78 µm, respectively. Compared with the central
region differences, the other eight regional differences were slightly smaller on all scanners except the
Topcon 3D OCT-1000, where the largest differences were in the inner regions.
As agreement in its technical sense is proportional to the SD of measurement differences,39 any systematic
difference is disregarded. The central region macular thickness agreement between the Zeiss Stratus OCT
and Zeiss Cirrus OCT was 10.5 µm (n = 30; 95% CI 7.1 to 13.9 µm), between the Zeiss Stratus OCT and
Topcon 3D OCT-1000 was 6.9 µm (n = 13; 95% CI 3.26 to 10.5 µm) and between the Zeiss Stratus OCT
and Heidelberg Spectralis was 12.7 µm (n = 14; 95% CI 6.3 to 19.1 µm).Interscanner thickness conversion
Using a single correction for all nine regions and rerunning the mixed-model analysis resulted in very
similar measurements from all the scanners for the central region. However, statistically signiﬁcant
differences still remained; in the outer regions the Zeiss Cirrus OCT and Heidelberg Spectralis were up to
16 µm lower than the Zeiss Stratus OCT and the Topcon 3D OCT-1000 up to 7 µm higher. Reﬁning the
model and using three regional constants per scanner, where correction values were calculated for the
central, inner and outer regions, resulted in very few statistically signiﬁcant differences remaining and
the average errors were now all ≤ 3 µm, with the largest errors in the inner nasal region.
The above strategy assumes additive correction alone is sufﬁcient. The need for possible multiplicative
correction was tested by plotting the difference between measurements from two scanners against the
mean thickness measured on the two scanners. Figure 8 shows the comparison of Zeiss Stratus OCT and
Zeiss Cirrus OCT measurements for the central region. If an additive constant is sufﬁcient to correct the
difference then the line of regression should have a zero gradient. However, as Figure 8 shows, the
regression line has a gradient of −0.17, which is signiﬁcantly different from a zero gradient (p < 0.001).
Although only regions 1 and 9 are signiﬁcantly different from zero gradient, probably owing to
the small sample size, the bar chart in Figure 9 of estimated gradients for all nine regions shows
a clear trend, with negative gradients in the central and inner regions and positive gradients in the
outer four regions.17
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FIGURE 7 Box and whisker plots of macular thickness measurements for the nine ETDRS regions shown in Figure 29
for the four scanners. The plots show the median (central stripe), interquartile range (box) and full range (whiskers),
excluding outliers (+) which are defined as observations beyond 1.5 times the interquartile range from the box.
C, Zeiss Cirrus OCT; H, Heidelberg Spectralis; T, Topcon 3D OCT-1000; Z, Zeiss Stratus OCT.
ABLE 2 Differences between other scanners and the Zeiss Stratus in each for each ETDRS region based on a
ixed-model analysis
ETDRS region
Zeiss Cirrus OCT vs.
Zeiss Stratus OCT
(20 volunteers; 30 eyes)
Topcon 3D OCT-1000 vs.
Zeiss Stratus OCT
(7 volunteers; 13 eyes)
Heidelberg Spectralis vs.
Zeiss Stratus OCT
(10 volunteers; 14 eyes)
Diff. (µm) 95% CI Diff. (µm) 95% CI Diff. (µm) 95% CI
1 58.2 56.8 to 59.7 28.1 26.0 to 30.1 78.5 76.5 to 80.4
2 49.9 48.5 to 51.3 32.9 30.9 to 35.0 75.0 73.1 to 76.9
3 54.1 52.6 to 55.5 35.0 32.9 to 37.1 79.0 77.0 to 80.9
4 50.3 48.8 to 51.7 32.2 30.1 to 34.2 74.5 72.6 to 76.4
5 49.7 48.3 to 51.1 30.1 28.2 to 32.1 75.5 73.7 to 77.4
6 44.7 43.0 to 46.4 30.3 27.8 to 32.7 66.6 64.4 to 68.8
7 45.6 44.2 to 47.0 29.8 27.9 to 31.7 64.3 62.5 to 66.1
8 44.4 42.9 to 46.0 28.2 26.0 to 30.4 62.7 60.6 to 64.7
9 43.3 41.8 to 44.8 27.0 24.8 to 29.2 67.5 65.5 to 69.5
Mean inner 51.0 49.8 to 52.2 32.5 30.8 to 34.2 76.0 74.4 to 77.6
Mean outer 44.5 43.4 to 45.7 28.7 27.1 to 30.4 65.3 63.8 to 66.8
Diff., difference.
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Conclusions
Thickness measurements differ signiﬁcantly between scanners. An additive correction using three separate
correction values, for the central, inner and outer regions, resulted in average errors of ≤ 3 µm.
As explained in Chapter 2, there were two criteria for judging that MO was present. The ﬁrst was that the
central ETDRS region thickness should be > 250 µm, or any of the inner ﬁve regions should be > 300 µm.
The ﬁnal decision on the presence of MO was made by examination of the OCT images for the presence
of intraretinal cyst or subretinal ﬂuid. As the thickness measurement was primarily being used to identify
those images that should be subjected to a visual examination, it was judged that the accuracy provided
by using the additive correction was sufﬁcient.21
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Chapter 4 Characteristics of study dataIntroductionThis chapter describes the data collected for this study. An initial analysis focuses on describing the subject
characteristics and the lesions that were present. This is followed by comparisons of subjects with and
without MO according to OCT.Methods for demographicsThe demographics of the data are described for all subjects and separately for those subjects whose MO
status could and could not be determined based on the information from OCT of both eyes. Univariate
methods are used to identify any substantial differences between them. Thereafter, subjects with
undetermined MO status are excluded from all analyses. Demographic data for subjects with MO in either
eye (or both) are compared with those without MO using simple univariate methods to identify potentially
important subject characteristics.
The proportions of subjects identiﬁed as having retinal thickening in the central region and within ETDRS
regions 1–5 in four different scanners were compared. The data from each centre were described in terms
of the number of subjects included and excluded, and the presence of MO in one or both eyes. The
presence or absences of different lesions per eye within one DD, and for exudates within one to two DD,
are compared across centres.
Combinations of lesions (M/DHs, BHs and exudates) are then considered. Subjects are classiﬁed into
mutually exclusive categories according to their most serious feature in the eye under consideration. The
categories are: exudates present within one DD (regardless of other lesions), BHs present within one DD
(but not exudates), M/DHs present within one DD (but not exudates or BHs), no lesions present within one
DD, or lesions other than M/DHs, BHs or exudates present within one DD. These lesion combinations are
also compared across centres by eye. Visual acuity is considered as a three category variable visual acuity
better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse)
and visual acuity missing. The presence of MO is considered in relation to these categories. More complex
analyses are left for the statistical modelling described in Chapter 5.ResultsOf 3540 subjects recruited into the study, 370 could not be used for the study (Figures 10 and 11)
according to the exclusion criteria given in Chapter 2 and one subject was excluded from part of the study
due to lost retinal photographs. Demographic data for all subjects, those included in further analyses and
those excluded, are presented in Table 3. Where several mutually exclusive categories are presented, the
percentages sum to 100% down the page. If there are only two possible categories, such as gender, then
the percentage in the named group is presented (e.g. 60.1% of subjects are male).
Excluded subjects
The centres were not able to verify the quality of all aspects of a particular subject's information at the
time of recruitment. However, checks of eligibility, and the quality and availability of data meant that
370 subjects were excluded for a variety of reasons, some for more than one reason. In 329 cases it was
not possible to assess the thickness of the macula in one or both eyes and so the subject could not be
classiﬁed as having MO present or absent, and in a further 41 cases retinal photographs from both eyes23
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Selected based on
photographic signs
(n = 3540) 
Eligible
(n = 3170)
Positive by manual
grading strategy 16
(n = 1599)   
Negative by manual
grading strategy 16
(n = 1505)   
Macula
oedema
present
(n = 214) 
Macula
oedema
absent
(n = 1389) 
Macula
oedema
present
(n = 29) 
Macula
oedema
absent
(n = 1538) 
Inadequate quality 
photograph
(n = 66) 
Positive
by OCT 
(n = 4)
Negative
by OCT
(n = 62) 
Positive
(n = 1603)
Negative
(n = 1567)
Excluded
OCT failure in at least
one eye (n = 329;
including n = 10 two
inadequate photographs)
•
• Two inadequate
photographs (n = 41)
IGURE 10 Study design for recruitment, with manual grading strategy 16 (see Table 19) as the diagnostic test and
ith the reference standard of MO presence. ‘Positive’ means that the image was judged to have MO.
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wwere of inadequate quality. The reasons, sometimes overlapping, for OCT failure included an enucleated
eye (one subject), errors in identifying the boundaries of the macula, low signal, evidence of movement of
the eye, positional error of the image or loss of the image. Of the 370 subjects excluded, 12 subjects were
found to have had previous laser treatment in one or both eyes. Sixty-eight subjects had poor clarity in
one or both photographs and nine subjects had an incorrect ﬁeld of view in one or both photographs.
For some subjects, both OCT and photographs were inadequate.
There were some statistically signiﬁcant differences between the 3170 subjects included in further analyses
and the 370 excluded. The large size of the study meant that some differences of small magnitude were
found to be statistically signiﬁcant. The excluded subjects tended to be older by 6 years and were slightly
more likely to be female. Asian or Black subjects were slightly more likely to be excluded (14.4% and 14.0%)
rather than Caucasian (9.8%). A higher percentage of subjects with type 2 diabetes were excluded (11.2%)
compared with subjects with type 1 diabetes (7.7%). Those with worse visual acuity (log-MAR ≥ 0.3) were
more likely to be excluded. There were clear differences between percentages of subjects excluded on the
four scanners: 15.9% of subjects on the Zeiss Stratus OCT, 13.9% on the Topcon 3D OCT-1000, 7.3% on
the Heidelberg Spectralis and 1.4% on the Zeiss Cirrus OCT. These ﬁndings should not be interpreted in
isolation. They could have been inﬂuenced by the fact that older people are more likely to have opacity and
because different scanners (with different qualities) were used in different centres.Prevalence of thickening and macular oedema
Among the 3170 subjects included in further analyses, there were signiﬁcant differences in the
percentages with thickening in region 1 [greatest for Zeiss Cirrus OCT (19.1%) and least for Zeiss StratusNIHR Journals Library www.journalslibrary.nihr.ac.uk
Selected based on
photographic signs
(n = 3540) 
Eligible
(n = 3169)
Excluded
    • OCT failure in at least 
 one eye (n = 329;
 including n = 10 two
 inadequate photographs)
    • Two inadequate photographs
 (n = 41)
    • Image unavailable (n = 1)
Positive by automated
analysis
(n = 1135)   
Negative by 
automated analysis
(n = 1961)   
Macula
oedema
present
(n = 201) 
Macula
oedema
absent
(n = 953) 
Macula
oedema
present
(n = 42) 
Macula
oedema
absent
(n = 1973) 
Inadequate quality (1 or 2 
eyes) and negative (0 or 1 
eye) by automated analysis
(n = 73) 
Positive
(n = 1154)
Negative
(n = 2015)
Positive by 
manual grading 
(strategy 16) 
(n = 19)
Negative by 
manual grading 
(strategy 16)
(n = 54) 
IGURE 11 Study design for recruitment, with automated image analysis as the diagnostic test and with the
eference standard of MO presence. ‘Positive’ means that the image was judged to have MO.
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rOCT (12.9%); comparison of all scanners p = 0.002] and also the percentages with thickness in at least
one of the regions 1–5 [greatest for Zeiss Cirrus OCT (30.4%) and least for Heidelberg Spectralis (20.4%);
comparison of all scanners p < 0.001]. The results are presented in Table 4. Note that the percentages sum
to 100% across the page in every third column.
There were clear differences between percentages of subjects with MO in at least one eye on the
four scanners: 11.8% of subjects scanned on Zeiss Cirrus OCT had MO, 8.7% on Heidelberg Spectralis,
6.5% on Topcon 3D OCT-1000 and 4.5% on Zeiss Stratus OCT (see Table 4). However, the type of
scanner was almost entirely confounded with centre as most centres used a single type of scanner and
some types of scanners were only used in a single centre. So the differences between scanners, as seen in
the percentages with MO, could be due to differences between centres or other confounding factors.
All 243 subjects classiﬁed as having MO had thickening in at least one of the ﬁve inner regions.
However, not all of those with thickness in at least one of these regions were classiﬁed as having MO after
further investigation.Counts of subjects and eye by centre
The numbers and percentages of subjects from each centre included and excluded from the study are
presented in Table 5. The percentages of subjects sum to 100% across the table. Eyes may be excluded for
more than one reason so percentages relating to eyes will not sum to 100% across the columns.25
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TABLE 3 Demographic information for all 3540 subjects recruited
Characteristic
All
subjects, n %
Subject
included
in further
analyses, n %
Subject
excluded
from further
analyses, n %
p-value
(included
vs.
excluded)
N 3540 3170 370
Age, years
(median, IQR)a
60 49, 70 60 49, 69 66 53, 75 < 0.001
Sex (male) 2128 60.1 1925 60.7 203 54.9 0.034
Ethnicity
Caucasian 2968 83.8 2678 84.5 290 78.4 0.036b
Asian 431 12.2 369 11.6 62 16.8
Black 86 2.4 74 2.3 12 3.2
Other 29 0.8 25 0.8 4 1.1
Unknown 26 0.7 24 0.8 2 0.5
Diabetes:
Type 1 768 21.7 709 22.4 59 15.9 0.013c
Type 2 2761 78.0 2452 77.4 309 83.5
Unspeciﬁed 5 0.1 4 0.1 1 0.3
Unknown 6 0.2 5 0.2 1 0.3
Amblyopia
(yes either eye)
110 3.1 86 2.7 24 6.5
Glitazone use
(yes)
198 5.6 177 5.6 21 5.7 1.000
Visual acuity
better leftc
3079 87.0 2807 88.5 302 81.6 0.001
Visual acuity
worse leftc
435 12.3 348 11.0 65 17.6
Visual acuity
left missing
18 0.7 15 0.5 3 0.8
Visual acuity
better rightc
3079 87.0 2794 88.1 285 77.0 < 0.001
Visual acuity
worse rightd
435 12.3 361 11.4 74 20.0
Visual acuity
right missing
26 0.7 15 0.5 11 3.0
Heidelberg
Spectralis
508 14.4 471 14.9 37 10.0 < 0.001
Topcon 3D
OCT-1000
870 24.6 749 23.6 121 32.7
Zeiss Cirrus OCT 910 25.7 897 28.3 13 3.5
Zeiss Stratus OCT 1252 35.4 1053 33.2 199 53.8
IQR, interquartile range.
a For each group of subjects, the three numbers presented for age are the median age in years and 25th and 75th
percentiles (the IQR) in years.
b Comparison of four categories as smallest combined.
c Comparison of three categories as smallest combined.
d Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
CHARACTERISTICS OF STUDY DATA
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TABLE 4 Thickness and presence of MO by OCT scanner
Scanner
Thickness in ETDRS region 1
(either eye)
Thickness in any ETDRS
region 1–5 (either eye) MO in either eye
Yes No Total Yes No Total Yes No Total
Heidelberg
Spectralis
72 399 471 96 375 471 41 430 471
15.3% 84.7% 100.0% 20.4% 79.6% 100.0% 8.7% 91.3% 100.0%
Topcon 3D
OCT-1000
110 639 749 165 584 749 49 700 749
14.7% 85.3% 100.0% 22.0% 78.0% 100.0% 6.5% 93.5% 100.0%
Zeiss Cirrus
OCT
171 726 897 273 624 897 106 791 897
19.1% 80.9% 100.0% 30.4% 69.6% 100.0% 11.8% 88.2% 100.0%
Zeiss Stratus
OCT
136 917 1053 238 815 1053 47 1006 1053
12.9% 87.1% 100.0% 22.6% 77.4% 100.0% 4.5% 95.5% 100.0%
Total 489 2681 3170 772 2398 3170 243 2927 3170
15.4% 84.6% 100.0% 24.4% 75.6% 100.0% 7.7% 92.3% 100.0%
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Demographics by macular oedema status
There were 3170 subjects with known MO status according to OCT: 243 with MO and 2927 without MO.
Demographics are presented in Table 6. Where several mutually exclusive categories are presented, the
percentages will sum to 100% when read down the table. If there are only two possible categories, such
as gender, then the percentage in the named group is presented (e.g. 60.5% of subjects with OCT MO
present are male). The percentages in Table 6 are calculated using the denominators of 243 and 2927, the
total number with MO and the total number without MO. Percentages given in the text below are
different and are calculated from the number with MO and a characteristic divided by the total number
with that characteristic.
There were some statistically signiﬁcant differences between the 243 subjects with MO and the
2927 subjects without MO. The subjects with MO tended have older median age by 8 years than those
without MO. There were no differences in the percentage with MO by gender, glitazone use or amblyopia.
A higher percentage of Caucasians (8.4%) had MO compared with other ethnic groups (3–4%). A higher
percentage of subjects with type 2 diabetes (8.7%) had MO compared with subjects with type 1 diabetes
(3.9%). Those with worse visual acuity (log-MAR ≥ 0.3) or missing visual acuity were more likely to have
MO. The age, diabetes type and visual acuity results were likely to have been confounded with each other
and this issue was addressed using multivariate analyses.Counts of subjects and eyes with macular oedema by centre
There were differences in the percentages of subjects with MO by centre (Table 7). Aberdeen, Dundee and
Oxford had a far higher prevalence of MO than the other centres. However, these could be due to
differences in demographics, presence of lesions, different interpretations of the recruitment strategy or, as
noted above, due to differences between scanners. The fact that differences between centres may be
measured or unmeasured is why centre was included in the models as an adjustment variable. There were
very few subjects with MO in both eyes (0–2.2%) across the seven different centres.
Presence of different types of lesion
Photographic feature information was missing for three left eyes and two right eyes so the denominator
for left eyes was 3167 and for right eyes was 3168. Counts of subjects and eyes with MO and features
in each eye are presented in Table 8. The same table split by centre is presented in in Appendix 3
(see Table 40). Subjects can have several different lesions or none within each eye.27
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ABLE 6 Demographics by OCT MO status
Characteristic
MO+ve (either eye) MO−ve (both eyes)
p-value
(oedema Y/N)n % n %
N 243 2927
Age, years (median, IQR)a 67 58, 75 59 48, 69 < 0.001
Sex (male) 147 60.5 1778 60.7 0.993
Ethnicity 0.015
Caucasian 223 91.8 2455 84.5
Asian 16 6.6 353 12.1
Black 2 0.8 72 2.5
Other/unknown 2 0.8 47 1.6
Diabetes < 0.001b
Type 1 28 11.5 681 23.3
Type 2 213 87.7 2239 76.5
Unspeciﬁed 2 0.8 2 0.1
Unknown 0 0.0 5 0.2
Amblyopia (either yes) 83 2.8 3 1.2 0.204
Glitazone use (yes) 10 4.1 167 5.7 0.372
Visual acuity (L) < 0.001
Better 163 67.1 2644 90.3
Worse 77 31.7 271 9.3
Missing 3 1.2 12 0.4
Visual acuity (R) < 0.001
Better 164 67.5 3630 89.9
Worse 74 30.5 287 9.8
Missing 5 2.1 10 0.3
Scanner < 0.001
Heidelberg Spectralis 41 16.9 430 14.7
Topcon 3D OCT-1000 49 20.2 700 23.9
Zeiss Cirrus OCT 106 43.6 791 27.0
Zeiss Stratus OCT 47 19.3 1006 34.4
Mutually exclusive categories < 0.001
Exudates less than one DD 144 59.3 880 30.1
Blots (no exudates) less than one DD 51 21.0 372 12.7
Microaneurysms less than one DD 44 18.1 1327 45.3
Exudates one to two DD 0 0.0 27 0.9
No relevant diabetic retinopathy features
more than two DD
4 1.6 321 11.0
−ve, negative; +ve, positive; IQR, interquartile range; L, left; N, no; R, right; Y, yes.
a For those subjects with MO+ve and MO-ve, the three numbers presented for age are the median age in years and
25th and 75th percentiles (the IQR) in years.
b Comparison of three categories of diabetes (type 1, type 2 and other) as unknown and unspeciﬁed combined for statistical test.
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51T29
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TABLE 7 Counts of subjects and eyes with MO by centre
Centre
Count of
subjects
included in
all analyses
Patients
with MO
in any eye
(%)
Count
of MO
in both
eyes
Subjects
% of
MO in
both
eyes
Count
of MO
in one
eye
% of
MO in
one
eye
Counts
of MO
in no
eyes
% of
MO in
no
eyes
Aberdeen 909 109 (12.0) 11 1.2 98 10.8 800 88.0
Birmingham 842 31 (3.7) 10 1.2 21 2.5 811 96.3
Dundee 254 31 (12.2) 4 1.6 27 10.6 223 87.8
Edinburgh 218 14 (6.4) 0 0.0 14 6.5 204 93.6
Liverpool 416 12 (2.9) 2 0.5 10 2.4 404 97.1
Dunfermline 159 7 (4.4) 1 0.6 7 3.8 152 95.6
Oxford 372 39 (10.5) 8 2.2 31 8.3 333 89.5
Total 3170 243 (7.7) 36 1.1 207 6.5 2927 92.3
CHARACTERISTICS OF STUDY DATA
30Mutually exclusive groups of lesions
Mutually exclusive (non-overlapping) groups of features were identiﬁed so that every eye could be
classiﬁed into one group and one group only. The groups for comparison were (1) M/DH only (not BH or
exudates), (2) BH but not exudates (BH only + BH and M/DH only), and (3) exudates (regardless of any
other feature being present). Prior to recruitment the three mutually exclusive groups of lesions were
expected to be present in 11.3%, 1.4% and 3.5% of all scanned images with 83.8% of images having no
M/DHs, BHs or exudates. Within the 16.2% of images expected to have lesions (the target population for
this study), the three groups of lesions were expected to be found in 69.8%, 8.6% and 21.6% of
images, respectively.
In this study, considering the left eyes only, the three groups of lesions were found in 40.3% (M/DHs only
within one DD), 8.4% (BH only or BH and M/DHs within one DD) and 20.4% (exudates only or with M/
DHs or BHs within one DD). In addition, 28.1% had no lesions within one DD and 2.8% had other lesions
within one DD. Very similar percentages were found in the right eyes: 41.7%, 8.7% and 18.9% with
27.9% having no lesions and 2.8% having other lesions. This information is presented by centre in
Appendix 3 (see Table 41).
As these percentages did not match those expected, particularly those for M/DHs only, weighting of the
subjects according to the features of their worst eye was considered necessary. This will be addressed
in the next chapter.
The mutually exclusive features within one DD in the left and right eyes are compared in Table 9. The
percentages shown in this table are out of the total of 3165 that had lesion information from both eyes.
Two hundred and twenty-two subjects (7.0%) had exudates in both eyes, 39 subjects (1.2%) had BHs in
both eyes and 566 subjects (17.9%) had M/DHs in both eyes. Of the 351 subjects (11.1%) that appear to
have none or other features within one DD in both eyes, 27 had exudates between one and two DD in at
least one eye, some had features such as ﬂames, drusen or CWS and 268 did not appear to have any
obvious features within one DD or exudates within two DD.
Conclusions
There were some signiﬁcant differences between the 3170 subjects retained for further analyses and the
370 (10.5%) which were excluded. Excluded subjects were slightly older, more likely to be female, more
likely to be Black or Asian and more likely to have type 2 diabetes or worse visual acuity. A higherNIHR Journals Library www.journalslibrary.nihr.ac.uk
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TABLE 9 Counts of subjects and percentages by mutually exclusive categories of features within one DD in left eye
and right eye
Left eye
(mutually exclusive categories)
Right eye (mutually exclusive categories)
Exudates in
one DD
BHs
(no exudates)
in one DD
M/DHs
(no BHs or
exudates) in
one DD
None/other
in one DD Total
Exudates in one DD 222 (7.0) 42 (1.3) 224 (7.1) 159 (5.0) 647 (20.4)
BHs (no exudates) in one DD 38 (1.2) 39 (1.2) 108 (3.4) 81 (2.6) 266 (8.4)
M/DHs (no BHs or exudates)
in one DD
206 (6.5) 120 (3.8) 566 (17.9) 382 (12.1) 1274 (40.3)
None/other in one DD 132 (4.2) 76 (2.4) 419 (13.2) 351 (11.1) 978 (30.9
Total 598 (18.9) 277 (8.8) 1317 (41.6) 973 (30.7) 3165 (100.0)
CHARACTERISTICS OF STUDY DATA
32percentage of subjects were excluded using the Zeiss Stratus OCT and Topcon 3D OCT-1000 than the
Heidelberg Spectralis and Zeiss Cirrus OCT. There were also differences in exclusions by centre, but these
were confounded by the scanner used.
The prevalence of MO differed greatly by centre ranging from 3.7% to 12.2%. It also differed between
scanners, ranging from 4.5% to 11.8%.
In simple analyses, patient characteristics associated with MO were older age, Caucasian ethnicity, and
having type 2 diabetes rather than type 1.There was no association between gender, amblyopia and
glitazone use with MO.
The presence of MO was associated with worse visual acuity.
The types and distributions of lesions in subjects recruited for this study were not typical of what would
be found in a cohort of people attending screening with lesions. Subjects with more severe lesions such
as exudates and BHs were over-represented and those with more minor lesions such as M/DHs were
under-represented. Consequently, weighting of the data was necessary for the more complex analyses to
reﬂect what would occur in practice.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Chapter 5 Inferring the presence of macular
oedema using retinal photographsIntroductionThis chapter addresses the ﬁrst aim of the project, namely to investigate whether or not particular
distributions and combinations of lesions (M/DHs, BHs and exudates), assessed manually or automatically,
are more speciﬁc surrogate markers of MO than current grading practice, using OCT as the
reference standard.
Initially statistical modelling was carried out to see if any of the current manual photographic screening
strategies included everything that might be considered important. In the second part of this chapter this
information is used to inform the inclusion of various eye and subject characteristics within computer-
assisted manual photographic screening strategies and full automated strategies for detecting MO.
National screening programmes in the UK all agree that exudates within one DD of the centre of the fovea
should be used to infer the presence of referable MO. However, there is disagreement as to how BHs or
M/DHs within one DD of the centre of the fovea should be used. The value of BHs or M/DHs in relation to
MO is therefore of particular interest.
The various lesions and lesion combinations within a single eye are investigated in relation to the presence
of MO in that eye. Counts of the three main types of lesions are investigated in a similar way. The ﬁndings
in Chapter 4, and from the analyses of single eyes, were used to guide the analyses predicting MO (in
either eye) from information on the subject and the two separate eyes.
As noted in Chapter 4, the combinations of lesion types and better and worse visual acuity did not occur
in this sample in the same proportions as expected from a cohort of all subjects attending retinal
screening. More complex analyses were weighted so that the results might better reﬂect what is expected
in such a cohort.Methods for statistical modellingCombinations of lesions (M/DHs, BHs and exudates) were considered in relation to MO. Subjects were
classiﬁed into mutually exclusive categories according to their most serious feature in the relevant eye. The
ﬁve categories were:
l exudates present within one DD (regardless of other lesions)
l BHs present within one DD (but not exudates)
l M/DHs present within one DD (but not exudates or BHs)
l other minor lesions (no M/DHs, BHs or exudates present) within one DD
l no lesions present within one DD.
These lesion combinations were also compared across centres by eye. Visual acuity was considered as a
three category variable: better visual acuity (log-MAR < 0.3), worse visual acuity (log-MAR ≥ 0.3) and visual
acuity missing.33
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34Single eye analyses
In order to investigate whether or not particular distributions and combinations of lesions identiﬁed by
manual screening (M/DHs, BHs and exudates) were valuable markers of MO, single eyes were considered
separately. Chi-squared tests were used to identify potential risk markers and confounding factors. Logistic
regression analyses were used on data from one eye only to identify features identiﬁed by manual
screening that might be important for predicting the presence of MO within the relevant eye. Different
representations of features including presence, count and distribution were considered.
Initially the presence of features within one DD (and for exudates within one to two DD) was investigated
in relation to MO within the same eye. In these initial analyses, only single features were considered, the
other features being ignored. Following that, analysis combinations of features were considered. The
presence of exudates between one and two DD was considered as a separate variable. These logistic
regression analyses considered the lesion variable alone (unadjusted), after adjusting for centre, and after
adjusting for centre, demographic variables and visual acuity in that eye.
Counts of the different types of lesions (exudates, BHs and M/DHs) within one DD (and for exudates within
one to two DD) were ﬁrst considered singly and then in combination in logistic regression analyses for MO in
the relevant eye. These analyses were also adjusted ﬁrst for centre, and then for demographic variables and
visual acuity in that eye. The ranges of counts of lesions were not the same for different types of lesions and
there was concern that results of analyses of counts could be dominated by high counts. As a sensitivity
analysis, counts of lesions were collapsed into zero, one, two, three, four, ﬁve and more than ﬁve, and this
count variable was included in the logistic regression analysis as if it was a discrete count. This was to ensure
that any relationships observed were robust to the inﬂuence of very high counts.
There is particular interest in the contribution of M/DHs to the prediction of MO as M/DHs are included in
current manual grading practice in England, but not in Scotland. In order to investigate whether or not larger
numbers of M/DHs were useful in predicting MO, the counts of all three types of lesions were collapsed even
further so they could be included in the logistic regression models as ordered categories: zero, one, two and
more than two. The opportunity to observe non-linear increases in the odds of MO with increasing numbers
of lesions was provided by this alternative representation of counts of lesions as four ordered categories.
As noted earlier, the combinations of lesion types and better and worse visual acuity did not occur in the
proportions expected from a cohort of subjects attending retinal screening and so data weighting was
necessary. Weighting of sample data is common in sample surveys either where the sampling scheme uses
unequal probabilities by design or if the data are known to be unrepresentative of the population,43 often
due to disproportionate non-response.44 If the sample is known to be substantially different to the
population in the distribution of one or more key variables then an analysis of the raw data can produce
biased estimates of prevalence. Reweighting can correct for bias in the estimates, but may have the effect
of increasing the variances and complicating the analysis.43 In the current study, if a statistic, such as the
sensitivity of a diagnostic algorithm, differs between types of subjects, then the estimate of sensitivity
based on the raw sample data could be biased towards the sensitivity within subjects who are
over-represented and away from the sensitivity within those under-represented. The under-representation
of subjects with only M/DHs was of particular concern. The simplest form of weight, sometimes called
direct weights or post-stratiﬁcation weights, was used.44–46
The weighting of subjects was performed as follows. The proportions of subjects falling into the ﬁve
categories were calculated for the study sample, the expected proportions in the ﬁve categories being
known from a previous study.30 Weights were obtained by dividing the proportions of subjects in the study
sample by the proportions in the population and then multiplying by a factor of 3170/2845 to account for
the zero weighting of 325 subjects with either no lesions or only very mild lesions in either eye. Where
appropriate, the analyses described above were repeated after weighting. Ideally weighting would have been
done to correspond to the population proportions of the ﬁve groups within each centre, but these were not
known at each centre. This weighting was also used in the health economics analyses in Chapter 6.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Both eyes analysis
Information on features from both eyes was combined in order to look at the prediction of presence
of MO (in one or both eyes) per subject. The most serious feature in either eye was given priority in
determining the classiﬁcation of the subject by their lesions. The mutually exclusive categories chosen were:
l any exudates in either eye
l any BHs (but no exudates) in either eye
l more than two M/DHs in either eye (but no exudates or BHs)
l exactly two M/DHs in the eye with most M/DHs (but no exudates or BHs)
l exactly one M/DH in the eye with most M/DHs (but no exudates or BHs)
l those with no M/DHs in either eye and those subjects with lesions which were not M/DHs, BHs or
exudates in either eye.
Poor vision was classiﬁed as worse (if visual acuity was log-MAR ≥ 0.3 in either eye or if visual acuity was
missing in one eye and log-MAR ≥ 0.3 in the other), better (if visual acuity was log-MAR < 0.3 in both
eyes) or missing (if visual acuity was missing in one eye and better in the other or missing in both eyes).
Logistic regression was used to investigate this representation of the lesions in relation to predicting the presence
of MO in at least one eye. The analysis was repeated ﬁrst for centre and visual acuity, and then for centre, visual
acuity and demographic factors. The analyses of both eyes together were repeated after weighting.Results of statistical modelling
Presence of individual lesion types in relation to macular oedema
In Table 10 the presence or absence of a particular type of lesion in the relevant eye is considered. No
adjustments were made for other lesions that might also have been present. A large difference between
the percentages of subjects with MO and without MO and with a certain type of lesion present may be
due to the presence of another type of lesion.
Macular oedema was roughly ﬁve times more prevalent among subjects with an exudate, a BH or a M/DH
present within one DD compared with those with the same lesion absent (see Table 10). The prevalence of
MO was also greater, albeit by a lesser amount, for subjects having an exudate within one to two DD, but
no consideration was given whether or not there was an exudate within one DD as well. Too few eyes had
CWS for a robust analysis. There were few eyes with ﬂame haemorrhages or drusen so although there
were sufﬁcient eyes for these comparisons to be made, multivariate analyses were not considered
appropriate. There did not appear to be any evidence of a relationship between the presence of drusen
and the presence of MO in the relevant eye.
Subjects with worse visual acuity were about ﬁve times as likely to have MO in the relevant eye as those
with better visual acuity.
Only a small number of subjects had amblyopia and, of these, very few had MO. There were no signiﬁcant
differences in the percentages with MO between those using and not using glitazone. In later analyses
adjustment was made for glitazone use, but this was not possible for amblyopia because of the small
numbers of subjects.
When mutually exclusive groups of lesions were considered, highly signiﬁcant differences in the percentages
with MO were found. More than 10% of subjects with exudates or with BHs (but not exudates) had MO in
the same eye. The percentage with MO was just over 2% of those with just M/DHs present in the same eye,
about 1% of those with lesions excluding M/DHs, BHs and exudates and < 1% with no lesions in that eye.35
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Visual acuity was not available for 15 left eyes, two of which had MO, and for 15 right eyes, four of which
had MO.Logistic regression analyses of single eyes
Most of the following tables in this section are for the left eye only. Analyses of the right eyes were also
completed but since they showed almost identical relationships these results have not been presented.
Table 11 shows the results of logistic regression analysis of a single eye with the outcome variable of MO
in that eye. The odds ratio (OR) shows the increase in the odds of having MO in a subject with a
characteristic compared with a subject without that characteristic. For a measured variable, such as age,
the OR represents the change in the odds of having MO if that variable were to increase by one unit of
measurement (1 year older) relative to the same subject without that increase. If multiple variables are
included in the same logistic regression model then the OR for a single variable represents the increase in
the odds of having MO if that variable were to increase by one unit of measurement, or to change to a
different category, compared with a subject with all other characteristics and measurements held ﬁxed.
In Table 11, the top category for each of the categorical variables is chosen as the reference group with
OR shown as 1 and no CI displayed. The choice of the reference group is arbitrary and this does not affect
statistical signiﬁcance. The other ORs presented are relative to this reference group and a 95% CI is
displayed in the next two columns. If this 95% CI includes 1 it shows that the OR is not signiﬁcantly
different to 1 (the null value) and so p > 0.05. If the 95% CI excludes 1 it indicates that this measured
variable is signiﬁcant for MO with p < 0.05 or that this categorical variable is signiﬁcant with p < 0.05 and
the relevant category is signiﬁcantly different to the reference category in terms of the odds of having MO.
The ﬁrst three columns of numbers show ORs and the lower and upper 95% conﬁdence limits for each
variable considered separately (unadjusted). The fourth to sixth columns show the ORs and 95% CIs for the
variables adjusted for differences between centres. Ideally simultaneous adjustments would be made for
centre and scanner type, but they are highly confounded with each other and so could not be included
together in the same model. The feature results were similar regardless of whether they were adjusted for
centre or scanner so adjustment has only been made for centre. The seventh to the ninth columns show the
ORs and 95% CIs for the variables adjusted for centre, gender, age, glitazone and diabetes (type 1, type 2
and secondary/unknown). The last three columns show the ORs and 95% CIs for the variables adjusted for
centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/unknown) and visual acuity.
When the mutually exclusive groups of lesions were included in the model, subjects with BHs (either on their
own or BH with M/DHs) had 5.0 times the odds of having MO and subjects with exudates had 6.4 times the
odds of having MO, both compared with those with only M/DHs. These ORs changed by only modest amounts
as adjustments were made for centre and other characteristics to ORs of 3.6 and 6.7. Of these other variables,
only centre, age and visual acuity were signiﬁcant with older age being associated with higher odds of MO by
4% per additional year older (OR = 1.037; 95% CI 1.020 to 1.054). When visual acuity was included, having
worse visual acuity signiﬁcantly increased the odds of MO by a factor of 3.9 (95% CI 2.6 to 5.9).
An analysis of counts of lesions found that higher numbers of M/DHs, BHs and exudates within one DD
signiﬁcantly increased the odds of having MO when considered separately or together. The relationships
were maintained after adjustment for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/
unknown) and visual acuity. Initially, counts of exudates between one to two DD appeared to be associated
with greater odds of MO, but as this ceased to be signiﬁcant after adjusting for exudates within one DD so it
was dropped from subsequent models. It is important to note that the count of M/DHs within one DD was
statistically signiﬁcant after adjusting for centre, the count of BHs and the count of exudates. This suggested
that having a lot of M/DHs was still useful for predicting MO.
The OR for counts of BHs was larger than for the other lesions. This does not mean BHs were more
important, but that the increase in the odds of MO for each additional BH was larger than for each37
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51additional M/DH or exudate. It was thought that this could be a consequence of there being a smaller
range of counts of BHs across subjects than the range of counts of M/DHs or exudates.
The maximum numbers of exudates and M/DHs within a single eye of a single subject were 59 and 50,
respectively, much higher than the maximum of 16 BHs within a single eye of a single subject. A sensitivity
analysis was carried out with the counts of lesions ﬁtted as a discrete measured variable taking a maximum
value of six (so zero, one, two, three, four, ﬁve, and more than ﬁve). The ORs (not shown) were larger for
each extra lesion of any type. The inferences of these results were consistent with those shown for raw
counts meaning that differences in ranges of counts of different lesions were not responsible for the larger
ORs for counts of BHs compared with ORs for counts of exudates or M/DHs.
See Table 42 for the corresponding data for the right eye.
A simple descriptive analysis of count data was completed representing the counts of lesions of the three
main types as ordered categories: zero, one, two and more than two (Table 12). The percentages of
subjects with MO increased from 1% to 2% to > 3% when the number of M/DHs within one DD
increased to more than two. These results suggested that this might be a useful representation when
investigating the value of M/DHs in predicting MO.TABLE 12 Macular oedema status per eye by presence of features in that eye
Lesions category
within one DD
in relevant eye
MO status in relevant eye
No OCT MO
found in
left eye
OCT MO
found in
left eye
Total in
left eye
No OCT MO
found in
right eye
OCT MO
found in
right eye
Total in
right eye
One M/DH,
no exudate, no BH
488 5 493 492 8 500
99.0% 1.0% 100.0% 98.4% 1.6% 100.0%
Two M/DHs,
no exudate, no BH
251 5 256 298 6 304
98.0% 2.0% 100.0% 98.0% 2.0% 100.0%
Three or more
M/DHs, no exudate,
no BH
508 18 526 499 17 516
96.6% 3.4% 100.0% 96.7% 3.3% 100.0%
Only BH, no M/DH,
no exudate
61 2 63 56 4 50
96.8% 3.2% 100.0% 93.3% 6.7% 100.0%
BH + one M/DH,
no exudate
45 2 47 43 1 44
95.7% 4.3% 100.0% 97.7% 2.3% 100.0%
BH + two M/DHs,
no exudate
25 0 25 41 1 42
100.0% 0.0% 100.0% 97.6% 2.4% 100.0%
BH + three or more
M/DHs, no exudate
108 23 131 106 25 131
82.4% 17.6% 100.0% 80.9% 19.1% 100.0%
Exudate + any other
lesion
566 81 647 531 67 598
87.5% 12.5% 100.0% 88.8% 11.2% 100.0%
None/other 971 8 979 967 6 973
99.2% 0.8% 100.0% 99.4% 0.6% 100.0%
Total 3023 144 3167 3033 135 3168
95.5% 4.5% 100.0% 95.7% 4.3% 100.0%
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40This pattern was also reﬂected in the results presented in Table 13, which shows that the odds of having
MO increased by a non-signiﬁcant factor with one or two M/DHs within one DD in comparison with
having no M/DHs. However, the OR of having MO dramatically increased to 6.4 when there were more
than two M/DHs. This relationship was maintained (OR = 5.2; 95% CI 3.0 to 8.9) after adjusting for the
counts of other lesions represented in the same way, and also centre, gender, age, glitazone, diabetes and
visual acuity. The fact that the count of several M/DHs within one DD was statistically signiﬁcant after
adjusting for centre, the count of BHs, the count of exudates and visual acuity, suggested that while
having any M/DHs might be of little value in predicting MO, having a lot of M/DHs in an eye was still
useful for predicting MO in that eye. See Table 43 for the corresponding data for the right eye.
The unweighted analyses presented in Tables 11 and 13 were repeated using weighted analyses, the
results are presented in Tables 14 and 15. These analyses had the effect of up-weighting data from
subjects with M/DHs and down-weighting data from subjects with more serious lesions. This small inﬂation
had no inﬂuence on the ORs, but made CIs narrower by a very small amount. See Tables 44 and 45,
respectively, for the corresponding data for the right eye.TABLE 13 Relationship of individual lesions within one DD to left eye MO (ORs; analysis unweighted)
Left eye
Feature category
within DD
(mutually exclusive)
Unadjusted
ORa
Lower
95% CI
Upper
95% CI
Adjusted
ORb
Lower
95% CI
Upper
95% CI
Adjusted
ORc
Lower
95% CI
Upper
95% CI
Zero M/DHs 1.00 1.00 1.00
One M/DH 0.87 0.41 1.85 0.78 0.35 1.72 0.90 0.41 2.01
Two M/DHs 1.85 0.90 3.79 1.69 0.79 3.60 1.90 0.89 4.10
More than
two M/DHs
6.27 3.89 10.11 4.18 2.45 7.13 5.16 2.97 8.94
Zero BHs 1.00 1.00 1.00
One BH 4.75 3.11 7.24 3.12 1.96 4.98 2.82 1.76 4.54
Two BHs 6.54 3.21 13.34 2.46 1.07 5.61 2.29 0.98 5.34
More than
two BHs
20.45 11.08 37.72 6.84 3.39 13.78 5.30 2.61 10.79
Zero exudates 1.00 1.00 1.00
One exudate 3.30 1.70 6.41 2.39 1.15 4.99 2.81 1.33 5.92
Two exudates 3.25 1.45 7.31 2.83 1.12 7.11 3.81 1.51 9.64
More than
two exudates
6.98 4.84 10.07 4.09 2.69 6.19 5.04 3.26 7.78
Visual acuity
betterd
1.00 1.00 1.00
Visual acuity
worsed
6.07 4.24 8.68 5.32 3.51 8.07 3.95 2.55 6.12
Visual acuity
unknown/missing
4.87 1.08 21.91 7.78 1.39 43.43 4.02 0.66 24.58
a Unadjusted results.
b Adjusting for centre, other features and visual acuity.
c Adjusting for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/unknown) and visual acuity.
There were too few with amblyopia to adjust for this.
d Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
NIHR Journals Library www.journalslibrary.nihr.ac.uk
TA
B
LE
14
R
el
at
io
n
sh
ip
o
f
in
d
iv
id
u
al
le
si
o
n
s
to
le
ft
ey
e
M
O
(a
n
al
ys
is
w
ei
g
h
te
d
)
Le
ft
ey
e
Fe
at
u
re
ca
te
g
o
ry
(m
u
tu
al
ly
ex
cl
u
si
ve
)
U
n
ad
ju
st
ed
O
R
a
Lo
w
er
95
%
C
I
U
p
p
er
95
%
C
I
A
d
ju
st
ed
O
R
b
Lo
w
er
95
%
C
I
U
p
p
er
95
%
C
I
A
d
ju
st
ed
O
R
c
Lo
w
er
95
%
C
I
U
p
p
er
95
%
C
I
A
d
ju
st
ed
O
R
d
Lo
w
er
95
%
C
I
U
p
p
er
95
%
C
I
M
/D
H
1.
0
1.
0
1.
0
1.
0
BH
no
t
ex
ud
at
e
4.
4
2.
1
9.
1
3.
6
1.
7
7.
6
3.
1
1.
5
6.
7
3.
1
1.
4
6.
8
Ex
ud
at
e
+
an
y
6.
0
3.
9
9.
2
5.
2
3.
3
8.
2
6.
3
3.
9
10
.1
5.
8
3.
6
9.
4
C
o
u
n
t
o
f
le
si
o
n
s
o
f
e
a
ch
ty
p
e
M
/D
H
1.
22
1.
17
1.
27
1.
17
1.
11
1.
22
1.
17
1.
12
1.
23
1.
17
1.
12
1.
23
BH
2.
52
2.
01
3.
16
1.
51
1.
18
1.
94
1.
43
1.
11
1.
84
1.
41
1.
09
1.
83
Ex
ud
at
e
1.
19
1.
14
1.
23
1.
14
1.
10
1.
18
1.
15
1.
11
1.
20
1.
15
1.
11
1.
20
Ex
ud
at
e
in
a
on
e
to
tw
o
D
D
e
1.
05
1.
03
1.
07
a
U
na
dj
us
te
d
re
su
lts
.
b
A
dj
us
tin
g
fo
r
ce
nt
re
.
c
A
dj
us
tin
g
fo
r
ce
nt
re
,
an
d
th
e
ot
he
r
fe
at
ur
es
.
d
A
dj
us
tin
g
fo
r
ce
nt
re
,
ge
nd
er
,
ag
e,
gl
ita
zo
ne
,
di
ab
et
es
(t
yp
e
1,
ty
pe
2
an
d
se
co
nd
ar
y/
un
kn
ow
n)
an
d
vi
su
al
ac
ui
ty
.
Th
er
e
w
er
e
to
o
fe
w
w
ith
am
bl
yo
pi
a
to
ad
ju
st
fo
r
th
is
.
e
C
ou
nt
s
of
ex
ud
at
es
be
tw
ee
n
on
e
an
d
tw
o
D
D
is
no
n-
si
gn
iﬁ
ca
nt
af
te
r
ad
ju
st
in
g
fo
r
th
e
pr
es
en
ce
of
ex
ud
at
es
w
ith
in
on
e
D
D
an
d
so
is
dr
op
pe
d
fr
om
su
bs
eq
ue
nt
m
od
el
s.
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51
41
© Queen's Printer and Controller of HMSO 2013. This work was produced by Olson et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
ABLE 15 Relationship of individual lesions within one DD to left eye MO (OR; analysis weighted)
Left eye
Feature category
(mutually exclusive)
Unadjusted
ORa
Lower
95% CI
Upper
95% CI
Adjusted
ORb
Lower
95% CI
Upper
95% CI
Adjusted
ORc
Lower
95% CI
Upper
95% CI
Zero M/DHs 1.00 1.00 1.00
One M/DH 0.81 0.36 1.81 0.85 0.37 1.98 0.91 0.39 2.10
Two M/DHs 1.74 0.79 3.79 1.94 0.86 4.37 2.06 0.91 4.69
More than two
M/DHs
5.18 2.94 9.14 4.32 2.33 8.00 4.96 2.64 9.32
Zero BHs 1.00 1.00 1.00
One BH 6.06 3.41 10.77 2.78 1.43 5.40 2.49 1.27 4.88
Two BHs 8.82 3.19 24.43 2.21 0.66 7.39 1.97 0.58 6.76
More than two BHs 23.37 10.00 54.60 5.95 2.20 16.06 4.85 7.79 13.18
Zero exudates 1.00 1.00 1.00
One exudate 3.87 1.65 9.08 2.39 0.92 6.21 2.78 1.06 7.31
Two exudates 3.81 1.33 10.90 2.74 0.83 9.04 3.41 1.02 11.36
More than two
exudates
8.18 5.28 12.67 3.96 2.36 6.66 4.67 2.73 7.99
Visual acuity betterd 1.00 1.00 1.00
Visual acuity worsed 7.40 4.91 11.14 6.22 3.91 9.89 4.85 2.99 7.88
Visual acuity
unknown/missing
4.58 0.52 40.08 9.09 0.69 119.12 5.38 0.37 78.04
a Unadjusted results.
b Adjusting for centres and visual acuity.
c Adjusting for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/unknown) and visual acuity.
There were too few with amblyopia to adjust for this.
d Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
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42TWhen the mutually exclusive groups of lesions were included in the model, subjects with BHs (alone or BH
with M/DHs) had 4.4 times the odds of having MO and subjects with exudates had 6.0 times the odds of
having MO, both compared with those with only M/DHs. After adjusting for centre and other characteristics,
these ORs changed by only modest amounts to 3.1 and 5.8, respectively. Of these other variables, only
centre, age and visual acuity were signiﬁcant with older age being associated with higher odds of MO by
3% per additional year older (OR = 1.031; 95% CI 1.011 to 1.051). When visual acuity was included, having
worse visual acuity signiﬁcantly increased the odds of MO by a factor of 3.8 (95% CI 2.3 to 6.3).
An analysis of counts of lesions found that higher counts of M/DHs, BHs and exudates within one DD,
considered separately and together, signiﬁcantly increased the odds of having MO. The relationships were
maintained after adjustment for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/
unknown) and visual acuity. Initially, counts of exudates between one to two DD appeared to be
associated with greater odds of MO, but this ceased to be signiﬁcant after adjusting for exudates within
one DD so this count was dropped from subsequent models.
It is important to note here, as with the unweighted analyses, that the count of M/DHs within one DD is
statistically signiﬁcant after adjusting for centre and the count of BHs and the count of exudates. This
suggests that having a lot of M/DHs is still useful for predicting MO.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51The OR for counts of BHs was again larger than for the other lesions. This does not mean that BHs were
more important, but that the increase in the odds of MO for each additional BH was larger than for each
additional M/DH or exudate. It was thought that this could be a consequence of there being a smaller
range of counts of BHs across subjects than the range of counts of M/DHs or exudates, but as with the
unweighted analyses, a sensitivity analysis showed that this was not the case.
This pattern of the increasing prevalence of MO with increasing numbers of lesions was also reﬂected in
the results presented in Table 13. The odds of having MO increased by a non-signiﬁcant factor with one or
two M/DHs within one DD in comparison to having no M/DHs and the OR of having MO dramatically
increased to 5.2 when there were more than two M/DHs. This relationship was maintained (OR = 5.0; 95%
CI 2.6 to 9.3) after adjusting for the counts of other lesions represented in the same way: centre, gender,
age, glitazone, diabetes and visual acuity.
Some of the ORs presented in Table 15 were large with very wide CIs, particularly those for having several
BHs. This was because weighting had the effect of reducing the apparent number of subjects with BHs
and subjects with MO. This would tend to make the estimates of ORs and their CIs more volatile. After
adjustment for centre, gender, age, glitazone use, diabetes type and visual acuity these estimates of the
ORs for having BHs were more stable and had inferences more similar to the earlier unweighted analyses.
The CIs for missing visual acuity were very wide and the width varied greatly because of the very small
numbers with missing visual acuity.Relationship of individual lesions in both eyes to macular oedema in either
eye (analysis unweighted)
Single eye analyses are simple to interpret and are helpful in establishing factors which might contribute to
a prediction model. However, they do not show how a strategy might work on a subject where
information about the possibility of MO comes from both eyes. Mutually exclusive groups were deﬁned
taking information about lesions within one DD from both eyes (Table 16). The most serious lesions in
either eye took priority in assigning subjects to six groups. Any exudates within one DD in either eye
meant the subject was assigned to the exudates group. A BH within one DD in either eye, without any
exudates, meant the subject was assigned to the BH group. For those with M/DHs in both eyes (and no
BHs or exudates) or M/DHs (and no BHs or exudates) in one eye and no exudates or BH in the other, the
group was deﬁned by the number of M/DHs within one DD in the eye with the most M/DHs. A subject
with no M/DHs, BHs or exudates within one DD was assigned to the ‘None/other both eyes’ group.
Subjects were also classiﬁed into three groups according to visual acuity [better visual acuity (log-MAR
< 0.3; Snellen 6/9.5 or better) in both eyes, worse visual acuity (log-MAR ≥ 0.3; Snellen 6/12 or worse) in
at least one eye, missing visual acuity in both eyes or missing visual acuity in one and better visual acuity in
the other]. The percentage of subjects with MO was calculated for each combination of visual acuity and
lesions. There was a substantial two- to fourfold increase in the percentage with MO if visual acuity was
worse rather than better in all of the lesion groups. There were very few subjects with MO among those
subjects with better visual acuity and zero to two M/DHs within one DD in either eye.
Logistic regression of the relationship of individual lesions in both eyes to
macular oedema in either eye (analysis unweighted)
Odds ratios for three models for predicting MO are presented in Table 17. From left to right these models
include: only lesion type and the count of M/DHs (the unadjusted ORs for visual acuity are also presented here);
lesion type and the count of M/DHs adjusted for centre and visual acuity; and lesion type and the count of
M/DHs adjusted for centre, visual acuity and demographic variables. Exudates, BHs or more than two M/DHs
within one DD in either eye were all predictive of having MO, as was worse visual acuity. Having one or two
M/DHs within one DD in an eye did not appear to be any different to having none/other mild lesions. The odds
of having MO were increased by factors of 11.2 for having at least one eye with an exudate, 5.9 for having at
least one eye with a BH (but no exudates), 3.4 for having more than two M/DHs relative to having eyes with a
maximum of one M/DH in either. Having a M/DH in one or both eyes was not signiﬁcantly different to having
a maximum of two M/DHs in either eye or having no lesions or mild lesions (not a M/DH, BH or exudate).43
© Queen's Printer and Controller of HMSO 2013. This work was produced by Olson et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
ABLE 16 Presence of MO in either eye by most severe lesion present within one DD, count of M/DHs present
ithin one DD and visual acuity
Lesion
grouping
Better visual acuity in
both eyes
Worse visual acuity in at least
one eye
Visual acuity missing in both
eyes or missing in one and
better in the other
MO either
eye
MO
absent Total
MO either
eye
MO
absent Total
MO either
eye
MO
absent Total
None/other
both eyes
1 278 279 3 67 70 0 2 2
0.4% 99.6% 100.0% 4.3% 95.7% 100.0% 0.0% 100.0% 100.0%
At most
one M/DH,
either eye
4 416 420 4 63 67 0 2 2
1.0% 99.0% 100.0% 6.0% 94.0% 100.0% 0.0% 100.0% 100.0%
At most
two M/DHs
in either eye
6 258 264 2 39 41 0 0 0
2.3% 97.7% 100.0% 4.9% 95.1% 100.0% 0.0% 0.0% 0.0%
More than
two M/DHs,
either eye
17 475 492 11 69 80 0 1 1
3.5% 96.5% 100.0% 13.8% 86.2% 100.0% 0.0% 100.0% 100.0%
BH
(not exudate),
either eye
22 296 318 29 74 103 0 3 3
6.9% 93.1% 100.0% 28.2% 71.8% 100.0% 0.0% 100.0% 100.0%
Exudate,
either eye
82 752 834 61 126 187 1 1 2
9.8% 90.2% 100.0% 32.6% 67.4% 100.0% 50.0% 50.0% 100.0%
Total 132 2475 2607 110 438 548 1 9 10
5.1% 94.9% 100.0% 20.1% 79.9% 100.0% 10.0% 90.0% 100.0%
Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
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wHaving worse visual acuity was predictive of MO and appeared to increase the odds of having MO by a
factor of 3.3. Having worse visual acuity increased the size of the odds of MO for all types of lesion and
the size of this increase was not signiﬁcantly different between lesions types.
The ORs for the fully adjusted model including lesions, centre, visual acuity and demographic variables are
given in the ﬁnal three columns. Other variables which were signiﬁcant in this fully adjusted model were
age and centre. For every additional year older the odds of having MO increased by a factor of 1.035
(95% CI 1.022 to 1.049) in other words by 3.5% per year older.
Subjects with one M/DH within one DD in one or both eyes were taken as the reference group so ORs for
having MO in either eye are calculated compared with this group. It was not appropriate to take the group
with no lesions/other lesions as the reference group for the analyses of both eyes because many of this
group would be zero weighted in the weighted analyses.
The 95% CI for the OR of having MO in those with, at most, two M/DHs within one DD in either eye
relative to at most one M/DH in either eye included 1. This was also true of the CI for no lesions or lesions
other than M/DHs, BHs or exudates in either eye. This meant that there was no signiﬁcant difference in the
odds of having MO in these subjects compared with subjects with at most one M/DH within one DD in
either eye. The fact that the count of several M/DHs within one DD was statistically signiﬁcant after
adjusting for centre, the count of BHs and the count of exudates suggested that having a lot of M/DHs
within one DD was still useful for predicting MO. This remained true after adjusting for other variables
including visual acuity.NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 17 Relationship of individual lesions within one DD to both eyes MO (OR; analysis unweighted)
Both eyes
Feature category
(mutually exclusive)
Unadjusted
ORa
Lower
95% CI
Upper
95% CI
Adjusted
ORb
Lower
95% CI
Upper
95% CI
Adjusted
ORc
Lower
95% CI
Upper
95% CI
At most one M/DH,
either eyed
1.00 1.00 1.00
At most two M/DHs,
either eye
1.62 0.60 4.36 1.62 0.59 4.41 1.59 0.58 4.38
More than two
M/DHs, either eye
3.09 1.40 6.84 3.00 1.34 6.71 3.35 1.49 7.55
BH (not exudate),
either eye
8.22 3.85 17.53 6.19 2.85 13.42 5.89 2.70 12.85
Exudate, either eye 9.85 4.79 20.25 8.77 4.20 18.33 11.21 5.31 23.66
None/other both
eyes
0.69 0.21 2.32 0.55 0.16 1.85 0.49 0.15 1.67
Visual acuity bettere 1.00 1.00 1.00
Visual acuity worsee 4.70 3.58 6.17 4.25 3.18 5.70 3.35 2.46 4.56
Visual acuity
unknown/missing
1.44 0.19 11.11 3.03 0.36 25.73 2.09 0.25 17.86
a Unadjusted results.
b Adjusting for centre and visual acuity.
c Adjusting for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/unknown) and visual acuity. There
were too few with amblyopia to adjust for this.
d Subjects with one M/DH within one DD in one or both eyes are taken as the reference group.
e Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51TIf the 11 subjects with missing visual acuity were excluded, the results were almost identical to those
above. With this restriction it was possible to include an interaction between visual acuity and the feature
category. There was no evidence of an interaction between these variables and this suggested that both
lesion category and visual acuity were important in predicting presence of MO, but the strong effect of
having worse visual acuity did not vary between different lesion groups.
The receiver operating curves shown in Figure 12 correspond to the three models presented in Table 17.
The model that included only the lesion categories within one DD in at least one eye [at least one M/DH,
two M/DHs, more than two M/DHs, at least one BH (but no exudates), at least one exudate] had a receiver
operating characteristic curve made up of straight lines between the points (sensitivity and 1-speciﬁcity)
corresponding to the threshold being changed to include an extra category. For example, if only subjects
with at least one exudate were referred, then the sensitivity and speciﬁcity would be 0.59 and 0.70,
respectively. If subjects with at least one exudate and subjects with at least one BH were referred, then the
sensitivity and speciﬁcity would be 0.80 and 0.57, respectively (1 − speciﬁcity = 0.43). The other two
receiver operating characteristic curves correspond to the other two models presented in Table 17 where
one model included lesion type and the count of M/DHs, centre and visual acuity, and the other model
included lesion type and count of M/DHs, centre, visual acuity and demographic variables. There were
gains in sensitivity and speciﬁcity from choosing more complex models as would usually be expected.
Relationship of individual lesions in both eyes to macular oedema in either
eye (analysis weighted)
Similar models to those in Table 17 are presented in Table 18 for weighted data. Subjects with no lesions
in either eye or only lesions other than exudates, BHs and M/DHs within one DD were removed from this
analysis. For the weighted data exudates, BHs or more than two M/DHs within one DD in either eye were45
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IGURE 12 Receiver operating characteristic curves for models that are presented in Table 17 for MO in one eye or
oth eyes. VA, visual acuity.
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bTABLE 18 Relationship of individual lesions within one DD to both eyes MO (analysis weighted)
Both eyes
Feature category
(mutually exclusive)
Unadjusted
ORa
Lower
95% CI
Upper
95% CI
Adjusted
ORb
Lower
95% CI
Upper
95% CI
Adjusted
ORc
Lower
95% CI
Upper
95% CI
At most one M/DH,
either eye
1.00 1.00 1.00
At most two M/DHs,
either eye
1.62 0.77 3.43 1.61 0.75 3.45 1.63 0.75 3.52
More than two
M/DHs, either eye
3.09 1.69 5.64 3.09 1.67 5.71 3.45 1.86 6.42
BH (not exudate),
either eye
8.21 3.96 17.01 6.23 2.92 13.27 5.91 2.75 12.70
Exudate either, eye 9.85 5.53 17.56 8.82 4.83 16.11 10.96 5.92 20.29
Visual acuity betterd
Visual acuity worsed 4.70 3.42 6.45 4.01 2.85 5.62 3.28 2.29 4.68
Visual acuity
unknown/missing
2.09 0.14 31.31 3.28 0.20 53.19 2.34 0.14 38.17
a Unadjusted results.
b Adjusting for centre and visual acuity.
c Adjusting for centre, gender, age, glitazone, diabetes (type 1, type 2 and secondary/unknown) and visual acuity.
d Visual acuity better (log-MAR < 0.3; Snellen 6/9.5 or better), visual acuity worse (log-MAR ≥ 0.3; Snellen 6/12 or worse).
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51all predictive of having MO, as was worse visual acuity (see Table 18). Having one or two M/DHs within
one DD in an eye did not appear to change the odds of MO.
There were some large ORs observed in the table, again due to the down-weighting of the subjects with
more severe groups of lesions so the estimates were more volatile than for the unweighted analyses. This
was less pronounced after adjustment for other variables. The odds of having MO were increased by
factors of 11.0 for having at least one eye with an exudate, 5.9 for having at least one eye with a BH (but
no exudates) and 3.5 for having more than two M/DHs within one DD relative to having eyes with a
maximum of one M/DH within one DD in either. Having a maximum of two M/DHs within one DD in
either eye was not signiﬁcantly different to having a M/DH in one or both eyes.
Having worse visual acuity was predictive of MO and appeared to increase the odds of having MO by a
factor of 3.3. Having worse visual acuity increased the size of the odds of MO for all types of lesion and
the size of this increase was not signiﬁcantly different between lesions types.
The ORs for the fully adjusted model including lesions, centre, visual acuity and demographic variables are
given in the ﬁnal three columns. Other variables which were signiﬁcant in the fully adjusted model
were age and centre. For every additional year older the odds of having MO increased by a factor of
1.029 (95% CI 1.014 to 1.044); in other words by 3.0% per year older.
As for the unweighted analysis, the 95% CI for the OR of having MO in those with at most two M/DHs
within one DD in either eye relative to at most one M/DH within one DD in either eye included 1.
This was also true of the CI for no lesions or lesions other than M/DHs, BHs or exudates in either eye.
This meant that there was no signiﬁcant difference in the odds of having MO in for these subjects
compared with subjects with at most one M/DH in either eye. The fact that the count of several M/DHs
within one DD was statistically signiﬁcant after adjusting for centre, the count of BHs and the count of
exudates suggested that having a lot of M/DHs was still useful for predicting MO. This remained true after
adjusting for other variables including visual acuity.
If the data were restricted to exclude those with missing visual acuity as well as those with no features or
features other than M/DHs, BHs and exudates, the results were almost identical to those described above.
With this restriction it was again possible to include an interaction between visual acuity and
feature category.
There was no evidence of an interaction between these variables and this suggested that both lesion
category and visual acuity were important in predicting presence of MO, but the effect of having worse
visual acuity did not vary between different lesion groups.Strategies for detecting macular oedemaFindings from the statistical analysis were used to inform the inclusion of various eye and subject
characteristics that might be considered within computer-assisted manual strategies and fully automated
strategies. The strategies for detecting MO modelled in this study can be categorised as follows.
1. Manual grading strategies These use features, similar to those in existing national criteria, which can be
identiﬁed by visual inspection by trained graders.
2. Computer-assisted manual annotation grading strategies These use more detailed features obtained by
manual annotation which are then combined by a software classiﬁer to determine a likelihood that MO
is present.47
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483. Fully automated annotation grading strategies where no human intervention is required These use
features determined by image analysis software. As with computer-assisted manual strategies, these
features are combined by a software classiﬁer to determine a likelihood that MO is present.Manual grading strategies
The manual strategies used the following photographic features:
l M/DH within one DD
l M/DH between one DD and two DD
l BH within one DD
l BH between one and two DD
l exudates within one DD
l exudates between one DD and two DD.
In addition, the following feature was used:
l visual acuity worse than or equal to Snellen 6/12 (log-MAR 0.3).
Eighteen different combinations of these features were modelled as the manual grading strategies and are
listed in Table 19. Manual grading strategies 1 and 2 model the current practice in the English and the
Scottish national programmes, respectively. The statistical analysis in the earlier part of this chapter showed
that exudates, BHs and M/DHs within one DD, as well as reduced visual acuity, all signiﬁcantly increase the
risk of having MO. Furthermore, the risk increases with the number of lesions present within one DD.
Lesions outside of one DD, including exudates, were not found to be predictive of MO. Manual grading
strategy 4 (M/DHs within one DD only), manual grading strategy 5 (M/DHs or BHs within one DD), manual
grading strategy 9 (M/DHs within two DD) and manual grading strategy 10 (M/DHs or BHs within two DD)
investigate red lesions alone. Manual grading strategy 6 (exudates within one DD) and manual grading
strategy 11 (exudates within two DD) examine bright lesions alone. Manual grading strategy 15 considers
visual acuity alone. The remainder of the manual grading strategy 16 strategies explore combinations of
red and bright lesions with visual acuity.
Computer-assisted manual annotation grading strategies
A computer-assisted manual annotation grading strategy differs from manual grading in that an
automated classiﬁer (described later) is used to combine the image information. This means that improved
performance can be achieved because of the association between features. Also, it is possible to include
more complex features, such as the number and area of lesions, although this would require additional
grading time. As shown in Table 20, the computer-assisted manual annotation grading strategy also used
computer intensity measurements within the macula (as explained below), visual acuity and other
patient information.
Fully automated annotation grading strategies
Like the computer-assisted annotation grading strategies, the fully automated annotation grading
strategies take advantage of richer information within the image, but with all the information derived
automatically from the image without any human intervention. Clearly, as the automated lesion detection
system approaches the performance of the manual observer, the performance of the fully automated
annotation systems should be similar to the best computer-assisted annotation grading strategies. Three
fully automated annotation grading systems were tested, two of which incorporated visual acuity and
other patient information (see Table 20). The automated analysis produces technical failures (i.e. images of
insufﬁcient quality for automated analysis) and these were handled by using manual grading strategy 16
as illustrated in the ﬂowchart in Figure 13.NIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 19 Simple manual strategies
Manual
strategy
M/DH
within
one DD
M/DH
within
two DD
BH within
one DD
BH within
two DD
Exudate
within
one DD
Exudate
within
two DD VA ≥ 0.3
1 VA VA ✗ Groupa
2 ✗ ✗
3 VA (3 +)b VA VA ✗ VA
4 ✗
5 ✗ ✗
6 ✗
7 VA ✗ ✗ ✗
8 ✗ ✗ ✗
9 ✗ ✗
10 ✗ ✗ ✗ ✗
11 ✗ ✗
12 ✗ ✗ ✗ ✗
13 ✗ ✗ ✗ ✗ ✗ ✗
14 ✗ ✗ ✗ ✗
15 ✗
16 VA ✗ ✗
17 VA VA ✗ VA ✗ ✗
18 VA (3+)b ✗ ✗
VA, visual acuity.
a Exudates between one and two DD are only included if they comprise a ‘group’. The deﬁnition of group varies from
centre to centre in the English screening programme.
b Three or more M/DHs within one DD.
An ✗ in a column indicates the feature is positive if any lesions of that type are present. A number indicates that a certain
number of that feature must be present before it is considered positive. A ‘visual acuity’ in a column indicates that the
feature is only considered positive if the visual acuity is log-MAR 0.3 or worse. EX indicates the presence of exudates and
M/DH microaneurysm.
ABLE 20 Computer-assisted manual annotation (CAM) and fully automated (FA) grading strategies
Strategy
Information from
manual annotations
Information from
automated image analysis
Visual
acuity
Patient information
(age/diabetes type/male or female)
CAM ✗ ✗a ✗ ✗
FA1 ✗
FA2 ✗ ✗
FA3 ✗ ✗ ✗
a Computer intensity measurement only.
An ✗ in a column indicates the feature set was used.
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Patients with
maculopathy
Normal
Normal
No
abnormality Abnormality
Refer
Slit-lamp examination
Technical failure
Maculopathy
Inadequate quality
Macular disease
assessment positive
Manual grading
(as strategy 16)
1. Maculopathy
2. Technical failure
3. Normal
Automated macular disease
assessment
1. Macular disease
2. Inadequate quality
3. Normal
No macular
oedema OCT scan
(if present)
Do not refer
FIGURE 13 A fully automated annotation grading strategy, using manual grading to determine the outcome for
technical failures from automated macular disease assessment. Manual grading strategy 16 was used because it
performs best relative to the receiver operating characteristic curves shown in Figure 16 while making a reasonable
compromise of sensitivity and specificity.
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This section describes the image analysis methods used in the computer-assisted annotation manual and
fully automated annotation grading strategies.Computer intensity measurements
It was noted that in subjects with MO the macular area often appears darker than the surrounding retina
(although this must be distinguished from pupillary shadows, which are a common artefact when the pupil
diameter is small). This effect is even more noticeable when imaging using infrared illumination, where the
wavelengths are absorbed more strongly by the oedema. To quantify this difference in the macular
intensities the following measures were calculated automatically from the retinal photographs (Figure 14).
1. The ratio of the mean red and mean green colour channel values within one DD.
2. The ratio of the mean red and mean green colour channel values in the annular region between one
and two DD.NIHR Journals Library www.journalslibrary.nihr.ac.uk
IGURE 14 Regions of interest centred on the fovea, used to calculate the computer intensity measurements.
he first region, labelled ‘1’, is a circle with a diameter approximately equal to that of the optic disc. The second
egion, labelled ‘2’, is an annular region with an inner diameter of 1.5 disc diameters and outer diameter of a
disc diameters.
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T
r
23. The ratio of the mean green colour channel in the circular one DD region and the annular region
between one and two DD.
4. As above, but using the red colour channel.
Note that these measures may be affected by several common features such as reﬂections from the
internal limiting membrane in younger subjects (Figure 15c), the presence of bright exudate or drusen
lesions (Figure 15d) or a shadow cast by a small pupil (Figure 15e). However, the measures may have
predictive value despite these confounding factors.
Lesion detection and image quality assessment
In order to test automated grading strategies for MO detection, this project made use of software which
has been validated for use in diabetic retinopathy screening30,47–49 and described in previous technical
papers.50–54 A brief description of the automated methods is given here.
The black background was segmented and the image was corrected for uneven illumination. Next, the
location of the optic disc and the fovea were determined.53 The elliptic shape of the temporal arcades was
used as a guide to make a rough estimate of the optic disc position, which was then reﬁned using a
circular Hough transform. The position of the fovea was subject to geometric constraints relative to the
arcades and the disc, and was chosen at a local maximum response of a ﬁlter matched to the expected
foveal darkening.
Image clarity was assessed by performing small vessel detection within a disc surrounding the detected
fovea and then measuring the total vessel length. A decrease in clarity is expected to result in reduced51
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(a) (b)
(c) (d)
(e)
FIGURE 15 (a) Typical macular appearance with a dark region indicating the position of the centre of the fovea;
(b) example retina with a darker macular region; (c) retina showing substantial reflections from the internal
limiting membrane, which is often a feature in younger subjects; (d) bright and dark lesions can also affect the
greyscale measurements; (e) technical problems with the image, such as pupillary shadows, will affect the
greyscale measurements.
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51length of vessels being visible and the low between-person anatomical variation makes this a workable
assessment. Images that have poor quality were classed as ‘technical failures’.
Lesions (M/DHs, BHs and exudates) were then detected. A non-speciﬁc morphological ﬁlter was used to
determine candidate lesions by separating dot-like objects from the linear objects such as the vasculature.50
For M/DHs, the non-speciﬁc ﬁlter was applied at a single scale. For BHs and exudates, the non-speciﬁc ﬁlter
was applied at multiple scales and the results combined.52,54 Dark objects were detected for BHs and bright
objects were detected for exudates. The second stage of lesion detection performed more detailed analysis
of the candidate lesions, measuring such features as their area, contrast and, for the dark lesions, the
likelihood of it lying on a vessel. For exudates, the distance to the nearest detected M/DH was also used.
For each type of lesion, a set of images in which individual lesions had been annotated was used for
training. The training results and the candidate lesion features were supplied to an automated classiﬁer,
which produced a value corresponding to the likelihood of each candidate lesion being a true lesion.
Individual candidate lesion likelihoods were combined, as follows, for the candidates within circles
centred on the fovea with radii of one and two DD. For M/DHs, the likelihood was thresholded, so
allowing a M/DH count to be determined within one DD and two DD from the fovea. For BHs the
maximum was taken of the likelihoods of candidates within the one DD circle. For exudates, the mean of
the two highest likelihoods for candidates within one DD from the fovea and the mean of the three
highest likelihoods for candidates within two DD from the fovea was chosen. The outputs from the
automated analysis were thus:
l computer intensity measurements
l image clarity assessment
l count of M/DHs within one DD from the fovea
l count of M/DHs within two DD from the fovea
l count of M/DHs anywhere.
l likelihood of BHs within one DD from the fovea
l likelihood of BHs anywhere
l likelihood of exudates within one DD from the fovea
l likelihood of exudates within two DD from the fovea
l likelihood of exudates anywhere.ClassiﬁersThe computer-assisted manual and fully automated grading strategies use a classiﬁer to determine
whether or not oedema is present given a list of features, such as those above. The classiﬁer is an example
of supervised learning. It is trained using a set of data where it is known whether or not MO is present
(the MO status was based on the result of their OCT scan). Once the classiﬁer has been trained it can be
used to classify previously unseen individual cases giving a probability that oedema is present. The training
phase for the classiﬁer is often very time-consuming, but it is required to be done only once.
When evaluating classiﬁer performance it is vital to test using a completely separate set of subjects to
those used in the training phase, as recognising previously seen cases is likely to artiﬁcially boost the
performance. Very often the scarcity of true-positives or true-negatives means that there are not enough
cases to divide into separate testing and training sets. In such cases a form of cross-validation may be used
where the data are partitioned into subsets. For instance, the data could be divided into three subsets,
each containing an equal number of positive cases and an equal number of negative cases. The classiﬁer
would then be trained on two of the subsets and tested on the third. In this way the performance is
evaluated on the full data set. Increasing the number of subsets will give a greater conﬁdence in the result,
but will also increase the calculation time. The limiting case where each subject is a subset is known53
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54as leave-one-out testing, as the training is performed on the entire data set minus just a single
test subject.
For this study a classiﬁer known as the Random Forest classiﬁer was used by the computer-assisted and
fully automated strategies to combine the feature information and decide whether or not MO is present.
This is a non-parametric classiﬁer that makes no assumptions about the form of the feature distributions.
The Random Forest classiﬁer is an extension of classiﬁcation trees. It consists of many trees that all process
the same input features and then vote on which class the example belongs to. The ﬁnal class is the one
which achieves the most votes from all the trees in the forest. Like many non-parametric classiﬁers it
takes much longer to train than a classiﬁer such as a linear discriminant analysis classiﬁer, but classiﬁcation
is rapid.
The features used as inputs to the Random Forest classiﬁer are shown in Table 21.
Results
The sensitivities and speciﬁcities for predicting the presence of MO in at least one eye are presented in
Table 22 for each of the manual grading strategies listed in Table 19.
For completeness, positive and negative predictive values (percentage of those referred who have MO
present in at least one eye and percentage of those not referred who do not have MO) are presented in
Table 23 for the same manual grading strategies. As the calculations of sensitivity, speciﬁcity, positive
predictive value and negative predictive value are based on the same four counts of subjects in a table, very
similar patterns of performance of the strategies can be seen from Tables 22 and 23. For example, after
weighting the greater number referred under strategy 1 compared with strategy 2 gave higher sensitivity
and lower speciﬁcity of strategy 1 compared with strategy 2 (see Table 22) and also the lower positive
predictive value and higher negative predictive of strategy 1 compared with strategy 2 (see Table 23).
The classiﬁers used in the computer-assisted manual annotation and fully automated annotation grading
strategies have a numerical output on a continuous scale and hence the results for these strategies are
best displayed as receiver operating characteristics curves (Figure 16). Figure 16 also shows the sensitivity
and speciﬁcity for the manual strategies that were taken through to the economic analysis. These were
manual grading strategy 1 and manual grading strategy 2, respectively, the current English and Scottish
grading practices, and manual grading strategy 8 and manual grading strategy 16. Manual gradingTABLE 21 Features for use in the classiﬁer
Features Source
Manual lesion counts and positions (M/DH, BH, exudates) Manual annotation
Manual lesion areas Manual annotation
Retinopathy grade (R0 . . . R4) Manual grading (following Scottish grading scheme)
Visual acuity (log-MAR) Patient records
Patient information (age/diabetes type/male or female) Patient records
Computer intensity measurements Automated image analysis
Automatic clarity measure Automated image analysis
Automatic M/DH counts and position (one DD, two DD,
more than two DD)
Automated image analysis
Automatic BH counts and position Automated image analysis
Automatic exudate counts and position Automated image analysis
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IGURE 16 Unweighted and weighted receiver operating characteristics curves for fully automated annotation
rading (FA) and computer-assisted, manual annotation grading (CAM) strategies and including the operating
oint chosen for FA2. The performances of the manual strategies associated with current English [strategy 1 (S1)],
cottish [strategy 2 (S2)] grading practice and of the manual grading strategies used in the economic analysis
trategy 8 (S28) and strategy 16 (S16)] are also shown. AUC, area under the receiver operating characteristics curve;
A, visual acuity.
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INFERRING THE PRESENCE OF MACULAR OEDEMA USING RETINAL PHOTOGRAPHS
58strategy 16 was chosen because it performs best relative to the receiver operating characteristics curves
shown in Figure 16 while making a reasonable compromise of sensitivity and speciﬁcity. Manual grading
strategy 8 was chosen for its closeness to 100% sensitivity in order to test, in the economic analysis, a
strategy involving OCT scan of all patients with photographic surrogate markers of diabetic MO.
Of the fully automated annotation grading strategies, FA2 was chosen for economic analysis since it
performs better than fully automated annotation grading strategy FA1 and was similar to fully automated
annotation grading strategy FA3 (though with less input information).
In order to use fully automated annotation grading strategy FA2 in the economic analysis it was necessary
to choose an operating point for this strategy. The operating point was chosen to lie on a straight line
between manual grading strategy 16 and the top left corner of the weighted receiver operating
characteristics curve so that it achieves better sensitivity and speciﬁcity than manual grading strategy 16.
At this point fully automated annotation grading strategy FA2 achieves sensitivity 75.9% and speciﬁcity
73.7%. Further details of this operating point are included in Table 22. It should be noted that, for the
above reason, only this strategy is included in Table 22.
The computer-assisted manual annotation grading strategy, CAM, was not analysed further since manual
annotation of lesions was considered impractical in a screening context.Discussion and conclusionsThe statistical modelling of the data collected in the study showed that MO was strongly related to the
presence of lesions and was consistently higher in subjects with exudates or BHs within one DD than those
with just M/DHs within one DD. Having more than two M/DHs within one DD in an eye appeared to be of
particular importance in predicting the presence of MO. However, there was no evidence of a relationship
between MO and the presence or count of exudates between one and two DD after adjusting for the
presence, or count, of exudates within one DD.
Having worse visual acuity was associated with higher prevalence of MO.
The performance of various grading strategies for the detection of MO using retinal photographs and
other risk factors for MO were explored. Owing to lower recruitment of patients with only M/DHs in the
macula than occurs in the diabetic population, it was necessary to weight subjects to bring proportions to
those found in an earlier sequential study.30
After weighting, the fully manual grading strategies that model the current grading practices in England
and Scotland demonstrated different sensitivity and speciﬁcity. The higher sensitivity of the manual grading
system in England, at the expense of speciﬁcity, can be explained by the referral, in England, but not in
Scotland, of patients with M/DH within one DD who have visual acuity greater (worse) than log-MAR 0.3.
The modelling suggested that an ideal grading strategy would be one that takes into account the presence
and count of all three types of lesion within one DD and also visual acuity. The fully manual grading
strategy 16, that used M/DHs (provided that the visual acuity was worse than log-MAR 0.3), BHs and
exudates within one DD, demonstrated an improved speciﬁcity by approximately 4% relative to the current
grading practice in England, at similar sensitivity. It differs from the current grading practice in England, in
that BHs within one DD are referred regardless of visual acuity status, and exudates between one and two
DD are ignored. This is supported by the modelling that showed no evidence of a relationship between
MO and the presence, or count, of exudates between one and two DD after adjusting for the presence or
count of exudates within one DD.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51A grading strategy using automated analysis of the macula-centred image performs better than current
manual grading strategies. If automated analysis, data are combined with non-image data then further
improvements are obtained, largely due to the use of visual acuity. This was supported by the modelling
that showed that worse visual acuity was associated with higher prevalence of MO. As visual acuity is a
standard measurement performed during diabetic retinopathy screening this additional information could
be added to a fully automated strategy with little effort. Therefore, the fully automated annotation grading
strategy including visual acuity (FA2) was chosen for further analysis in the next chapter.
The optimum strategy in terms of area under its receiver operating characteristic curve was the
computer-assisted manual grading strategy, CAM. This uses the results of manual annotation of the
individual lesions in each image. This is a time-consuming procedure and so is unlikely to be considered for
routine grading practice. Therefore, this grading strategy was not taken forwards for economic analysis.59
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Chapter 6 Health economic evaluationAims and objectivesThe aim of this chapter is to assess the cost-effectiveness of alternative screening strategies for MO,
based on the identiﬁcation of different types and patterns of surrogate photographic markers. The
cost-effectiveness of introducing OCT to screening programme pathways, so as to further improve the
speciﬁcity of these referrals, is also assessed.
An initial analysis focuses on the cost per true case of MO appropriately detected and referred. However,
in most instances improvements in the sensitivity of referral criteria come at the expense of decreased
speciﬁcity. Thus, further analysis was undertaken to assess long-term cost-effectiveness, i.e. to ascertain
whether or not the increased costs associated with more sensitive grading strategies, resulting from more
referrals to ophthalmology clinics (appropriate and inappropriate), are worth incurring given the potential
health beneﬁts. A Markov microsimulation model was developed for this purpose.Assessment of cost per case of macular oedema detected
Overview
In previous chapters the sensitivity and speciﬁcity of the alternative screening strategies has been
established using the OCT outcome as the reference standard. There were 329 individuals in the data set
where the OCT outcome was a technical failure in at least one eye, resulting in unknown oedema status at
the patient level (OCT technical failure), and a further 41 individuals with two inadequate photographs.
These subjects were excluded from the analysis of sensitivity/speciﬁcity at the patient level, but the
expected costs associated with OCT technical failure were incorporated in the economic models comparing
alternative grading strategies involving the use of OCT within the screening programme.
The short-term costs to the NHS associated with the alternative referral criteria were estimated by applying
unit costs for screening and ophthalmology referral, according to the care pathway that patients in the
data set would be expected to follow under the alternative strategies. For strategies entailing the use of
OCT for patients within the screening programme, prior to referral, OCT costs were also applied. The
individual cost estimates were derived as described below.
Following this unadjusted analysis, a further analysis was undertaken whereby the proportions of patients
with different types/patterns of surrogate markers were weighted to reﬂect the relative frequency with
which these surrogate markers would be expected to arise in a consecutive screening cohort. In order to
achieve this, four patterns with retinal pathology categories were deﬁned based on the type and location
of surrogate markers present, and these were applied in a hierarchical manner such that patients were
assigned to the ﬁrst category for which either of their eyes met the inclusion criteria. The sensitivity and
speciﬁcity of the alternative grading strategies were determined separately for patients within each of
these categories. The resultant estimates were then applied in a decision tree model (Figure 17) where the
proportions of patients within each surrogate marker category were set equal to those observed in a prior
screening cohort study carried out in Grampian.33 This approach is equivalent to that used to estimate
weighted sensitivities and speciﬁcities in the previous chapter.
As the cost of a referral to the eye clinic was found to be a key driver of cost-effectiveness, and the
estimate for this parameter varied substantially between Scotland and England, separate analyses were
conducted for the two countries.61
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It was not feasible to consider all potential grading strategies in the economic analysis. The grading
strategies chosen included the current English manual grading strategy (1) and the current Scottish manual
grading strategy (2). Manual grading strategy 2 is one of the highest speciﬁcity simple manual grading
strategies after weighting, whereas manual grading strategy 1 represents a moderate sensitivity, moderate
speciﬁcity manual grading strategy (see Table 23). Based on examination of the patient-level sensitivities/
speciﬁcities of alternative simple manual strategies (see Table 23), manual grading strategy 16 was also
included as a potential alternative to manual grading strategy 1 (having similar sensitivity and higher
speciﬁcity). In addition, consideration was given to the potential cost-effectiveness of utilising the fully
automated annotation grading strategy with the inclusion of visual acuity (denoted FA2) running at an
operating point on its receiver operating characteristic curve (see Figure 16), with slightly higher sensitivity
and better speciﬁcity than manual grading strategy 16. Where automated grading ﬂagged a patient's
images as being of ‘insufﬁcient quality for grading’, these patients were modelled to fall back to manual
grading with manual grading strategy 16. Manual grading strategy 16 was chosen because of its similar
sensitivity and superior speciﬁcity to manual grading strategy 1.
The impact of combining the selected manual grading strategies with OCT within the screening pathway
prior to referral, to minimise false-positive referrals to eye clinics, was also assessed (see Figure 17). In
addition, the 100% sensitive manual grading strategy 8 (any exudate or BH within one DD, or any M/DH
within one DD and visual acuity ≥ 0.3 log-MAR) coupled with OCT prior to referral was considered.
The automated annotation grading strategy incorporating further patient characteristics was not included
in the economic analysis as this was incomparable with the simple manual grading strategies (which did
not utilise such information). Similarly, manual grading strategies relying on the full manual annotation of
all retinal images were not included as these would be impractical for clinical practice. Thus, in total nine
strategies were included in the analysis.Costs
Costs were estimated using a variety of sources as described below. All costs were expressed in UK sterling
for the 2009–10 ﬁnancial year. Although discounting was not required for the cost-effectiveness analysis,
the costs of capital items were annuitised over the useful lifespan of the item in question and a discount
rate of 3.5% per annum was applied to account for the opportunity cost of the investment over time.55
Table 24 summarises all the unit costs applied in the analysis of the cost per case detected.
Screening costs
Screening costs were estimated via a survey of participating centres and included the total equipment,
staff, space and overhead costs. For three of the participating screening centres these individual inputs
were costed using appropriate unit costs, and the resultant total cost was divided through by the number
of patients screened annually to give an estimate of the average cost per patient screened/graded (based
on digital photography with manual grading).
Capital equipment was costed using 2009/10 market prices and costs were annuitised over the useful
lifespan of each item as described above. Staff time was costed using published unit costs56 [Personal
Social Services Research Unit (PSSRU), 2010] reﬂecting the NHS salary, superannuation, national insurance,
training, overhead, and building space costs attributable to different grades of staff. The costs of
consumables were estimated based on programmes' reported non-staff/equipment expenditures.
Alternatively, two programmes had pre-existing charges available reﬂecting the cost per patient to the NHS
of providing screening. These costs were applied for these centres as they were felt to accurately reﬂect
the actual cost per patient to the NHS.
The resultant estimated cost per patient screened ranged from £32.02 to £64.56. Since the average
screening costs appeared to vary by country, because of differences in screening and grading protocols63
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ABLE 24 Unit costs applied in the cost-effectiveness analysis
Item Unit cost (£)
Range for
deterministic
sensitivity
analysis
Distribution
parameters
for probabilistic
sensitivity analyses Source
Screening programme costs
Cost per screen
(digital photography) in England
46.69 £32.50 to £64.56 Gamma Bottom-up
costing/charges
Cost per screen
(digital photography) in Scotland
33.13 £32.02 to £34.23 Gamma Bottom-up
costing
Marginal cost per OCT
examination (within the
screening programme)
31.96 £30.00 to
threshold
Gamma Reported
cost + bottom-up
costing
Marginal cost of slit-lamp
(within the screening programme)
27.29 £15.00 to £124.00 Gamma Bottom-up
costing
Eye clinic costs (England)
Outpatient with slit-lamp alone 124.00 £102.00 Department of
Health, 201057
Outpatient with OCT only 160.00 £137.00 Department of
Health, 201057
Outpatient with slit-lamp +OCT 160.00 £137.00 Department of
Health, 201057
Outpatient with
slit-lamp + ﬂuorescein
160.00 £137.00 Department of
Health, 201057
Weighted average cost per
initial referral
143.35 £120.81
Eye clinic costs (Scotland)
All diagnostic referrals 90.00 ISD, 201058
ISD, Information Services Division.
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64Tand stafﬁng structures, the average cost per patient in Scotland (£33.13) was applied in a
Scottish-speciﬁc analysis, whereas the average cost per screen in English centres (£46.69) was applied in
an English-speciﬁc analysis.Automated annotation grading costs
The cost of utilising the automated annotation grading algorithm represents one of the most uncertain
parameters in the model, at least within the English screening context. A version of automated disease/no
disease grading has already been implemented in Scotland, and it is estimated that it is currently achieving
a grading cost-saving to the screening programme [i.e. the additional cost of information technology (IT)
infrastructure and hosting are being more than offset by the savings made in terms of reduced manual
grading workload]. This is being achieved with automated disease/no disease grading taking place on a
central server with capacity to replace 40% of level 1 (disease/no disease) manual grading episodes in
Scotland. It is anticipated that the system could realise greater cost-saving to the screening programme if
scaled up further (i.e. further manual grading cost-savings may be greater than the marginal costs of
scaling up automation). Thus, it seems reasonable in this context to assume that using automated grading
to trigger referral for those with pathology in the macula would not increase the overall image grading
costs to the screening programme. Therefore, in the base-case analysis we assumed that the use of
automated annotation grading would have zero impact on net grading costs. However, given the current
level of uncertainty surrounding the use of automated grading in England and how it might be
implemented, we conducted a threshold sensitivity analysis around the marginal cost (per patient) ofNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51introducing automated grading for this group of patients. Of course, using automated grading in the
referral pathway for MO represents just one potential use of an automated grading system within
screening programmes.Optical coherence tomography costs (within screening pathway)
The additional cost of an OCT examination for patients with suspected MO, within the screening pathway,
was estimated based on the experience of two screening programmes offering OCT. The administration,
clinical staff time, equipment, maintenance, space and overhead requirements were costed using the
bottom-up approach described above. Total costs were divided through by the number of OCT screens
generated each year at the lead centre, to estimate the OCT costs per patient screened (see Appendix 2).
Given the uncertainty surrounding the cost of providing OCT within screening programmes (due to its
currently limited use), a threshold analysis was conducted to determine the maximum cost at which OCT
could be provided within screening programmes, prior to referral, while remaining cost-saving to the NHS.
For the maximally sensitive manual grading strategy (manual grading strategy 8 with OCT), it was assumed
that there would be a manual grading cost saving of £3.81 per patient within the English system (no need
for ﬁrst or second full disease grading). The savings were estimated based on a grading time of
4 minutes per patient at Agenda for Change band 5/6. The hourly costs of band 5 and band 6 graders
were assumed to be similar to those of band 5 and band 6 nurses (£26 and £31 per hour, respectively).56
A grading cost saving of £1.90 per patient was assumed for strategy 8 within the Scottish system (i.e. no
need for level 2 manual grading).Slit-lamp examination for patients classified as ungradeable
Since the application of the different strategies at the patient level resulted in different proportions of
patients being classiﬁed as photographic technical failures, it was necessary to incorporate the extra costs
of carrying out a slit-lamp examination for these patients within the screening programme. This was done
using the same bottom-up approach as was used to estimate the cost of OCT examination within
screening programmes – based on reported resource inputs required at a number of participating centres
(see Appendix 2). The cost estimates varied according to the staff grade conducting the examination. A
cost of £27.29 was applied in the base-case analysis (the average of two estimates based on an associate
specialist conducting the examination, and two estimates based on band 6 or band 7 graders conducting
the examination). Finally, since some centres refer patients to hospital eye services for photographic
technical failures, a sensitivity analysis was undertaken whereby the payment by results (PbR) outpatient
tariff57 was applied for slit-lamp examinations occurring within the screening programme (£124).Initial referral costs
The costs associated with initial referral to the eye clinic were based on a survey of participating centres,
which ascertained the average number of clinic visits required to conﬁrm or refute a diagnosis of MO
(one visit), and the proportions of patients following alternative diagnostic pathways: (1) slit-lamp
biomicroscopy alone (46%); (2) OCT alone (4%); (3) slit-lamp biomicroscopy followed by OCT (47%); or
(4) slit-lamp biomicroscopy followed by ﬂuorescein angiography (3%).
For the English-speciﬁc analysis, it was determined how alternative diagnostic procedures mapped to the
Ofﬁce of Population Censuses and Surveys (OPCS) procedure codes and consequently the Department of
Health, Healthcare Resource Groups (HRGs). Under this approach, an OCT examination mapped to the
OPCS procedure code ‘Tomography evaluation of retina’ (C87.3), whereas ﬂuorescein angiography
mapped to the OPCS code ‘Fluorescein angiography of the eye’ (C86.5). Both these codes mapped to the
HRG BZ23Z (Vitreous Retinal Procedures, Category 1), the charge for which was £160 according to the
PbR 2010 national tariff.57 Initial referrals where slit-lamp alone was used to guide diagnosis were charged
against the tariff for outpatient attendances [ophthalmology outpatient ﬁrst attendance (£124)]. A
sensitivity analysis was also conducted whereby OCT upon referral and referral without OCT was costed
according to the corresponding HRGs in the NHS reference costs.5965
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66For Scottish programmes, the average Information Services Division, NHS National Services Scotland,
specialty cost59 for a consultant-led ophthalmology outpatient attendance was applied for all initial
referrals to ophthalmology clinics (£90).Analysis of cost per case detected
The cost per case detected was assessed by determining the expected screening, referral and treatment
costs, and the expected number of true cases of MO referred under the alternative grading strategies.
Initially, the analysis was conducted by applying the unadjusted sensitivity and speciﬁcity estimates in the
decision tree model, with the prevalence of MO set equal to that observed in the clinical data set (7.7%).
To capture the expected costs associated with OCT technical failure, for grading strategies incorporating
OCT, the observed OCT technical failure rate (10.5%) was applied and those experiencing a technical
failure were modelled to incur the cost of both the OCT examination within the screening programme
and a subsequent referral to the eye clinic. Patients assigned the outcome of photographic technical
failure by a particular strategy were modelled to receive a slit-lamp examination within the screening
programme. It was assumed that these patients would receive a slit-lamp examination which
would ultimately result in the correct outcome being assigned (refer or recall). Thus, a number of
patients correctly identiﬁed as having MO with each strategy are in fact identiﬁed following a
slit-lamp examination.
A comparison of the proportions of patients in the surrogate marker categories with the proportions
observed in these categories in the prior cohort study (Table 25) suggested oversampling in the current
study of patients with BHs or exudates within one DD and undersampling of patients with only M/DHs in
the macula, or exudate(s) between one and two DD. To adjust for this in the cost-effectiveness analysis,
patients were ﬁrst assigned to one of the surrogate marker categories in Table 25. Moving through the
categories in descending order they were assigned to the ﬁrst category that either of their eyes satisﬁed.
The prevalence of MO and the sensitivity/speciﬁcity of the alternative referral strategies were then
estimated separately for each of the patient surrogate marker categories (Table 26) and applied in the
decision tree model with the categories reweighted using the frequency proportions provided in Table 25.
These frequency proportions were estimated using a subset of 1099 patients with surrogate markers
arising in a consecutive cohort of 6370 individuals (with complete data) screened in Grampian.33 They are
suggestive of a maculopathy incidence rate (based on an English referable maculopathy grade) of ∼ 6.3%.
The process of frequency weighting patients in the decision model is equivalent to the design weighting
procedure carried out for the statistical analysis.
Results were expressed for a cohort of 3170 patients with lesions within two DD centred on the fovea.
Total screening and referral costs, true cases detected and false-positive referrals were tabulated for each
strategy. Each grading strategy was compared incrementally in terms of its additional cost per extra case of
MO detected in comparison with the most speciﬁc strategy. The results are presented both with and
without the use of OCT prior to referral. The cost and effect of each grading strategy is also plotted
graphically on the cost-effectiveness plane, with a line joining those grading strategies that represent
potentially cost-effective options dependent on decision makers' willingness to pay per extra case of MO
detected (cost-effectiveness frontier).TABLE 25 Patient category proportions used in the cost-effectiveness analysis
Category Proportion 95% CI
1. Exudate(s) within one DD 203/1099 = 0.185 0.163 to 0.209
2. BH(s) within one DD 50/1099 = 0.045 0.034 to 0.058
3. M/DH(s) (no BHs) within one DD 829/1099 = 0.754 0.729 to 0.779
4. Exudate(s) between one and two DD 17/1099 = 0.015 0.009 to 0.024
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68Sensitivity analysis
Deterministic sensitivity analysis
Owing to uncertainty surrounding the per patient cost of providing OCT within a screening programme's
pathway, a threshold analysis was undertaken to determine the maximum cost at which OCT could be
provided within screening, prior to referral, while still resulting in cost-savings to the NHS. Further
deterministic sensitivity analysis was undertaken to assess the sensitivity of ﬁndings to the relative
frequency of different surrogate marker categories within the screening cohort, the marginal cost
associated with automated grading, the cost of slit-lamp examination, and the cost of referrals to
ophthalmology (i.e. applying the lower reference costs).Probabilistic sensitivity analysis
In order to characterise the uncertainty surrounding modelled point estimates of costs and effects, arising
from the joint uncertainty surrounding all input parameters, appropriate probability distributions were
speciﬁed for each parameter in the model. Probabilities (sensitivities, speciﬁcities, prevalence, and
frequency proportions) were speciﬁed as beta or Dirichlet distributions using the observed clinical data,
whereas cost distributions for screening and OCT were speciﬁed based on the observed range of
estimated values for each event. In the base-case analysis the screening cost distribution was centred on
the average per patient cost estimate, and a gamma distribution was assumed. A variance parameter was
selected such that the high and low screening cost estimates (see Table 24) were contained within the
2.5th to 97.5th percentiles of the distribution. Although referral unit costs were applied deterministically in
the models, the proportion of patients receiving only a slit-lamp examination on referral to the eye clinic
was allowed to vary within a uniform distribution, reﬂecting the reported variation in this parameter across
participating centres (0–95%).Results
Cost per case detected
Table 26 shows the number and proportion of patients in the clinical data set who would be referred/
recalled by the alternative grading strategies, by surrogate marker category and the presence/absence of
diabetic MO. These data were used to populate the decision tree model so that cost-effectiveness could be
estimated based on the patient category frequencies observed within the current study, and also with the
more realistic frequency weights from the prior cohort study.33
Tables 27 and 28 show the anticipated costs and consequences, from one round of screening, of using the
alternative grading strategies to screen patients in the clinical data set in their unadjusted frequencies
(applying English and Scottish screening and referral costs, respectively). Tables 29 and 30 show the
expected costs and outcomes for a screening cohort of the same size, but with the patient categories
reweighted to reﬂect their expected frequency within screening programmes. Table 29 presents the
ﬁndings applying the English unit costs for screening and referral, whereas Table 30 shows the same
results applying Scottish unit costs. Figures 18 and 19 compare all the grading strategies graphically on the
cost-effectiveness plane (applying English and Scottish costs, respectively). Grading strategies falling above
or behind the lines joining points on the plane represent options that are dominated (more costly and less
effective than alternative options) under base-case assumptions. Those grading strategies falling on the
lines offer potentially cost-effective options dependent on decision makers' willingness to pay per extra
case of MO detected.
The results show that, although manual grading strategy 2 (current Scottish practice) is slightly more
sensitive, less speciﬁc and more costly than the manual grading strategy 1 (current English practice), based
on the unweighted analysis (see Tables 27 and 28), the reweighting reverses this ﬁnding such that manualNIHR Journals Library www.journalslibrary.nihr.ac.uk
ABLE 27 Estimated screening and referral costs and true cases of MO detected under alternative referral criteria
or the 3170 subjects with usable OCT status and photographs – based on English screening and referral costs)
Strategy
Number
of MO
cases
Total
cost (£)
MO cases
detected
and
referred (n)
False-positive
referrals (n)
Incremental
cost (£)
Incremental
cases
Incremental
cost per case
detected (£)
Strategy 2 243 358,015 200 1250 a a a and b
Strategy 1 243 356,806 198 1243 −1209 −2 605b,c
Strategy 16 243 379,743 214 1389 21,728 14 1552
FA2d 243 314,986 201 253 −43,029 1 Dominant
Strategy 2+OCT 243 243,637 200 131 a a a and b
Strategy 1+OCT 243 243,104 198 130 −533 −2 267b,c
Strategy 16+OCT 243 252,433 214 145 8796 14 628
FA2 +OCTd 243 229,355 201 145 −14,282 1 Dominant
Strategy 8+OCT 243 299,979 241 269 56,342 41 1374
FA, fully automated.
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Represents a cost-saving per case missed relative to the reference strategy.
d Figures in table based on assumption that fully automated grading can be implemented at zero net increase in grading costs.
ABLE 28 Estimated screening and referral costs and true cases of MO detected under alternative referral criteria
or the 3170 subjects with usable OCT status and photographs – based on Scottish screening and referral costs)
Strategy
Number
of MO
cases
Total
cost (£)
MO cases
detected
and
referred (n)
False-positive
referrals (n)
Incremental
cost (£)
Incremental
cases
Incremental
cost per case
detected (£)
Strategy 2 243 237,433 200 1250 a a a and b
Strategy 1 243 236,799 198 1243 −634 −2 317b,c
Strategy 16 243 251,064 214 1389 13,631 14 974
FA2d 243 210,171 201 253 −27,262 1 Dominant
Strategy 2+OCT 243 182,909 200 131 a a a and b
Strategy 1+OCT 243 182,592 198 130 −317 −2 158.50b,c
Strategy 16+OCT 243 190,200 214 145 7291 14 520.79
FA2 +OCTd 243 170,229 201 145 −12,680 1 Dominant
Strategy 8+OCT 243 235,848 241 269 52,939 41 1291.20
FA, fully automated.
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Represents a cost-saving per case missed relative to the reference strategy.
d Figures in table based on assumption that fully automated grading can be implemented at zero net increase in grading costs.
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ABLE 29 Screening and referral cost per true case of MO detected under alternative referral criteria (for 3170 patients);
djusted for expected frequency of different patient categories and based on English screening and referral costs
Strategy
Adjusted
number
of MO
cases
Total
cost (£)
MO cases
detected
and
referred (n)
False-positive
referrals (n)
Incremental
cost (£)
Incremental
cases
Incremental
cost per case
detected (£)
Strategy 2 176 255,448 105 628 a a a
Strategy 1 176 310,791 128 995 55,343 23 2406b
Strategy 16 176 293,345 129 872 37,897 24 1579b
FA2c 176 281,465 134 786 26,017 29 897
Strategy 2+OCT 176 197,955 105 67 a a a
Strategy 1+OCT 176 218,896 128 105 20,941 23 910b
Strategy 16+OCT 176 213,296 129 92 15,341 24 639b
FA2 +OCTc 176 209,688 134 82 11,733 29 405
Strategy 8+OCT 176 305,187 176 307 107,232 71 1510
FA, fully automated.
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Figures in table based on assumption that fully automated grading can be implemented at zero net increase in grading costs.
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aTABLE 30 Screening and referral cost per true case of MO detected under alternative referral criteria (for 3170 patients);
adjusted for expected frequency of different patient categories and based on Scottish screening and referral costs
Strategy
Adjusted
number
of MO
cases
Total
cost (£)
MO cases
detected
and
referred (n)
False-positive
referrals (n)
Incremental
cost (£)
Incremental
cases
Incremental
cost per case
detected (£)
Strategy 2 176 173,246 105 628 a a a
Strategy 1 176 207,825 128 995 34,579 23 1503b
Strategy 16 176 196,882 129 872 23,636 24 985b
FA2c 176 189,231 134 786 15,985 29 551
Strategy 2+OCT 176 145,848 105 67 a a a
Strategy 1+OCT 176 163,509 128 105 17,661 23 768b
Strategy 16+OCT 176 158,530 129 92 12,682 24 528b
FA2+OCTc 176 155,148 134 82 9300 29 321
Strategy 8+OCT 176 242,392 176 307 96,544 71 1360
FA, fully automated.
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Figures in table based on assumption that fully automated grading can be implemented at zero net increase in grading costs.
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Fgrading strategy 2 becomes substantially less sensitive, more speciﬁc and less costly than manual grading
strategy 1 (see Tables 29 and 30). The results in Tables 29 and 30 also suggest that manual grading
strategy 16 would dominate strategy 1. The automated grading strategy (coupled with the linear classiﬁer
and fall back to manual strategy 16 in the event of automated technical failure) would also dominate
manual grading strategy 1 and manual grading strategy 16 assuming it could be implemented without
increasing net grading costs to a programme. A common ﬁnding from the base-case analyses is that the
addition of OCT to each grading strategy (within the screening programme) prior to referral, results in a
reduction in costs to the health service, with no decrement in the number of MO cases detected.
The incremental cost per extra case of MO detected varies by grading strategy. Considering the more sensitive
manual grading strategy 16 compared with manual grading strategy 2 (see Tables 29 and 30), the additional
cost per extra case detected ranges from £1579 (English costs) to £985 (Scottish costs). When the manual
grading strategies are coupled with OCT, these incremental costs fall to £636 and £528, respectively.
Although the automated annotation grading strategy dominates manual grading strategies 1 and 16 under
the base-case assumption of zero net increase in grading costs, it costs £897 per additional case detected and
referred in comparison with manual grading strategy 2 (applying English screening and referral costs). This
incremental cost drops to £405 when the grading strategies are coupled with OCT prior to referral. The
100% sensitive strategy 8 (OCT for all patients with any exudate or BH less than one DD, or any M/DH less
than one DD and visual acuity ≥ 0.3 log-MAR) costs an additional £1510 per extra case detected in
comparison with the most speciﬁc grading pathway (manual grading strategy 2 + OCT) when applying English
referral costs, and £1360 per extra case detected when applying Scottish referral costs. In comparison with
manual grading strategy 16 plus OCT, strategy 8 costs £1955 and £1784 per extra case detected and referred
when applying English and Scottish referral costs, respectively.71
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72Deterministic sensitivity analysis
Considering manual grading strategy 1 (current English practice), threshold analysis suggests that the cost
of implementing OCT within the screening pathway (to reduce false-positive referrals) can rise to ∼ £113
per patient before it starts increasing the overall cost per true-positive referral above the level obtained in
its absence (assuming English referral costs). The corresponding threshold cost for OCT coupled with
manual grading strategy 2 is ∼ £110. Applying the lower Scottish referral costs, the OCT threshold costs
fall to £71 and £69 for manual grading strategies 1 and 2, respectively. To put this in perspective, if an
associate specialist were to perform OCT examinations within screening, and applying the same input
assumptions as those used for the cost estimate based on a band 6 retinal screener (see Appendix 2), the
corresponding cost would be ∼ £64. As expected, lower referral costs also improve the cost-effectiveness
of the more sensitive, less speciﬁc manual grading strategies.
Further sensitivity analysis was undertaken to determine the threshold for the net incremental grading cost
associated with automated annotation grading that would result in it no longer dominating manual
grading strategy 1 in terms of the cost per case detected and referred. This showed that the automated
classiﬁer would remain dominant over manual grading strategy 1 up to an additional cost of ∼ £9.00 per
patient graded (assuming English referral costs). The threshold cost drops to ∼ £3.00 when considering the
manual grading strategies coupled with OCT. Note that an alternative operating point could also be
established on the automated classiﬁer to obtain improved speciﬁcity for the same sensitivity as any of
other simple manual grading strategies.
The results of further sensitivity analyses are presented in Table 31. In general, the ordering of grading
strategies was not found to be particularly sensitive to variation in key model parameters.
Probabilistic sensitivity analysis
The probabilistic analysis characterises the joint uncertainty surrounding the estimated incremental costs
and cases of MO detected with each of the alternative strategies (Figures 20–22). The acceptability curves
indicate the probability of each grading strategy being the preferred option given different values of
decision makers' maximum willingness to pay per extra case of MO detected and referred. The preferred
option changes as this threshold increases.
Applying English referral costs (see Figure 20), manual grading strategy 2 (Scottish criteria) coupled with
OCT has the highest probability of being considered cost-effective up to a ‘willingness-to-pay’ threshold of
∼ £450 per extra case of MO detected. Above this ratio, automated annotation grading (coupled with
OCT) has the higher probability of being the preferred option up to a ‘willingness-to-pay’ threshold of
∼ £2450. Note, however, that this is dependent on the assumption that automated annotation grading
can be implemented without increasing grading costs to the screening programme. Above a
‘willingness-to-pay’ threshold of ∼ £2450, manual grading strategy 8 coupled with OCT has the highest
probability of being preferred on grounds of cost-effectiveness. Figure 21 indicates that a similar pattern of
results is obtained when applying the Scottish referral costs, although the thresholds for adopting the
more sensitive (less speciﬁc) manual grading strategies are slightly lower because of the lower referral
costs. Figure 22 indicates the choices between manual grading strategies when the automated grading
procedures are taken out of the comparison (applying English costs). Under this scenario manual grading
strategy 16 plus OCT has the higher probability of being the preferred option above a ‘willingness-to-pay’
threshold of ∼ £800 per case detected and referred, before manual grading strategy 8 plus OCT takes over
above the ‘willingness-to-pay’ threshold of ∼ £2000 per additional case.NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 31 Deterministic sensitivity analysis ﬁndings
Scenario Strategy Cost (£)
True-positive
referrals
Incremental
cost-effectiveness
ratio (£)
Frequency weight for category
4 patients 0.15 rather than 0.227
Strategy 2 271,899 120 a
Strategy 1 324,244 138 2908b
Strategy 16 307,053 142 1598b
FA2a 286,188 143 621
Strategy 2 + OCT 205,220 120 a
Strategy 1 + OCT 224,538 138 1073b
Strategy 16 + OCT 219,450 142 647b
FA2 +OCTc 212,407 143 312
Strategy 8 + OCT 303,818 186 1494
Lower eye clinic referral costs
(based on NHS reference costs64
rather than PbR tariff)
Strategy 2 238,907 105 a
Strategy 1 285,492 128 2025b
Strategy 16 270,789 129 1328b
FA2c 260,693 134 751
Strategy 2 + OCT 194,108 105 a
Strategy 1 + OCT 213,665 128 850b
Strategy 16 + OCT 208,327 129 592b
FA2 +OCTc 204,814 134 369
Strategy 8 + OCT 294,278 176 1411
OCT cost per patient
(within screening
programme) = £50
Strategy 2 255,448 105 a
Strategy 1 310,791 128 2406b
Strategy 16 293,345 129 1579b
FA2a 281,465 134 897
Strategy 2 + OCT 221,300 105 a
Strategy 1 + OCT 254,802 128 1457
Strategy 16 + OCT 245,247 129 998b
FA2 +OCTc 239,159 134 616b
Strategy 8 + OCT 405,109 176 2589
FA, fully automated.
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Figures in table based on assumption that fully automated grading can be implemented at zero net increase in
grading costs.
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74Assessing long-term cost-effectiveness
Model overview
In order to estimate the longer-term cost-effectiveness of the alternative referral criteria, a Markov
microsimulation model was developed to simulate the progression of MO and visual loss in referred and
un-referred patients over time (Figure 23). Patients with MO referred to the eye clinic were modelled to
receive treatment and incur a lower risk of disease progression and visual impairment. Costs associated
with screening, referral, treatment, ongoing monitoring and vision loss were incorporated in theNIHR Journals Library www.journalslibrary.nihr.ac.uk
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76model – as were utility weights associated with varying degrees of visual loss – allowing costs and QALYs
to be estimated over a number of years.
A microsimulation approach was used whereby individual patients with characteristics matching those of
the patients in the clinical data set were randomly selected into the model one at time and simulated to
progress. The modelled cohort consisted of patients with any surrogate photographic markers within one
DD of the fovea, and also those with exudates between one and two DD. The relative proportions of
patients with different types of macular features were adjusted to reﬂect their expected frequency within
screening programmes (using the frequency weights in Table 25).
Based on the initial visual acuity in each eye, patients were assigned to one of six health states deﬁned by
their visual acuity in the better-seeing eye; visual acuity in the better-seeing eye is generally considered to
be the better determinant of health-related quality of life,60 and the health-related quality of life in patients
with diabetic retinopathy is more commonly reported according to visual acuity in the better-seeing eye.
These health states are represented by the nodes emanating from the Markov (strategy 5) node in
Figure 23. The model was constructed to cycle on a 6-monthly basis (the average time interval between
screening/monitoring appointments for patients with observable but non-referable maculopathy) with the
tree to the right of the Markov health states representing the clinical pathways that simulated patients
could follow within each cycle of the model. Tracker variables were used to update patient history and
screening/referral decisions so that the pathway taken by patients in subsequent cycles of the model could
be determined based on this prior information.
Patients were simulated to enter the model at an index screening visit. The adjusted sensitivity and
speciﬁcity of the different strategies (see Table 22) were applied to patients within the alternative arms of
the model. Depending on the sensitivity/speciﬁcity of the screening strategy, patients could then either be
referred to the eye clinic or remain in the screening programme. The visual acuity of eyes with MO
remaining in the screening programme was modelled to improve/deteriorate at the rates observed for
untreated eyes in the ETDRS,61 while eyes with MO referred to the eye clinic were assumed to receive
timely treatment and improve/deteriorate at the rates observes for laser-treated eyes in the ETDRS and a
more recent UK-based observational study.61,62 The change in visual acuity for each eye with MO was
modelled using 6-monthly probabilities of improvement/deterioration derived from the aforementioned
studies. Eyes without MO were assumed to remain stable until the development of MO. At the end of
each model cycle each patient was assigned the appropriate health state for the subsequent model cycle,
based on the updated visual acuity in their better-seeing eye (furthest right nodes in Figure 23).
Health state utility weights obtained from the available literature63 were used to quality adjust the time
spent by patients in each visual acuity state, so as to generate QALYs. Health state utilities reﬂect the
relative desirability of different states of health on a scale where zero represents death and one represents
full health. So, for example, a year spent in the health state ‘visual acuity ≥ 74 letters’, which was assigned
a utility weight of 0.83, would generate 0.83 QALYs (see Utilities for further details).
Costs associated with screening, referral, treatment, clinical observation and legal blindness (visual acuity
≤ 35 ETDRS letters) were incorporated into the model. For strategies where OCT monitoring was not
available within the screening programme, referred patients with no MO were modelled to remain under
6-monthly observation in the eye clinic. Patients not referred to the eye clinic at any given screening visit
were assumed to undergo screening again one year later – when they would again experience a
probability of being referred to the eye clinic. In the base-case analysis it was assumed that patients with
and without MO would face a constant probability of being referred each year, based on the adjusted
sensitivity and speciﬁcity of the strategy in question (see Tables 29 and 30). As an alternative we
conducted a sensitivity analysis where it was assumed that patients not referred on the index screening
visit would remain non-referable (according to their surrogate markers) for 2 years and 5 years. During
these time periods the visual acuity in eyes with MO was modelled to deteriorate at the rates observed for
untreated eyes.64NIHR Journals Library www.journalslibrary.nihr.ac.uk
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based on UK life tables combined with hazard ratios for all-cause mortality associated with diabetes.65,66
Further details of the model structure, parameters and assumptions are provided opposite.Modelled cohort
The modelled cohort consisted of patients with any surrogate photographic markers within one DD of the
fovea, and also those with exudates between one and two DD. In sampling patients for entry into the
model the frequency proportions from Table 25 were applied so that simulated patients in the different
surrogate marker categories would appear in the model with the same relative frequency as anticipated
within screening programmes. The clinical characteristics [age, gender, type of diabetes, visual acuity (in
each eye), macular surrogate marker category, retinopathy grade, and MO status (no MO/MO in right eye/
MO in left eye/MO in both eyes)] of simulated patients were recorded using tracker variables, some of
which were modelled to update over time (age, visual acuity, MO status).The grading strategies
The grading strategies chosen for comparison included those examined in the cost-effectiveness analysis.
This included the highly speciﬁc grading strategy 2, and the more sensitive and less speciﬁc grading
strategy 1, strategy 16, and the automated annotation grading strategy FA2 (set at ∼ 75.9% sensitivity
and 73.7% speciﬁcity). These grading strategies were assessed both with and without the presence of
OCT screening prior to referral to the eye clinic. The maximally sensitive grading strategy 8 coupled with
OCT was also assessed.Progression to macular oedema
Eyes with no MO at baseline were modelled to progress to MO using cumulative incidence data reported
by Younis et al.67,68 for a screening cohort in Liverpool. Younis et al. reported the yearly cumulative
incidence of referable maculopathy, up to 6 years, in patients with no retinopathy, background retinopathy
and mild pre-proliferative retinopathy in their worst eye at baseline. The reported yearly cumulative
incidence rates were used to estimate the annual risks of progression to referable maculopathy conditional
on survival. These annual risks were then averaged and converted to average 6-monthly risks. Finally, these
probabilities were converted into probabilities of developing OCT-positive MO, based on the positive
predictive value of the English referral criteria for MO (manual strategy 1) from Table 29. For eyes with
moderate/severe retinopathy at baseline, the 3-year incidence of clinically signiﬁcant MO, as reported for
the placebo arm in the Protein Kinase C-DRS2 trial,69 was used to estimate 6-monthly probabilities of
progression. As an alternative approach to estimating rates of progression to MO in patients with type 2
diabetes, the proportion of patients (with varying degrees of retinopathy at baseline) receiving
photocoagulation for MO at 6 years was estimated from the UK Prospective Diabetes Study70 and used to
generate 6-monthly probabilities of progression for the eyes of modelled patients (Table 32).TABLE 32 Six-monthly risks of developing MO in eyes of patients without MO at baseline
Retinopathy grade in
worst eye at baseline
6-monthly risk of
MO (T2DM)
6-monthly risk of
MO (T1DM)
6-monthly risk of treatment
for MO (T2DM)
None 0.0004 0.0004 0.0007
Background 0.0032 0.0032 0.0021
Mild pre-proliferative 0.0201 0.0275 0.0183
Pre-proliferative 0.121 0.121 0.0183
Proliferative 0.121 0.121 0.0183
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
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78Based on the observed proportion of patients recruited to the clinical study with MO in both eyes (12% of
those with MO in any eye), it was assumed that 12% of incident MO cases would present with both eyes
affected. It was also assumed that for patients with MO in one eye, the risk of developing MO in the other
eye would be increased. In a case–control study, Bhavsar and Subramanian71 found that a prior history of
‘clinically signiﬁcant’ MO in either eye signiﬁcantly increased the risk of progression from subclinical MO to
‘clinically signiﬁcant’ MO [unadjusted OR = 8.07 (CI 2.75 to 23.63)]. In a prospective cohort study,
Varma et al.72 found the incidence of ‘clinically signiﬁcant’ MO in the second eye of patients with ‘clinically
signiﬁcant’ MO in one eye to be double the incidence of ‘clinically signiﬁcant’ MO in a ﬁrst eye. It was
therefore assumed that the risk of eyes developing MO by underlying retinopathy grade (see Table 32)
would increase similarly for simulated patients with MO already present in one eye.
A simplifying assumption of the model was that no eyes lose vision prior to the development of MO. This
assumption should have limited impact on the comparison of alternative referral strategies, as any patient
at risk of vision loss from proliferative retinopathy would in practice be referred to ophthalmology services
regardless of whether or not MO was suspected. The rates of vision loss applied to eyes with MO in the
model may also capture vision loss resulting from co-existing retinopathy.Progression of visual impairment in eyes with macular oedema
The visual acuity of referred eyes with MO was modelled to deteriorate/improve at the rates observed for
laser-treated eyes with ‘clinically signiﬁcant’ MO, as deﬁned by the ETDRS, whereas non-referred eyes with
MO were modelled to deteriorate at the rates observed for untreated eyes with ‘clinically signiﬁcant’ MO.64Non-referred eyes
Owing to the long-established clinical practice of laser treatment for the prevention of visual loss in eyes
with ‘clinically signiﬁcant’ MO,64 there is a lack of contemporaneous data on visual acuity outcomes for
untreated eyes. Thus, non-referred eyes with MO were modelled to follow the visual acuity course
observed for eyes with ‘clinically signiﬁcant’ MO randomised to deferral of treatment in the ETDRS.64
Although improved glucose control may reduce the rate at which patients now develop ‘clinically
signiﬁcant’ MO,73 the deﬁnition of MO used in the current analysis maps closely to the ETDRS deﬁnition of
‘clinically signiﬁcant’ MO, and there is no evidence available to suggest that untreated eyes with ‘clinically
signiﬁcant’ MO currently lose vision any slower than they did when ETDRS was undertaken. The main
visual acuity outcome reported by the ETDRS was MVL, deﬁned as the loss of 15 letters (three lines) or
more on the ETDRS visual acuity chart.64 Approximately 29% of eyes with ‘clinically signiﬁcant’ MO
assigned to deferral of laser photocoagulation had reached this end point by 36 months, and a
subsequent report showed that ∼ 40% of patients in this group had MVL at 5 years.61 In addition, it was
assumed that no untreated eyes with MO would improve by more than 10 letters (two lines) without
treatment, but that a constant proportion of untreated eyes (∼ 20%) would be improved by between ﬁve
and nine letters (one to two lines) over follow-up.64 These probabilities were decomposed to generate
6-month transition probabilities using the method reported by Craig and Sendi,74 such that non-referred
eyes with MO progressed as per deferred eyes with ‘clinically signiﬁcant’ MO in the ETDRS (Figure 24). A
simplifying assumption was that patients with deteriorating vision would not present to the eye clinic
without being referred through the screening programme. This assumption works in favour of more
sensitive strategies. A further assumption was that, for patients losing 15 letters or more, the average
degree of visual loss would be 20 letters – this yielded a proportion of modelled eyes transiting to severe
vision loss (< 24 letters) that was consistent with observations in the ETDRS. For patients with both eyes
affected by MO, perfect positive correlation in visual acuity outcome was assumed between eyes.
Referred eyes
The ETDRS originally demonstrated that laser photocoagulation reduced the risk of MVL from MO by 50%
at 3 years.64 The effect was concentrated in patients with ‘clinically signiﬁcant’ MO, in whom it was also
somewhat greater (∼ 12% of eyes with ‘clinically signiﬁcant’ MO receiving immediate laser treatment had
MVL at 36 months, as compared with 29% in the deferred group). At 5 years, ∼ 22% of treated eyes with
centre involved ‘clinically signiﬁcant’ MO had reached this outcome. It also showed that mild improvementNIHR Journals Library www.journalslibrary.nihr.ac.uk
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51(six letters or more) was more common in laser-treated eyes (∼ 40% at 3 years), but that < 3% of treated
eyes showed improvement ≥ 15 letters. However, more recent randomised controlled trials assessing the
effectiveness of triamcinolone75 and ranibizumab76 compared with laser, for the treatment of centre
involved MO, suggest better outcomes can now be achieved. Elman et al.77 showed that 51% of
laser-treated eyes were improved by ﬁve or more letters at 12 months, and 15% were improved by
15 letters or more. Elman et al.76 also showed the proportion of laser-treated eyes demonstrating
moderate improvement and deterioration (10 letters or more), compared with baseline, to be relatively
stable between 12 and 24 months. The Diabetic Retinopathy Clinical Research Network trial of
triamcinolone demonstrated even more favourable outcomes for laser-treated eyes at 36 months, with
62% of eyes improved by ﬁve letters or more and 26% of eyes improved by 15 letters or more. However,
a recently published study of visual acuity outcomes for eyes treated with laser in routine clinic practice in
the UK reported less favourable results.68 This study of a 100 consecutive patients undergoing laser
treatment for MO in a routine hospital setting found that only 28% of eyes had improved by ﬁve or more
letters at 3 years and that 9% had improved by 15 letters or more (12% by 5 years).
In this study, referred eyes were modelled to deteriorate/improve at the rates observed for treated eyes in
the ETDRS. However, since there is some evidence that improvements of 15 letters or more are more
common with contemporary treatment protocols, the probability of eyes achieving this gain was modelled
based on the study by Jyothi and Sivaprasad.68 For modelled eyes that had lost 15 letters or more prior to
referral, it was assumed that no improvement in visual acuity would be possible on initiation of treatment.
This assumption and the treatment assumptions, in general, favour the more sensitive strategies.
The resultant modelled proportions of eyes with macular oedema experiencing the alternative visual acuity
outcomes (over time, with and without referral) are plotted in Figure 24.Mortality
The model allowed the age- and gender-speciﬁc 6-monthly mortality risk to be referenced for each
simulated patient during each cycle of the model. These all-cause mortality risks for the UK general
population were adjusted upwards using published age- and diabetes-speciﬁc hazard ratios for all-cause
mortality.65,66 Thus, mortality was modelled based on age, gender and type of diabetes. Although this
approach may overestimate mortality somewhat for the general diabetic population, it has also been noted
that the mortality risk for patients with MO is increased relative to the mortality risk for diabetic patients
without MO.78Costs and resource use
Costs associated with screening, OCT and initial referral were incorporated as shown in Table 24.
In addition, costs of treatment and ongoing outpatient monitoring (for referred patients with and79
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80without MO) were incorporated in the model. All future costs were discounted at a rate of 3.5% per year,
in line with the current recommendations from Her Majesty's Treasury. In relation to the capture of
ongoing screening, monitoring and treatment costs, the following assumptions were applied.Screening costs
For simulated patients not referred to the eye clinic under alternative grading strategies at any given
screening appointment, the average cost of a further screening appointment was applied one year later.
The impact of applying a 6-month screening interval, to reﬂect the fact that many patients with features in
the macula are often monitored within screening programmes on a 6-monthly basis, was also assessed
through sensitivity analysis. For strategies involving the use of OCT within screening programmes
(prior to referral), the cost of providing photographic screening and an OCT examination was applied on a
6-monthly basis for patients sent for OCT but subsequently found not to have MO.Follow-up up observation for eye clinic referrals without macular oedema
For strategies not utilising OCT within the screening programme, patients referred to the eye clinic without
MO (not requiring treatment) were assumed to require follow-up monitoring within the hospital eye
service every 6 months. This was assumed to incur the cost for an ophthalmology outpatient attendance
(with ∼ 50% of patients receiving an OCT examination at each visit) (see Table 24). For strategies utilising
OCT within the screening programme, it was assumed that photo-positive patients without MO would be
monitored on a 6-monthly basis with digital photography and OCT within the screening programme until
the point in time when they developed MO.Initial treatment cost for those with macular oedema
Since a survey of participating centres, and review of current National Institute for Health and Care
Excellence and Scottish Medicines Consortium guidance, suggested that laser still formed the mainstay of
treatment for MO in the UK, it was assumed that all patients with MO referred to ophthalmology would
receive this treatment modality. This was costed using the appropriate NHS reference cost,58 with the
OPCS code ‘laser photocoagulation to lesion of the retina’ (C826) mapping to the HRG category BZ23Z
(Retinal Vitreous Procedures-Category 1). Treatment was assumed to occur in both eyes if both eyes had
MO as determined by the OCT outcome.Ongoing treatment costs for those with macular oedema
For costing ongoing laser treatment after initial treatment, the numbers of treatments observed for
patients with MO in a UK-based cohort,68 at 3 years (1.54) and between 3 and 5 years (0.2), were used to
estimate corresponding average 6-monthly costs of treatment. Patients undergoing treatment were also
assumed to require 3-monthly monitoring as outpatients [£117 per visit based on the weighted average of
the cost for a follow-up ophthalmology attendance (£67) and the cost of OCT in an outpatient setting
(£160)]. Laser treatment was assumed to stop completely 5 years after initial treatment and also if patients
entered the severe visual loss state (< 24 ETDRS letters in the better-seeing eye). We also carried out
sensitivity analysis assuming that the same treatment effects could be obtained with no further laser
treatment beyond 3 years.Cost of legal blindness
In addition to the above costs, 6-monthly health and social care costs associated with legal blindness were
estimated and applied to simulated patients in the model when visual acuity in the better-seeing eye fell
below 35 letters (Table 33). These costs were taken from a study by Meads and Hyde79 and inﬂated to the
base costing year (2009/10).
Utilities
A review of the literature for health state utilities associated with MO revealed only one study where
suitable utility weights had been elicited from a sample of the UK general population. This study reported
directly elicited standard gamble utilities for a range of diabetic retinopathy health states deﬁned in terms
of best corrected visual acuity,63 which would correlate well with visual acuity in a patients better-seeingNIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 33 Costs associated with legal blindness (visual acuity <35 letters in the better-seeing eye)
State costs Unit cost (£) Low High Source
Better-seeing eye < 35 letters
Annual cost of legal blindness (ﬁrst year) 6455 1375 17,100 Meads and Hyde79
Annual costs of legal blindness (ongoing) 6295 1325 16,800 Meads and Hyde79
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51eye. This same study also reported alternative European Quality of Life-5 Dimensions (EQ-5D) weights
derived from the responses of diabetic patients with varying degrees of visual acuity. However, the sample
size for the EQ-5D weights was small, especially for the lower acuity states. For this reason the direct
standard gamble weights were used to adjust time spent by simulated patients in the different visual acuity
states of the model (Table 34). We also assessed the impact of assuming that these utility weights would
correlate with the visual acuity in the patient's worse-seeing eye (an assumption favouring more
sensitive strategies).
Analysis
The model was analysed using Monte Carlo simulation, whereby a random number generator was used to
simulate the progression of individual patients through the model one a time. Initially, the model was
analysed over a 5-year period. Thereafter, further longer-term analyses were undertaken, assuming
the same ongoing risks of vision loss as estimated for treated and untreated eyes in the ﬁfth year of the
model. The mean costs, years free of MVL (in either eye) and QALYs accruing to patients under the
alternative referral strategies were compared to estimate incremental cost-effectiveness ratios. In order to
characterise uncertainty surrounding these ratios, deterministic and probabilistic sensitivity analyses were
undertaken.80 The base-case analysis was carried out using English-speciﬁc cost data.
Probabilistic sensitivity analysis was undertaken by assigning distributions to model parameters where the
data sources and approach to estimation provided sufﬁcient information for this to be done. Beta
distributions for the adjusted sensitivity and speciﬁcity estimates (of alternative grading strategies) were
derived from the probabilistic simulations carried out for the analysis of the cost per case detected. Second
order distributions for mean screening, OCT, referral and treatment costs were assigned by selecting
variance parameters that ensured feasible low and high estimates (for each cost parameter) fell within the
2.5th and 97.5th percentile of the resultant distribution. Parameters excluded from the probabilistic
sensitivity analysis included the underlying probabilities of visual loss and visual gain, and the probabilities
of developing MO. The methods used to derive these probabilities precluded the estimation of uncertainty
due to sampling variation, and so the impact of variation in these parameters was addressed through
deterministic sensitivity analysis.ABLE 34 Health state utilities used in the cost-effectiveness model
Visual acuity state Standard gamble utility weight (SD) EQ-5D utility weight (SD)
BSE ≥ 74 letters 0.83 (0.16) 0.75 (0.23)
BSE 60–73 letters 0.75 (0.20) 0.50 (0.30)
BSE 46–59 letters 0.68 (0.23) 0.68 (0.29)
BSE 36–45 letters 0.65 (0.23)a 0.605 (0.39)a
BSE 24–35 letters 0.63 (0.23) 0.53 (0.47)
BSE < 24 letters 0.58 (0.26) 0.34 (0.36)
BSE, best seeing eye.
a Inferred by interpolation between utilities for visual acuity states above and below.T81
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82The results of the probabilistic sensitivity analysis are presented in the form of cost-effectiveness
acceptability curves, a standard method for characterising the uncertainty surrounding estimates of
cost-effectiveness. Deterministic sensitivity analysis was also used to assess the sensitivity of ﬁndings to
various structural assumptions, the implications of using alternative sources of cost data and the
incorporation of higher health and social care costs associated with legal blindness (see Table 33).ResultsTable 35 shows the expected costs, years free from MVL and QALYs for patients screened using the
alternative strategies over a 5-year period. Although the strategies are noticeably different in terms of
expected costs to the health service, they are harder to separate in terms of their impact on MVL and
QALYs. Under the base-case analysis the differences are very small, though they slightly favour the more
sensitive strategies. The introduction of OCT for all screen-positive individuals prior to referral reduces the
expected costs of all strategies under the base-case costing assumptions.
Tables 36 and 37 show the impact of extending the time horizon of the analysis to 10 and 20 years,
respectively. The result is a wider gap between the strategies in terms of the expected QALYs and years
free from MVL, and improved cost-effectiveness of the more sensitive strategies compared with the less
sensitive strategies. For example, the additional cost per QALY gained from using strategy 16 as compared
with manual grading strategy 2 (current Scottish referral criteria without OCT) decreases from £882,307
(at 5 years) to £353,927 at 20 years. The corresponding additional cost per year free from MVL is £38,457
at 5 years and £22,583 at 20 years.
The longer-term cost-effectiveness results mirror the pattern observed in the short-term analysis
(see Table 29), in that the addition of OCT results in cost-savings without reducing the health beneﬁts. As
per the short-term results, the automated strategy FA2 (with fall-back to manual strategy 16) also
dominates strategies 1 and 16 under the assumption of zero net increase in grading costs associated with
the introduction of automated grading. Furthermore, strategy 16 remains essentially dominant over, or
very cost-effective in comparison with, strategy 1. Figure 25 shows the cost-effectiveness frontier when
considering all strategies together.
Deterministic sensitivity analysis
Table 38 presents the ﬁndings from a number of deterministic sensitivity analyses, assessing the sensitivity
of ﬁndings to a number of structural and parameter assumptions in the model. Only when a number of
parameters were simultaneously weighted in favour of the more sensitive grading strategies did the
incremental cost per QALY estimates for these strategies begin to approach the accepted threshold range
(£20,000–30,000 per QALY) in comparison with the most speciﬁc strategy (strategy 2 + OCT) (scenario 9,
see Table 38). Considering the cost-effectiveness of fully automated annotation grading compared with
manual grading strategy 16, the analysis suggests that automated grading could remain dominant up to a
marginal net increase in grading cost of ∼ £2.00 per patient (assuming strategies are used in combination
with OCT prior to referral).
A threshold analysis was also performed to ascertain the threshold at which OCT would cease to be
cost-saving when used in combination with photographic screening/grading (on a 6-monthly basis) as part
of the screening pathway to monitor patients with suspected MO (rather than monitoring them on a
6-monthly basis as eye clinic outpatients). When applying English screening and referral costs, the marginal
cost of providing OCT within screening could reach ∼ £58 and remain cost-saving. In the Scottish context,
the corresponding threshold cost for OCT drops to ∼ £47. The choice between grading/screening
strategies was not found to be sensitive to the cost of providing slit-lamp examinations. The results were
also found to be generally insensitive to the costs associated with legal blindness and the rate of
progression to MO in those with no MO at the outset.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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HEALTH ECONOMIC EVALUATIONF86Probabilistic sensitivity analysisFigures 26 and 27 summarise the results of the probabilistic sensitivity analysis, applying base-case
structural assumptions over a 20-year time horizon. The analysis accounts for the joint uncertainty
surrounding screening, referral and treatment costs, as well as the uncertainty surrounding the sensitivity/
speciﬁcity of the alternative screening strategies, the relative frequencies of different pathology categories
(see Table 25), and the utility weights applied to the visual acuity states. Since the methods for estimating
the probabilities of progression to visual loss and MO did not enable the estimation of appropriate
portability distributions, the probabilistic sensitivity analysis did not incorporate the uncertainty surrounding
these parameters.
The ﬁgures demonstrate how the probability of the more sensitive grading strategies being cost-effective
increases as societies ‘willingness to pay’ per QALY or year free of MVL increases. With QALYs as the unit
of health outcome (see Figure 26), manual grading strategy 2 with OCT (the most speciﬁc and least costly
strategy) retains the highest probability of being the preferred option up to a ‘willingness to pay’ threshold
of ∼ £240,000, at which point the automated grading strategy (coupled with OCT) takes over. However,
with years free from MVL as the unit of outcome, this ceiling ratio drops to ∼ £12,000 (see Figure 27).
These threshold values assume that the cost of implementing automated grading is offset by cost-savings
resulting from reductions in manual grading time.DiscussionThe cost-effectiveness modelling has demonstrated how costs to the health service increase as more
sensitive referral strategies are adopted over more speciﬁc screening strategies.
A useful ﬁnding is that given the relatively high costs associated with referrals to hospital outpatient eye
clinics, the incorporation of OCT within screening pathways, targeted towards those with suspected MO,
could reduce costs to the NHS without reducing the number of OCT-positive cases of MO detected
and referred.
When looking at the grading strategies based on observing the presence of surrogate photographic
markers, the addition of OCT prior to referral reduced the overall costs of detection and referral without
impacting on the number of OCT-positive MO cases detected.
The OCT costs were based on the experience of the lead centre, where a band 6 screener carries out the
OCT examinations under the supervision of a consultant ophthalmologist. However, deterministic
sensitive analysis suggests that, if used in combination with retinal photography (on a 6-monthly basis)NIHR Journals Library www.journalslibrary.nihr.ac.uk
TABLE 38 Deterministic sensitivity analysis conducted over a 20-year time horizon
Scenario Strategy
Cost
(mean) (£)
Years free
from MVL
(mean)
QALYs
(mean)
Incremental
cost per year
free of MVL (£)
Incremental
cost per
QALY (£)
1. Application of Scottish
screening, referral and
treatment costs
Strategy 2 1643 10.2631 8.7029 a a
Strategy 1 1805 10.2703 8.7033 22,503b 364,890b
Strategy 16 1763 10.2700 8.7033 17,372b 272,251b
FA2c 1730 10.2709 8.7034 11,086 171,082
Strategy
2 + OCT
1446 10.2631 8.7029 a a
Strategy
1 + OCT
1572 10.2703 8.7033 17,502b 283,803b
Strategy
16 +OCT
1539 10.2700 8.7033 13,463b 210,995b
FA2 +OCTc 1512 10.2709 8.7034 8410 129,787
Strategy
8 + OCT
1719 10.2788 8.7038 17,427 304,924
2. Cases missed by
strategies at index
screening visit also
missed in subsequent
screening visit
(3-year delay)
Strategy 2 2155 10.2552 8.7025 a a
Strategy 1 2368 10.2632 8.7030 26,369b 465,247b
Strategy 16 2313 10.2628 8.7030 20,636b 346,475b
FA2c 2271 10.2636 8.7030 13,691 219,383
Strategy
2 + OCT
1806 10.2552 8.7025 a a
Strategy
1 + OCT
1959 10.2632 8.7030 18,941b 334,192b
Strategy
16 +OCT
1919 10.2628 8.7030 14,759b 247,796b
FA2 +OCTc 1888 10.2636 8.7030 9678 155,081
Strategy
8 + OCT
2109 10.2788 8.7038 12,844 234,722
3. Acuity in the
worse-seeing eye
determines visual
acuity state and
quality-of-life pay-off
Strategy 2 2269 10.2631 8.6722 a a
Strategy 1 2479 10.2703 8.6731 29,170b 247,056b
Strategy 16 2425 10.2700 8.6731 22,583b 179,967b
FA2c 2381 10.2709 8.6731 14,272 122,064
Strategy
2 + OCT
1920 10.2631 8.6722 a a
Strategy
1 + OCT
2070 10.2703 8.6731 20,836b 176,469b
Strategy
16 +OCT
2030 10.2700 8.6731 15,924b 126,900b
FA2 +OCTc 1999 10.2709 8.6731 10,067 86,099
Strategy
8 + OCT
2212 10.2788 8.6739 18,640 174,949
4. Differential discounting
(3.5% for costs, 1.5%
per annum for beneﬁts)
Strategy 2 2164 11.8596 10.0772 a a
Strategy 1 2374 11.8677 10.0777 25,676b 409,370b
continued
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TABLE 38 Deterministic sensitivity analysis conducted over a 20-year time horizon (continued )
Scenario Strategy
Cost
(mean) (£)
Years free
from MVL
(mean)
QALYs
(mean)
Incremental
cost per year
free of MVL (£)
Incremental
cost per
QALY (£)
Strategy 16 2320 11.8674 10.0777 19,837b 306,293b
FA2c 2277 11.8685 10.0778 12,620 191,675
Strategy
2 + OCT
1814 11.8596 10.0772 a a
Strategy
1 + OCT
1965 11.8677 10.0777 18,462b 294,357b
Strategy
16 + OCT
1925 11.8674 10.0777 14,115b 217,939b
FA2 +OCTc 1894 11.8685 10.0778 8934 135,699
Strategy
8 + OCT
2109 11.8772 10.0782 16,742 286,099
5. Laser treatment initiated
only in those with
MO with visual acuity
≥ 0.3 log-MAR
(≤ 70 ETDRS letters),
beneﬁt remains
unaffected
Strategy 2 2123 10.2631 8.7029 a a
Strategy 1 2333 10.2703 8.7033 29,170b 473,005b
Strategy 16 2278 10.2700 8.7033 22,438b 351,658b
FA2c 2235 10.2709 8.7034 14,272 220,244
Strategy
2 + OCT
1774 10.2631 8.7029 a a
Strategy
1 + OCT
1924 10.2703 8.7033 20,836b 337,861b
Strategy
16 + OCT
1884 10.2700 8.7033 15,924b 249,564b
FA2 +OCTc 1853 10.2709 8.7034 10,067 155,351
Strategy
8 + OCT
2067 10.2788 8.7038 18,704 327,263
6. Zero treatment costs
beyond 3 years
post diagnosis
Strategy 2 2031 10.2631 8.7029 a a
Strategy 1 2238 10.2703 8.7033 28,753b 466,248b
Strategy 16 2183 10.2700 8.7033 22,004b 344,852b
FA2c 2140 10.2709 8.7034 13,890 214,345
Strategy
2 + OCT
1682 10.2631 8.7029 a a
Strategy
1 + OCT
1829 10.2703 8.7033 20,419b 331,103b
Strategy
16 + OCT
1789 10.2700 8.7033 15,490b 242,758b
FA2 +OCTc 1758 10.2709 8.7034 9685 149,451
Strategy
8 + OCT
1969 10.2788 8.7038 18,321 320,562
7. Assume 40-letter loss
for all patients
experiencing MVL
Strategy 2 2306 10.2631 8.6916 a a
Strategy 1 2507 10.2703 8.6923 27,920b 299,223b
Strategy 16 2453 10.2700 8.6923 21,280b 223,383b
FA2c 2409 10.2709 8.6924 13,125 130,176
continued
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TABLE 38 Deterministic sensitivity analysis conducted over a 20-year time horizon (continued )
Scenario Strategy
Cost
(mean) (£)
Years free
from MVL
(mean)
QALYs
(mean)
Incremental
cost per year
free of MVL (£)
Incremental
cost per
QALY (£)
Strategy
2 + OCT
1956 10.2631 8.6916 a a
Strategy
1 + OCT
2098 10.2703 8.6923 19,724b 211,391b
Strategy
16 +OCT
2059 10.2700 8.6923 14,911b 156,520b
FA2 +OCTc 2027 10.2709 8.6924 9047 89,733
Strategy
8 + OCT
2237 10.2788 8.6930 17,938 197,632
8. All treatment beneﬁts
maintained beyond
5 years (i.e. no further
visual loss in those
treated successfully)
Strategy 2 2163 10.3409 8.7067 a a
Strategy 1 2373 10.3526 8.7073 17,953 321,117
Strategy 16 2319 10.3519 8.7073 14,073 245,183
FA2c 2275 10.3532 8.7074 9056 158,228
Strategy
2 + OCT
1814 10.3409 8.7067 a a
Strategy
1 + OCT
1964 10.3526 8.7073 12,823 229,369
Strategy
16 +OCT
1925 10.3519 8.7073 10,013 174,457
FA2 +OCTc 1893 10.3532 8.7074 6388 111,607
Strategy
8 + OCT
2107 10.3680 8.7081 10,776 209,912
9. Simultaneous application
of scenarios 2, 3 and 6;
combined with
application of a 40-letter
visual acuity loss for
those suffering MVL
Strategy 2 2613 10.2552 8.6511 a a
Strategy 1 2802 10.2632 8.6526 23,398b 133,098b
Strategy 16 2747 10.2628 8.6525 17,501b 97,443b
FA2c 2702 10.2636 8.6526 10,504 60,766
Strategy
2 + OCT
2264 10.2552 8.6511 a a
Strategy
1 + OCT
2393 10.2632 8.6526 15,970b 90,844b
Strategy
16 +OCT
2353 10.2628 8.6525 11,624b 64,719b
FA2 +OCTc 2319 10.2636 8.6526 6492 37,552
Strategy
8 + OCT
2500 10.2788 8.6552 10,004 58,093
a Reference strategy.
b Strategy more costly and less effective than an alternative strategy (dominated).
c Figures in table based on assumption that fully automated grading can be implemented at zero net increase in grading costs.
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FIGURE 26 Cost-effectiveness acceptability curves for the alternative strategies based on a 20-year time horizon and
using QALYs as the measure of effect.
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FIGURE 27 Cost-effectiveness acceptability curves for the alternative grading strategies based on a 20-year time
horizon and using years free from MVL as the measure of effect.
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90to monitor patients within screening, the use of OCT could remain cost saving up to an incremental cost
of ∼ £58 per patient.
In the Scottish context, this threshold cost drops to ∼ £47. To put this in perspective, if an associate
specialist were to perform OCT examinations within screening programmes, assuming the same time input
required by the band 6 retinal screener (see Appendix 2), the cost would be ∼ £64.
A Markov microsimulation model was developed to assess the longer-term cost-effectiveness of moving
from more speciﬁc to more sensitive and more costly grading strategies (e.g. manual grading strategy
2 + OCT, to manual grading strategy 1 + OCT, to manual grading strategy 16 + OCT, to automated
grading + OCT, to manual grading strategy 8 + OCT).
This analysis showed that while costs to health service increase substantially with the more sensitive/less
speciﬁc strategies, the associated increase in cases detected does not translate into large gains in health
outcomes over time.
The reason for the small differences in years free of MVL and QALYs between the strategies is down to a
number of factors.
First, the adjusted prevalence of MO in the modelled cohort was relatively low in the ﬁrst place, so only a
small proportion of the cohort was initially modelled to be at risk of visual loss (5.6%).
Second, although the relative difference in the adjusted sensitivity of the strategies appeared quite
substantial, the repetitive nature of screening diminishes the importance of this difference since anyNIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51patients missed in one round of screening have a chance of being picked up during the next round prior
to any visual loss occurring (i.e. only 12% of non-referred patients with MO were modelled to progress to
MVL within 1 year, compared with 5% of referred/treated patients as per the ETDRS).61,64
The expected QALYs for patients screened under the alternative grading strategies were particularly
insensitive to differences in grading strategy sensitivity. This is because the QALYs were determined by
visual acuity in the better-seeing eye of simulated patients.
Since the majority of patients missed by less sensitive grading strategies had MO in only one eye, and most
often their worse-seeing eye, any loss of vision in this eye did not impact on the patient's health-related
quality of life in the base-case scenario.
Despite the only very small differences in health outcomes between grading strategies, increases in grading
strategy sensitivity (with accompanying reductions in speciﬁcity) did result in substantial cost increases to
the health service over time, as a result of more subjects being sent for OCT or referred to eye clinics for
ongoing monitoring or treatment.
To assess the sensitivity of ﬁndings to the base-case parameter values and structural assumptions,
extensive deterministic sensitivity analysis was undertaken. As a best case scenario for the more sensitive
grading strategies, patients' visual acuity state and health-related quality of life status were assumed to be
driven entirely by acuity in the worse-seeing eye, and additional costs of treatment were assumed to cease
beyond 3 years (for the same treatment beneﬁt).
On top of this, it was assumed that cases missed by less sensitive grading strategies would continue to be
missed in subsequent rounds of screening for a period of 3 years (and be at increased risk of MVL in the
interim) and that those suffering MVL would lose on average 40 ETDRS letters. Under this relatively
unlikely scenario, the incremental cost per QALY estimates for the more sensitive grading strategies
remained unfavourable when compared with thresholds used to judge cost-effectiveness in the UK
(i.e. £20,000–30,000 per QALY).
These results would suggest that, given the repetitive nature of screening and the relatively slow
progression of visual loss from MO, the adoption of more sensitive/less speciﬁc screening strategies over
more speciﬁc/less sensitive grading strategies is unlikely to be considered cost-effective.
Conversely, the results would suggest that if signiﬁcant improvements in speciﬁcity can be achieved
without reducing sensitivity – for example, by adopting the more complex automated annotated grading
strategy based on automated image grading and pattern detection – such an approach could offer a more
cost-effective alternative than current grading strategies based on simple manual algorithms. This, of
course, will depend on the cost at which such a system can be implemented within different screening
contexts relative to the manual grading cost-savings that might be realised as a result.
To give an example, the results presented here would suggest that the automated annotation grading
strategy might continue to dominate grading strategy 16 up to a net increase in grading costs of ∼ £2.00
per patient with suspected MO (with OCT also being used prior to referral). However, more detailed
consideration would need to be given to how such a pathway would be implemented and how much it
would cost in different local contexts.Strengths and limitations
In order to assess longer-term cost-effectiveness, we created a ﬂexible model whereby the individual eyes
of each patient were modelled separately. This enabled us to assess the impact of different assumptions
about how loss of acuity in one eye or both eyes affects the health-related quality of life of patients
(i.e. either assuming the patient's better-seeing eye determines health-related quality of life or assuming
the worse-seeing eye determines health-related quality of life).91
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92We tried to use the best available evidence on the effects of laser treatment compared with no treatment
for those patients with MO, in order to assess the beneﬁts of improved detection and referral. In doing so,
we updated older effect proﬁles for laser treatment to accommodate the observation of improved
outcomes being associated with its use in more contemporary studies.68
A lack of contemporary data on progression of MO in untreated patients required the assumption that
patients without treatment would progress at the rate observed in the ETDRS.64
A weakness of the modelling related to the sample selection approach and the subsequent need to rely on
surrogate marker category frequency weights (obtained from a separate cohort study) to estimate the
likely sensitivity/speciﬁcity of the alternative options within routine screening. However, the overall ﬁndings
and conclusions were generally insensitive to the weighting process.
A further potential weakness was the assumption that all patients with MO would be treated with laser,
rather than intravitreal anti-vascular endothelial growth factor injections. This decision was taken based on
current National Institute for Health and Care Excellence guidance81 as well as a survey of participating
centres which suggested that laser still formed the mainstay of treatment throughout the study period.
Our model may be updated in the future to incorporate antivascular endothelial growth factor treatment.
It is possible that this could improve the cost-effectiveness of more sensitive referral strategies by improving
outcomes for additional patients detected and referred.
However, by the same token it might also improve outcomes for patients with MO missed by less sensitive
strategies but picked up at a subsequent screening visit (or presenting with clinical symptoms).Comparison with other studies
We are not aware of any other studies which have speciﬁcally assessed the cost-effectiveness of alternative
approaches to screening for diabetic MO. Many studies have assessed the cost-effectiveness of screening
for diabetic retinopathy82–85 in which detection of MO was one of the modelled beneﬁts.
In comparison with these previous screening models, our model provides more ﬂexibility for assessing the
impact on quality of life of MVL in one or both eyes; some previous studies applied more crude annual
risks of progression from MO directly to irreversible legal blindness (sometimes applying reported risks per
eye with MO at the level of the patient).Conclusions
The ﬁndings of the economic modelling would suggest that given the relatively low prevalence of MO in
patients with surrogate photographic markers, coupled with the repetitive nature of screening, the
adoption of more sensitive grading strategies is unlikely to be cost-effective unless this can be achieved for
no (or only a very small) decrease in speciﬁcity.
A further important ﬁnding from the economic analysis is that OCT within screening pathways
offers potential.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Chapter 7 DiscussionReason for studyThe risk of retinopathy increases with disease duration.1 Type 2 diabetes is often diagnosed several years
after onset and almost 40% of people with type 2 diabetes are found to have retinopathy at diagnosis.
This is potentially sight-threatening in between 4% and 8% of cases. Sixty per cent of people with type 2
diabetes will have retinopathy 20 years from onset.
There are two main mechanisms responsible for visual loss in diabetic retinopathy. The ﬁrst of these is
proliferative retinopathy and the development of new blood vessels. The second is MO, the build-up of
ﬂuid involving the area of the retina associated with best vision, the macula.
Although proliferative disease is most likely to lead to serious vision loss, MO is more common and is the
leading cause of MVL in people with diabetes. However, laser treatment is only moderately effective, at
best, for MO.
At the time of the introduction of national programmes for screening for diabetic retinopathy in the UK,
screening for diabetic MO was not deemed to meet strict World Health Organization guidelines
for screening.
Diabetic retinopathy at the macula (maculopathy) is more common than proliferative diabetic retinopathy
so retinal screening programmes have had to develop pathways to address this, although it is
acknowledged that the evidence base for doing so is limited.
The current recommended method of retinal screening for diabetic retinopathy is digital fundus
photography, a two-dimensional technology that cannot detect MO directly. Current photographic
grading schemes rely on a combination of surrogate markers, chosen by expert consensus, to infer the
presence of MO.
These manual grading schemes use combinations of features of retinopathy including M/DHs, BHs,
exudates and also visual acuity. At present, there is no consensus among the four nations as to which, and
how many, features should be used to infer the presence of diabetic MO.
Clinical experience from the Grampian Retinal Screening Programme and Liverpool Screening Programme
suggests that only 12–14% of these patients have evidence of MO, when examined by ophthalmologists
using slit-lamp biomicroscopy.Aim of the studyThe primary aim of the study was to determine the best photographic surrogate markers for detecting
potentially sight-threatening diabetic MO within English and Scottish national screening programmes.
Speciﬁcally we wished to:
(a) investigate whether or not particular distributions and combinations of lesions (M/DHs, BHs and
exudates), assessed manually or automatically, were more speciﬁc surrogate markers of MO than
current practice, using OCT as the reference standard
(b) assess the costs and consequences of using alternative distributions and combinations of these lesions
to screen for MO, using either automated or manual detection93
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DISCUSSION
94(c) model the long-term cost and quality-of-life implications of using alternative distributions and
combinations of surrogate markers to screen for MO.
Once the study was under way, several screening programmes were found to be using OCT as part of the
screening process to reduce false-positive referrals to the hospital eye service.
Consequently, we added a further aim to assess the costs and consequences of using OCT within retinal
screening programmes in addition to improving the photographic surrogate markers, as this would affect
how photographic markers would be used in future.Study designThis was a multicentre, prospective, observational cohort study. We recruited 3540 subjects attending one
of seven diabetic retinal screening programmes who had features of diabetic retinopathy visible within the
macular region.
The speciﬁc diabetic retinopathy features of interest as surrogate markers for MO were M/DHs, BHs and
exudates. All subjects were recruited and imaged at the participating centres in Aberdeen, Birmingham,
Dundee, Dunfermline, Edinburgh, Liverpool and Oxford.
All subjects had their best corrected visual acuity assessed followed by a single retinal photograph of each
eye. An OCT scan was acquired within 4 weeks of the retinal photograph.
The retinal photographs, OCT images and relevant demographic study data were uploaded using a
customised web-based tool developed for the study.
All the retinal photographs were annotated for features of retinopathy by a research nurse who had
3 years' experience working as a retinal grader.
Software was developed to enable the research nurse to annotate key retinal landmarks and all lesions
associated with maculopathy (M/DHs, BHs and exudates) as well as non-diabetic features with similar
appearance which could confound the analysis (ﬂame haemorrhages, drusen and CWS).Recruitment
A total of 3540 patients were recruited from the seven participating centres, of whom 370 were excluded
as either the retinal photographs or OCT images were not of adequate quality to meet the inclusion
criteria in the study. The median age of the remaining 3170 subjects was 60 years. Of these subjects,
60.7% were male and 84.5% were Caucasian. There was a preponderance of people with type 2 diabetes
(77.4%) compared with type 1 diabetes.
Of the 3170 patients, 243 (7.7%) were conﬁrmed as having MO after review of the OCT images. The
prevalence of MO differed greatly by centre, ranging from 3.7% to 12.2%. The prevalence of MO also
differed between scanners, ranging from 4.5% to 11.8%.Macular oedema and photographic features of retinopathy
The detection of MO was strongly related to the presence of lesions and was consistently higher in
subjects with exudates or BHs (without exudates) within one DD than in those with just M/DHs within
one DD.
The detection of MO was also strongly related to increasing counts of these three types of lesions. This
was true of all three types of lesion within one DD (adjusted for each other) including M/DHs.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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and two DD.
Having more than two M/DHs in an eye appeared to be of particular importance in predicting the
presence of MO.
Although it would normally be impractical in manual screening to count individual lesions, it would be
possible to identify an image with more than two M/DHs.Macular oedema and patient characteristics
Having poor visual acuity was associated with increased detection of MO. Other patient characteristics
associated with MO in univariate analyses were older age, Caucasian ethnicity and having type 2 diabetes
rather than type 1 diabetes.
These apparent relationships between higher detection of MO with older age, poor visual acuity and
type 2 diabetes were unlikely to have been entirely independent of each other.Development of grading strategies
In order to evaluate the best combination of photographic features that would help predict the presence
of MO on OCT, a number of grading strategies were explored including those currently used by
screening programmes.
In addition to features of retinopathy, the inclusion of those patient characteristics that were found to be
statistically signiﬁcant in a univariate analysis were modelled.
We compared the performance of three broad approaches, namely manual grading strategies, computer-
assisted manual annotation grading strategies and fully automated annotation grading strategies.
Because the proportion of patients recruited who had M/DHs only in the macula was lower than in the
typical diabetic population attending a screening programme, it was necessary to weight subjects to bring
proportions in line with those found in an earlier prospective cohort study.The clinical effectiveness of manual grading strategies
The effectiveness of manual grading strategies is demonstrated by the trade-off between sensitivity
and speciﬁcity.
The English grading system, which uses the largest number of features, is the most sensitive but the least
speciﬁc, whereas the Scottish grading system is the most speciﬁc and the least sensitive.
A number of new manual grading strategies were devised with the aim of improving on
existing approaches.
One of the manual grading strategies, labelled strategy 16, demonstrated an improved speciﬁcity by
approximately 4% relative to the current grading practice in England, for a similar sensitivity. It differs from
the current grading practice in England in that BHs within one DD are referred regardless of visual acuity
status, and exudates between one DD and two DD are not included in the selection criteria. This grading
strategy would appear to make grading easier and could improve appropriateness of referrals.
The current manual grading strategies that do not include visual acuity or the presence of M/DHs could be
improved by taking these into account.
Current manual grading strategies that include exudates between one and two DD could be improved by
removing this aspect.95
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96An ideal grading strategy would able to take into account the presence and count of all three types of
lesion within one DD and also visual acuity.The clinical effectiveness of computer-assisted manual annotation
grading strategies
The optimum grading strategy, in terms of area under its receiver operating characteristic curve, was the
computer-assisted manual annotation grading strategy, CAM. This uses the results of manual annotation
of the individual lesions in each image.
This is a time-consuming procedure and so is unlikely to be considered for routine screening practice.
Therefore, this manual annotation grading strategy was not taken forward for economic analysis.The clinical effectiveness of fully automated annotation grading strategies
Fully automated annotation grading strategies were developed using previously described algorithms for
detection of lesions of diabetic retinopathy.
The outputs of the lesion detectors were combined using an automated classiﬁer which was trained to
detect MO. Optionally, visual acuity and other non-image data were also input to the classiﬁer.
A grading strategy using automated analysis of the macula-centred image performs slightly better than
current manual grading strategies.
If automated annotation grading data are combined with non-image data, then further improvements are
obtained; a large proportion of this improvement is due to visual acuity alone. Because visual acuity is a
standard measurement performed during diabetic retinopathy screening, this additional information could
be added to a fully automated annotation grading strategy with little effort.Cost-effectivenessThe economic analysis was conducted in two phases. An initial analysis focused on the cost per true case
of MO appropriately detected and referred, both before and after adjusting for the expected frequency of
different surrogate marker categories within the screening cohort.
This process relied on the estimated sensitivity/speciﬁcity of the alternative grading strategies obtained
from the clinical data (see Table 23), combined with estimates of screening and referral costs obtained
from a variety of sources (see Table 24).
In addition to estimating the cost-effectiveness of alternative simple manual grading strategies, the
potential cost-effectiveness of using fully automated annotation grading, in combination with information
on visual acuity within a linear classiﬁer, was assessed.
Furthermore, we also assessed the cost-effectiveness of introducing OCT within the screening pathway, so
as to further improve the speciﬁcity of referrals for suspected MO.
Following this initial analysis, a Markov microsimulation model was developed and used to assess the likely
impact of the same grading/screening strategies on longer-term costs and health outcomes. This process
relied on epidemiological, cost and health state utility data derived from the published literature.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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including quality-adjusted life-years and long-term costs
(aims b and c, Chapter 2)
The cost-effectiveness modelling clearly demonstrates how costs to the health service increase as more
sensitive manual grading strategies are adopted over more speciﬁc grading strategies.
Despite the only very small differences in health outcomes between manual grading strategies, increases in
sensitivity (with accompanying reductions in speciﬁcity) did result in substantial increases in costs to the
health service over time, as a result of more subjects being sent for OCT or referred to eye clinics for
ongoing monitoring or treatment.
While the relative difference in the adjusted sensitivity of the manual grading strategies appeared quite
substantial, the repetitive nature of screening diminishes the importance of this difference since any
patients missed in one round of screening have a chance of being picked up during the next round prior
to any visual loss occurring.
Even assuming very favourable parameters for the more sensitive manual grading strategies, the
incremental cost per QALY estimates for the more sensitive grading strategies remained
unfavourable when compared with thresholds used to judge cost-effectiveness in the UK
(i.e. £20,000–30,000 per QALY).Cost-effectiveness of manual grading strategies compared with a fully
automated annotation grading strategy (aims b and b, Chapter 2)
The results would suggest that if signiﬁcant improvements in speciﬁcity can be achieved without reducing
sensitivity – for example, by adopting the more complex classiﬁer based on automated image grading and
pattern detection – such an approach could offer a more cost-effective alternative than current manual
grading strategies based on simple manual algorithms.Costs and consequences of using optical coherence tomography within
retinal screening programmes in addition to improving the photographic
surrogate markers
A valuable ﬁnding is that given the relatively high costs associated with referrals to hospital outpatient eye
clinics, the incorporation of OCT within the screening pathway, targeted towards those with suspected
MO, could potentially reduce costs to the NHS without reducing the number of OCT-positive cases of MO
detected and referred.
When looking at those grading strategies based on observing the presence of surrogate photographic
markers, the addition of OCT prior to referral, as part of the screening pathway, to each of these grading
strategies reduced the overall costs of detection and referral without impacting on the number of
OCT-positive MO cases detected.
The OCT costs were based on the experience of the lead centre, where a band 6 screener carries out the
OCT examinations under the supervision of a consultant ophthalmologist.
However, deterministic sensitive analysis suggests that if used in combination with retinal photography
(on a 6-monthly basis) to monitor patients within screening, the use of OCT could remain cost-saving up
to an incremental cost of ∼ £58 per patient. In the Scottish context, this threshold cost drops to ∼ £47.StrengthsThis was a multicentre study reﬂecting everyday clinical practice throughout the UK. This allowed for all
patients attending retinal screening programmes to be invited if they met the inclusion criteria.97
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DISCUSSION
98To avoid intercentre variation, all OCT operators were required to be accredited before submitting data for
the study. Operators submitted a portfolio that included the images collected using the OCT scanner they
would be using for the study.
The web-based system allowed for the centralisation of retinal image and OCT grading using
quality-assured graders.
The database of annotated images allowed us to explore in detail the relationships between the various
photographic features of retinopathy and the presence of MO seen with OCT.
We were also able to compare the clinical effectiveness and cost-effectiveness of the various existing
manual grading strategies on a single data set, thus highlighting their individual strengths and weakness.
We built on existing automated algorithms for assessing diabetic retinopathy. We were able to incorporate
the automated detections of features along with patient characteristics in a novel automated annotation
grading algorithm to optimise screening for MO.
The economic analysis included a survey of costs and pathways of implementation in the participating
centres. The results of the study can therefore be applied across England and Scotland.LimitationsSince its commercial launch in 1996, OCT technology has been continuously evolving. Improvements have
resulted in improved signal-to-noise ratio and axial and lateral resolution, and shortened acquisition times.
A number of scanners are now available, but there is poor agreement between retinal thickness
measurements made on the different scanners. It was decided to include a variety of scanners in order
to beneﬁt from the higher-quality images from the newer devices and to make the results more
generally applicable.
In order to include results from different OCT scanners, experiments were undertaken before the study
began to estimate the differences in thickness between the new scanners to allow corrections to be made.
The wide variation in MO detection between centres is most likely due to differences in the sensitivity of
the OCT scanner than true variations in prevalence.
The centres with the latest high-resolution scanners all detect a higher proportion of their subjects as
having MO than centres relying on older technology.
In centres with older scanners a proportion of the true cases of MO will be graded as having no MO. Such
cases will affect the estimated sensitivities and speciﬁcities of the different strategies.
Three hundred and seventy people were excluded from the ﬁnal analysis because an adequate quality
image could not be obtained either by retinal photography or by using OCT.
This was related to the type of scanner used and some patient-related characteristics such as poor visual
acuity and older age.
In the recruited cohort there was an under-representation of those with just M/DHs in the macula when
compared with a typical screening cohort. This reﬂected a variation in current practice between centres
with regard to how M/DHs in the macula region are handled by the screening programme.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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prospective cohort study. However, the overall ﬁndings and conclusions were generally insensitive to the
weighting process.
There was a lack of contemporary data on the progression of MO in untreated patients for economic
modelling. This required the assumption that patients without treatment would progress at the rate
observed in the ETDRS.64
We tried to use the best available evidence on the effects of laser treatment compared with no treatment
for those patients with MO, in order to assess the beneﬁts of improved detection and referral.
In doing so, we updated older effect proﬁles for laser treatment to accommodate the observation of
improved outcomes being associated with its use in more contemporary studies.68
A further potential weakness was the assumption that all patients with MO would be treated with laser,
rather than intravitreal antivascular endothelial growth factor injections.
This decision was taken based on current National Institute for Health and Care Excellence guidance,81 as
well as a survey of participating centres which suggested that laser still forms the mainstay of treatment.Implications for health careCompared with all current manual grading schemes, for the same sensitivity, a fully automated strategy,
using the automated detection of patterns of photographic surrogate markers, achieves a higher speciﬁcity
for detecting MO in people with diabetes, especially if visual acuity is included in the automated strategy.
Overall costs to the health service are likely to increase if more sensitive referral strategies are adopted over
more speciﬁc screening strategies for MO, for only very small gains in QALYs.
The addition of OCT to each screening strategy, prior to referral, results in a potential for a reduction in
costs to the health service with no decrement in the number of MO cases detected.
Retinal thickness measurements utilised by different scanners should be standardised.Recommendations for researchResearch should be undertaken into the most cost-effective method of screening for diabetic MO that
takes into consideration a treatment strategy where the timing of intervention is based on a patient's
perception of their visual disability.
This would also require research to be undertaken on the progression of MO in untreated patients and its
impact on quality of life.99
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retinal thickness
Macular oedema has traditionally been assessed clinically using a combination of slit-lampbiomicroscopy, stereo photography and stereo ﬂuorescein angiography. However, these techniques
have a number of limitations that make them unsuitable for this study. Foremost is that they offer only
qualitative assessments, which are also relatively insensitive to changes in retinal thickness. Furthermore,
slit-lamp examination does not provide a pictorial record and, together with stereo photography, is known
to be biased by the presence or absence of exudates. Angiography is a sensitive test for leakage, but not
for thickening. Best corrected visual acuity has also been used as a surrogate indication of thickening, but
is neither sensitive nor speciﬁc. Four imaging techniques that offer objective, quantitative measures of
macular thickening are described below. Table 39 lists the axial and lateral resolutions of the four methods.
Ultrasound
Ultrasound frequencies between 10MHz and 20MHz are the most useful for retinal imaging. Frequencies
as high as 50MHz have been used for high-resolution imaging of the anterior segment, but these have
insufﬁcient penetration for retinal imaging. Interfaces between materials with different acoustic properties
generate strong echoes, whereas materials that scatter the ultrasound beam return weaker echoes.
Fluid-ﬁlled structures, such as the vitreous, or cysts, neither reﬂect nor scatter ultrasound. Therefore, there
is strong contrast between MO and normal retinal tissue.
The two-dimensional cross-sectional ultrasound image is composed of a series of A-scans. These are single
axial proﬁles recording the strength of echoes from different tissue depths. One advantage of ultrasound
imaging is that it is not affected by optical opacities, such as cataract or vitreous haemorrhage. However, it
has relatively poor resolution (approximately 200 µm axially and laterally) and is an invasive technique,
requiring contact with the eye.Optical coherence tomographyOptical coherence tomography86 is a popular, rapid and non-invasive technique for cross-sectional retinal
imaging that has proved convenient for longitudinal studies and as a trial outcome measure.1,87 It is often
referred to as an optical analogue of ultrasound imaging, measuring backscattered light rather than
sound. However, unlike ultrasound, OCT is a non-invasive, non-contact technique. Nevertheless, much
OCT terminology has been borrowed from ultrasound imaging, such as the ‘A-scan’ (a signal vs. depth
proﬁle) and ‘B-scan’ (a collection of A-scans giving a two-dimensional cross-section). The ﬁrst commercial
OCT scanner was launched in 1996 by Carl Zeiss Meditec. It used a super-luminescent diode light source
and time domain interferometry based on a moving mirror and a Michelson interferometer.88 In 2001 Zeiss
released their most recent time domain OCT system, the Stratus OCT. Although faster than its
predecessors it still only acquires 400 A-scans/second, which limits the number of cross-sections that can
be acquired before eye movement is a problem. The latest generation of OCT scanners are based on
spectral domain techniques, which dispense with the moving mirror and are thereby able to increase the
acquisition rate by up to two orders of magnitude. Three such scanners, the Zeiss Cirrus OCT, Topcon 3D
OCT-1000 and Heidelberg Spectralis, were used in this study.
Prior to OCT, retinal cross-sections were possible only using ultrasound imaging. The introduction of OCT
improved the axial resolution of cross-sections by two orders of magnitude, allowing structures to be seen
in vivo that were formerly visible only by histological examination (Figure 28). Retinal thickness
measurements are calculated from the cross-sectional images using software to segment the inner and
outer limiting boundaries of the retina, although there is disagreement about which boundary best109
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ABLE 39 Summary of axial and lateral resolution of retinal thickness techniques. Note that the axial sampling
sed by the Zeiss Stratus OCT results in a much higher thickness map lateral resolution at the centre of the region
han at the periphery. Modern spectral domain scanners more commonly sample the area rectilinearly and have
onstant resolution across the map
Method Axial resolution (µm) Lateral resolution (µm)
Ultrasound (B mode) 150–200 250–500
OCT (cross-section) 2–15 10–20
OCT (Stratus map) 2–15 10 (centre)–1500 (edge)
Retinal Thickness Analyser 50 380
Heidelberg cSLO 150–300 10–20
cSLO, Confocal Scanning Laser Ophthalmoscope.
APPENDIX 1
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cFIGURE 28 Optical coherence tomography retinal cross-section.represents the lower limit of the retina. Although thickness measurements are calculated for every A-scan
line, these are usually combined to form a nine-region thickness map centred on the fovea, as shown in
Figure 29. This map layout was ﬁrst used by the ETDRS89 and later by the Age-Related Eye Disease Study.90
Retinal Thickness Analyser
The Retinal Thickness Analyser (RTA) was launched in 2000 by Talia Technology Ltd, based on research at
Johns Hopkins University.91 It consists of an integrated fundus camera and laser system for non-invasive
retinal thickness measurement.
The thickness measurement is based on the same principle as the slip-lamp biomicroscope. A green
(543 mm) helium–neon laser is projected as a slit, 3 mm in length and approximately 15 µm wide. The slit
is not projected perpendicularly onto the retinal surface, but at an oblique angle of 15 degrees, so that
light reﬂected from different depths results in a lateral displacement of the reﬂection: each 100 µm change
in depth results in a 27 µm lateral shift. These lateral displacements are recorded using a charge-coupled
device (image sensor; CCD) camera and automatic measurements used to generate a thickness map.NIHR Journals Library www.journalslibrary.nihr.ac.uk
Superior
Inferior
Nasal735 1
2
6
4
8
9Temporal
IGURE 29 Early Treatment Diabetic Retinopathy Study/Age-Related Eye Disease Study regions. The inner circle has a
iameter of 1mm, the middle circle a diameter of 3mm and the outer circle a diameter of 6mm. Left eyes are
eflected left-to-right such that the temporal region is always to the left and the nasal region to the right.
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d
rConfocal scanning laser ophthalmoscopeThe scanning laser ophthalmoscope produces an image by rapidly scanning a laser spot across the retina,
both horizontally and vertically. Any laser wavelength can be used, but red or infrared light is usually
chosen for three-dimensional imaging, as the longer wavelengths are able to penetrate deeper into the
retina. A three-dimensional image may be acquired by placing a confocal aperture in front of the detector.
This allows only light from a given depth range to be detected. A three-dimensional volume is formed
from a series of two-dimensional images at different depths, as selected by the confocal aperture position.
Although the confocal scanning laser ophthalmoscope has good lateral resolution (at least as good as a
fundus camera), the axial resolution is poor at around 150–300 µm, limiting the accuracy of the thickness
measurements and showing little or no anatomical features in the axial direction.111
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tomography and slit-lamp examination within the
screening programme
The following tables indicate the bottom-up cost calculations used to estimate the cost of OCTexaminations within screening programmes.
EquipmentOCT
machine
Unit
cost (£)
Useful
lifespan
EAC
(£)
Annual throughput
generated in
screening programme
Cost per
patient
screened (£) Source/notes
Scenario 1 36,000 10 4329 937 4.62 Centre information
Scenario 2 50,000 10 6012 937 6.42 Centre information
Annual service
contract
3403 937 3.63 Centre information
EAC, equivalent annual cost.Staff costsTask Band
Patients
screened
per day
clinic
Working
hours
per day
Time per
patient
(minutes)
Unit cost
per hour
(£)
Cost per
patient
(£) Source/notes
Administration
time
3 5 12.86 1.07 Centre-reported
data; PSSRU, 201056
Examination 6 24 7.5 18.75 31 9.69 Centre-reported
data; PSSRU, 201056
Associated
grading costs
6 5 31 2.58 Centre-reported
data; PSSRU, 201056
Additional L3
grader costs
Consultant 5 127 10.58 Centre-reported
data; PSSRU, 201056
Total 23.93
L3, level 3.©
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114Slit-lamp examination costsThe following tables indicate the bottom-up cost calculations used to estimate the cost of providing
slit-lamp examinations within screening programmes.
Equipment costsSlit-lamp Units Cost (£) Lifespan EAC (£)
Annual
throughput
Cost per
patient (£) Source/notes
Scenario 1 1 11,250 10 1353 3780 0.36 Centre reported;
assumes shared
Scenario 2 1 15,000 10 1804 450 4.01 Centre reported;
assumes exclusive to
screening programme
Scenario 3 2 22,500 10 2705 1307 2.07 Centre reported;
assumes exclusive to
screening programme
Scenario 4 1 15,000 10 1804 800 2.25 Centre-reported data
EAC, equivalent annual cost.Staff costsScenario
Clinic time
(hours)
Clinic
throughput
Time per
patient
(minutes)
Examiner
band
Unit cost
per hour
(£)
Cost per
patient (£) Source/notes
Scenario 1 4 13 0.308 Associate
specialist
90 27.69 Incorporates
oncosts,
overheads and
treatment
space; PSSRU,
201056
Scenario 2 3.5 8 0.438 Associate
specialist
90 39.38 Incorporates
oncosts,
overheads and
treatment
space; PSSRU,
201056
Scenario 3 3.5 12 0.292 Band 6 31 9.04 Incorporates
oncosts and
overheads;
PSSRU, 201056
Scenario 3 3.5 12 0.292 Band 7 36 10.50 Incorporates
oncosts and
overheads;
PSSRU, 201056
Average
scenario 3
9.77 Incorporates
oncosts and
overheads;
PSSRU, 201056
Scenario 4 3.5 10 0.350 Band 7 36 12.60 Incorporates
oncosts and
overheads;
PSSRU, 201056
NIHR Journals Library www.journalslibrary.nihr.ac.uk
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space (m2)
New build
cost per
m2 (£)
Total
cost
(£)
Lifespan
(years)
EAC
(£)
Use for
slit-lamp
Annual
attibutable
cost to
slit-lamp
examinations
(£)
Annual
maintenance
Annual
throughput
Cost
per
patient
(£)
25 3000 75,000 60 3007 0.20 601 200 984 0.81
EAC, equivalent annual cost.
Notes: Data from NHS Grampian Estates Department; assumes space used for slit-lamp 1 day a week, 41 weeks per year,
24 patients per day.Administration costs (all scenarios)Administrative staff time Unit cost (£)
Estimated cost per patient assuming similar to OCT clinic administration costs 1.07ConsumablesItem Unit cost (£)
Tropicamide or phenylephrine 2.5% (drops) 0.98
Letter and postage 0.30Total cost per slit-lamp examinationsScenario Total cost (£)
Scenario 1 30.40
Scenario 2 45.73
Scenario 3 15.01
Scenario 4 18.02
Average 27.29115
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modelling – additional dataPresence of different types of lesion at the seven centresLesion information was missing for three left eyes and two right eyes, so the denominator for left eyes was
3167 and for right eyes was 3168. Counts of subjects and eyes with MO and features by centre in each
eye within one DD unless otherwise speciﬁed. Subjects can have several different lesions or none in each
eye. Percentages have not been presented for very small counts.
Mutually exclusive groups of lesions by centre
Mutually exclusive (non-overlapping) groups of features were identiﬁed so that every eye could be
classiﬁed into one group and one group only. The groups for comparison were (1) M/DH only (not BH or
exudates); (2) BH, but not exudates (BH only + BH and M/DH only); and (3) exudates (regardless of what
else). Prior to the recruitment these lesions were expected to be present in 11.3%, 1.4% and 3.5% of
scanned images, but 69.8%, 8.6% and 21.6% of images with some lesions.
The percentages of left eyes in the groups: no lesions within one DD, M/DHs only within one DD, BHs only
or BHs with M/DHs within one DD, exudates only or with M/DHs or BHs within one DD, other lesions
within one DD were 28.1%, 40.3%, 8.4%, 20.4% and 2.8%, respectively. Very similar percentages were
found in the right eyes: 27.9%, 41.7%, 8.7%, 18.9% and 2.8%. These percentages, particularly those for
M/DHs only, did not match those in the paragraph above, and this was one reason why weighting of the
subjects according to the features of their worst eye was considered necessary.
Note that in Tables 43 and 45 there are some very large coefﬁcients and upper ends of the 95% CIs for
more than two BHs and for unknown visual acuity. This is a consequence of there being very few subjects
with these characteristics, giving very wide CIs, and several of them having MO, inﬂating the estimates of
ORs. These estimates are very volatile and should not be treated as a true reﬂection of the relationships
that would be found in population of screened people with lesions.117
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ABLE 41 Exclusive groups of features for comparison are (1) M/DH only (no BHs or exudates); (2) BH, but no
xudates (BH only or BH+M/DH only); and (3) exudates (regardless of what else)
Centre
No lesions
within
one DD
M/DH only
within
one DD
BH or BH +
M/DH within
one DD
Exudate +
any within
one DD
Other
within
one DD Total
Left eye
Aberdeen Count 193 306 115 270 25 909
% within
centre
21.2 33.7 12.7 29.7 2.8 100.0
Birmingham Count 225 441 51 97 28 842
% within
centre
26.7 52.4 6.1 11.5 3.3 100.0
Dundee Count 99 85 24 37 6 251
% within
centre
39.4 33.9 9.6 14.7 2.4 100.0
Edinburgh Count 42 68 23 83 2 218
% within
centre
19.3 31.2 10.6 38.1 0.9 100.0
Liverpool Count 200 145 15 50 6 416
% within
centre
48.1 34.9 3.6 12.0 1.4 100.0
Dunfermline Count 54 76 7 15 7 159
% within
centre
34.0 47.8 4.4 9.4 4.4% 100.0
Oxford Count 76 154 31 95 16 372
% within
centre
20.4 41.4 8.3 25.5 4.3 100.0
Total Count 889 1275 266 647 90 3167
% within
centre
28.1 40.3 8.4 20.4 2.8 100.0
Right eye
Aberdeen Count 239 314 92 244 20 909
% within
centre
26.3 34.5 10.1 26.8 2.2 100.0
Birmingham Count 206 450 53 103 29 841
% within
centre
24.5 53.5 6.3 12.2 3.4 100.0
Dundee Count 94 88 28 38 6 254
% within
centre
37.0 34.6 11.0 15.0 2.4 100.0
Edinburgh Count 35 88 30 62 3 218
% within
centre
16.1 40.4 13.8 28.4 1.4 100.0
Liverpool Count 177 153 20 50 15 415
% within
centre
42.7 36.9 4.8 12.0 3.6 100.0
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ABLE 41 Exclusive groups of features for comparison are (1) M/DH only (no BHs or exudates); (2) BH, but no
xudates (BH only or BH+M/DH only); and (3) exudates (regardless of what else) (continued )
Centre
No lesions
within
one DD
M/DH only
within
one DD
BH or BH +
M/DH within
one DD
Exudate +
any within
one DD
Other
within
one DD Total
Dunfermline Count 54 72 9 19 5 159
% within
centre
34.0 45.3 5.7 11.9 3.1 100.0
Oxford Count 80 155 45 82 10 372
% within
centre
21.5 41.7 12.1 22.0 2.7 100.0
Total Count 885 1320 277 598 88 3168
% within
centre
27.9 41.7 8.7 18.9 2.8 100.0
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1. Study summary
Full title
Improving the value of screening for diabetic macular oedema using surrogate photographic markers.Short title
Screening for diabetic MO using surrogate photographic markers.Official website
http://www.abdn.ac.uk/ismo/Funding
£432,174 from the National Institute for Health Research (NIHR) Health Technology Assessment (HTA)
programme. Grant reference 06/402/49.Ethical approval
Main REC: North of Scotland Research Ethics Committee.
REC ref: 07/S0801/107.
Date of approval: 17/12/07.Important dates
Start date: 1st May 2008.
50% target recruitment point: 1st May 2009.
100% target recruitment point: 31st October 2009.
End date: 30th April 2010.
Draft ﬁnal report due: 14th May 2010.Collaborators
Aberdeen University School of Medicine, NHS Grampian, NHS Tayside, NHS Lothian and Borders, Royal
Liverpool and Broadgreen University Hospital NHS Trust, Queen Margaret Hospital, Dunfermline, Oxford
Radcliffe Hospitals NHS Trust, Heart of England NHS Trust, Norfolk and Norwich University Hospitals
NHS Trust.Study objectives
The purpose of this study is to determine the best method for detecting sight-threatening macular
oedema using photographic surrogate markers for people with diabetes in the context of national
screening programmes.125
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126Background
Macular oedema is associated with several conditions which cause irreversible vision loss, including diabetic
retinopathy. It may be classiﬁed according to the ﬂuid distribution: diffuse oedema is a general thickening
of the central retina caused by either extensive capillary dilation or capillary closure, while focal oedema is
centred on speciﬁc vascular abnormalities, such as microaneurysms. Accumulated ﬂuid defocuses the
image on the retina, reducing visual acuity. If oedema persists, the increased pressure may lead to
irreparable photoreceptor damage or retinal detachment.
Since retinal thickening is not visible directly on the retinal photographs used by screening programmes,
people are referred to ophthalmology clinics on the basis of a range of surrogate photographic markers,
such as exudates within a certain distance of the foveal centre. Evidence from the Early Treatment of
Diabetic Retinopathy Study suggests that exudates may be a sensitive marker of macular oedema
(Bresnick 2000). However, as the ETDRS excluded patients with mild retinopathy in the absence of
exudate, the results are not applicable to screening programmes in the United Kingdom, where 60% of
patients have no visible signs of retinopathy and over 30% have only mild retinopathy. Evidence from
the Grampian Retinal Screening Programme suggests that only 12% of patients with surrogate markers
referred to an ophthalmologist have indications of macular oedema when examined by slit-lamp
biomicroscopy. Similarly, a retrospective analysis from Liverpool, including 257 patients referred from the
screening programme to the ophthalmology clinic between December 2001 and June 2002, found that
only 14% had evidence of macular oedema (unpublished data).
Macular oedema has traditionally been assessed clinically using a combination of slit-lamp biomicroscopy,
stereo photography and stereo ﬂuorescein angiography. However, these techniques have a number of
limitations. Foremost is that they are only qualitative assessments, which are relatively insensitive to
thickness changes. Furthermore, slit-lamp examination does not provide a pictorial record and, together
with stereo photography, is known to be biased by the presence or absence of exudates. Although the
angiogram is a sensitive test for leakage, the assessment of thickening is very subjective. Best corrected
visual acuity has also been used as a surrogate indication of thickening, but is neither sensitive nor speciﬁc,
being affected by several factors besides macular thickness.Study design
A total of 4000 patients with photographic signs of maculopathy (exudates within two disc diameter
radius, blots or dot haemorrhages within one disc diameter radius) shall be recruited from the seven
study centres. Each subject will have photography and optical coherence tomography on both eyes
where possible. 10% of patients are expected to have ungradeable images and will be unsuitable for
the study.
All relevant lesions visible in the colour photographs will be annotated by the research nurse in Aberdeen
using computer-assisted software. The optical coherence tomography images will be analysed both
quantitatively and qualitatively by the research nurse. Software will be developed to analyse the
distribution of retinal lesions in order to ﬁnd the signiﬁcance of the photographic marker patterns on the
likelihood of clinically signiﬁcant macular oedema.Proposed outcome measures
A sample of patients attending diabetic retinopathy-screening programmes will receive an optical
coherence tomography examination in addition to the standard digital photograph. An expert grader will
assess all digital images independently for the presence of different surrogate photographic markers. The
sensitivity and speciﬁcity of standard referral criteria (based on the presence of surrogate markers) will be
assessed using optical coherence tomography as the reference standard.NIHR Journals Library www.journalslibrary.nihr.ac.uk
DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Although manual grading will always have a role in the assessment of retinal images, the scale of the
current diabetes epidemic means that automation will have to play a key role if the Liverpool Declaration's
target of offering annual systematic screening to at least 80% of the estimated 35 million people with
diabetes in Europe is to be achieved. Furthermore, given the low speciﬁcity of current referral criteria, it is
important to investigate whether speciﬁcity can be improved using more complex patterns of surrogate
markers, using either computer-assisted annotation or fully automated computer analysis, so that scarce
ophthalmology resources are used most effectively.
Derived sensitivity/speciﬁcity estimates will be used to assess the costs and consequences (i.e. the number
of appropriate/inappropriate ophthalmology referrals) of using alternative surrogate markers, and patterns
of surrogate markers, for the detection of macular oedema, using manual, computer-assisted annotation
and fully automated detection systems.
It is important to look at the implications for health care delivery of introducing this technology into
systematic screening programmes for diabetic retinopathy. We will therefore model long-term costs and
outcomes (visual loss and quality adjusted life years) of the alternative screening strategies using
epidemiological literature and available cost estimates.Sample size calculation
If 33333 patients are screened across ﬁve centres, 4000 patients would be expected to have surrogate
markers (12%) of whom 400 would be expected to have macular oedema. If there are 4000 patients with
any markers, the power for detecting a change in the referral speciﬁcity of at least 20% will be much
higher than 80%.
However, a new diagnostic test (using a more speciﬁc combination of features) which has increased
speciﬁcity may also have decreased the sensitivity. Therefore, since there are fewer true cases with macula
oedema than true controls, the crucial issue for the power of this study is whether or not a small change
in sensitivity can be detected.
With 400 cases of macula oedema there will be 80% power to detect a difference in sensitivity of 3%
(99% vs. 96%) between two diagnostic tests (any markers vs. a speciﬁc combination of markers) when the
percentage of true cases where the diagnostic tests disagree is expected to be 5%. A McNemar's test of
equality of paired proportions has been used with a 0.05 signiﬁcance level.Research governance
Research activities at each of the participating centres will be carried out in accordance with the
Department of Health's Research Governance Framework for Health and Social Care. The project will be
registered with the Institute of Applied Health Sciences (University of Aberdeen) and each appropriate NHS
trust. Copies of the protocol and records of all important documents will be cross referenced and ﬁled so
that they are available at any given time. Records relating to all procedures carried out will be kept so that
the research process is clearly understandable and repeatable. NHS Grampian has agreed to act as the
sponsors for the study.
A Trial Steering Committee has been set up. The chair, Dr Caroline Styles, is a consultant
ophthalmologist in Fife with experience of retinal screening (she was later replaced by Dr Rod Harvey).
Professor Alex Elliot, a medical physicist from Glasgow, brings medical image processing experience.
Mr Steve Graham is the committee patient representative. Ms Alison Farrow is a retinal photographer
in Aberdeen (she was later replaced by Dr A Manivannan). Finally Dr John Olson and Professor Peter
Sharp are also members.127
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1282. Centre contact detailsCentre Principal investigator(s) Other contacts
University of Aberdeen and NHS Grampian Dr John Olson Dr Keith Goatman
Heart of England NHS Trust Professor Paul Dodson Ms Jane Pitt
NHS Tayside Professor Graham Leese
Dr John Ellis
NHS Lothian Dr Ken Swa Dr Shyamanga Borooah
Royal Liverpool & Broadgreen University Hospitals Trust Professor Simon Harding
Professor Deborah Broadbent
Dr Yalin Zheng
Oxford Radcliffe Hospitals NHS Trust Professor Victor Chong Ms Sue Beatty
Queen Margaret Hospital, Dunfermline Dr Caroline StylesDr John Olson is the project Chief Investigator (john.olson@nhs.net). For general enquiries about the study
contact Dr Keith Goatman (k.a.goatman@abdn.ac.uk).
Dr Caroline Styles (caroline.styles@nhs.net) is the chair of the Trial Steering Committee (later replaced by
Dr Rod Harvey).3. Patient selection and recruitment
Each centre shall collect data from 800 patients fulﬁlling the inclusion criteria below.Inclusion Criteria
Age 18 or older.
A trained grader conﬁrms that the fundus photograph of at least one eye shows diabetic eye disease
including any of:
Microaneurysms/dot haemorrhages within one disc diameter radius of the macula.
Blot haemorrhages within one disc diameter radius of the macula.
Exudates within two disc diameter radius of the macula.
Able and willing to provide signed informed consent.Exclusion Criteria
The patient has had macular or pan-retinal laser treatment [clariﬁcation to protocol added version 2.0].
The patient has had an intraocular injection [added in protocol version 2.0].
The patient is pregnant (since oedema may be present independent of gestational diabetes) [Added in
protocol version 2.0].
Intraocular surgery within one year of enrolment.
The screening fundus photograph is a technical failure (i.e. the macula vessels are not clearly visible and/or
the ﬁeld of view does not include a region of diameter two disc diameter radius s about the centre
of the macula).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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dilation is necessitated.
How patients are recruited will depend on the local set-up at each centre. In Aberdeen patients with
exudates or blots within 1 disc diameter radius (grade code M2) are routinely referred from the screening
service to see an ophthalmologist. These patients are now routinely offered optical coherence tomography
scans and therefore only need to be consented to allow their data to be used in the study. Patients with
exudates within 1 disc diameter radius and 2 disc diameter radius (grade code M1) will need to be invited
for an optical coherence tomography scan they would not normally receive, so will need to be consented
both for the imaging and use of data. Finally, patients with microaneurysms/dot haemorrhages within
1 disc diameter radius do not trigger a speciﬁc grade in the Scottish grading system and will have to be
manually chosen during screening grading. As for the M1 category, these patients will have to be invited
for an optical coherence tomography they would not normally receive, so will need to be consented both
for imaging and use of their data.4. Retinal photography, visual acuity and Glitazone
Visual acuity
Log-MAR (or Snellen if Log-MAR not available) pin-hole or best-corrected visual acuity measurement for
both eyes. [Best-corrected added version 2.1]
Record if the patient has a long-standing, non-diabetic reason for a low visual acuity measurement, for
instance due to amblyopia. This must be recorded on the web upload form. [Added version 2.1]Photography
Single views of both eyes:
Approximately 45 degree ﬁeld of view.
Approximately macula centred.
Colour digital photograph, at least 3 megapixels (ideally less than 7 megapixels and, if using JPEG
compression, set for highest quality).
Adequate ﬁeld of view (should show 2 disc diameter radius around centre of macula).
Adequate clarity (i.e. adequate to see macular microaneurysms, if present). If there are problems obtaining
a retinal photograph it is very likely to be difﬁcult obtaining an adequate optical coherence
tomography scan.
Mydriasis only necessary if pupil size too small for imaging. Camera small pupil facility acceptable providing
2 disc diameter radius visible around macula centre.
Note that the maximum allowed time between photography and optical coherence tomography is four
weeks to reduce errors due to lesion changes between photograph and optical coherence tomography.
Example images showing adequate and inadequate clarity and ﬁeld of view are available from the website.
(http://www.abdn.ac.uk/ismo/).Glitazone [Added version 2.1]
The glitazone class of drugs appears to be associated with diabetic macular oedema [1]. If the patient
has used any of the following drugs within the past six months this must be recorded on the web
upload form:129
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130Rosiglitazone: Avandia, Avandamet.
Pioglitazone: Actos Competact.
[1] Fong DS and Contreras R. Glitazone use associated with diabetic macular edema. American Journal of
Ophthalmology 2009;147:583–586.5. Optical Coherence Tomography
Optical coherence tomography scanner choice
When the project was ﬁrst proposed every centre had use of the Zeiss Stratus optical coherence
tomography scanner (often known as OCT3). Since the funding was granted a number of new instruments
based on a spectral domain method have become available. Initial tests on the Zeiss Cirrus, Topcon
OCT1000 and Heidelberg Spectralis show these new scanners have some advantages for this study. Hence
centres will not be required to use the Stratus but instead encouraged to use the best available equipment.
In order to reduce variation due to different manufacturers, models and operators:
Only accredited operators shall acquire scans.
It is recommended that, where possible, the same scanner is used for the duration of the study. If more
than one scanner is used the scanner used must be indicated. If a scanner must be replaced it may be
replaced by any model.
Dates of services and faults should be recorded in the study folder.Optical Coherence Tomography protocol
Two types of data are required from the optical coherence tomography scanner:
A thickness map divided into nine Early Treatment Diabetic Retinopathy Study regions centred on the
centre of the macula and with a diameter of 6 mm.
Orthogonal B-mode 6-mm cross-sections centred on the centre of the macula.
Speciﬁc instructions for different optical coherence tomography models are given in appendix A to
the protocol.Accreditation process
As in other multicentre imaging studies, to avoid inter-centre imaging variation all optical coherence
tomography operators are required to be accredited before submitting data for the study. Operators
should submit a simple portfolio of images (described below) collected using the optical coherence
tomography scanner intended for the study. Images will be checked for macula position, adequate image
quality and differences between thicknesses in the nine Early Treatment Diabetic Retinopathy Study
regions of the repeat scans. The accreditation images are as follows:
(a) Normal eyes
Repeat macula maps of the same normal eye as per scanner model protocol above.
(b) Macular oedema
Repeat macula maps of the same eye showing obvious macular oedema (i.e. central thickness at least
300 microns).NIHR Journals Library www.journalslibrary.nihr.ac.uk
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cross-sections (“cross hair scans”) also perform the cross-hair scan.Accreditation Upload procedure
Go to the study website: http://www.abdn.ac.uk/ismo/
Login using your supplied username and password. The admin functions will appear once you are logged
in. Select “Accreditation” from the menu and follow the instructions for uploading images.6. Data transferPhotographs and optical coherence tomography scans are transferred to Aberdeen using the web-based
upload service at:
http://www.abdn.ac.uk/ismo/
Log in using your supplied username and password and the admin functions will appear. Select “upload
data” and follow the on-screen instructions.
Note: the server automatically generates an anonymous subject ID. If you enter the subject name
and hospital ID number these will print a front sheet for your study folder, but will not be transmitted
to Aberdeen.Data protection and personal information
The personal patient information you enter is not transferred to the webserver, it is just used to produce
the print out.
However, patient information may appear on the photographs or optical coherence tomography images
which are transferred to Aberdeen. Although the University of Aberdeen webserver has been registered to
allow the storage of personal information, personal information is not required for this study we do not
wish to keep it, and have not sought ethical permission to do so. Therefore all personal information
will be automatically removed from images that are uploaded to Aberdeen. It is therefore vital that
if centres wish to be able to cross reference data from their own clinical records that they keep a local
copy of the anonymous study ID and real patient ID.Image grading
(a) Colour photographs
All fundus photographs will be assessed in Aberdeen by a trained reference grader. An experienced grader
will train the reference grader in the identiﬁcation of the features of diabetic retinopathy and in the use of
the software. The trainer will quality assure the annotations of 100 images as part of the training phase.
The following features will be noted:
Presence of microaneurysms/dot haemorrhages and blots within 1 disc diameter radius.
Presence of exudates within 1 disc diameter radius and 2 disc diameter radius.
All the above lesions will be annotated on images, using computer-assisted annotation software, to enable
pattern analysis of the lesion distributions.131
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132(b) Optical Coherence Tomography data
All the optical coherence tomography images will be graded quantitatively and qualitatively for area,
amount and site of retinal thickening based on the generated thickness maps. Optical coherence
tomography studies suggest that oedema may be reliably detected by slit-lamp biomicroscopy if it has a
retinal thickness of at least 300 µm (Hee 1998). This agrees with the Early Treatment Diabetic Retinopathy
Study, which used a reference thickness of 250 µm for “clinically signiﬁcant” macular oedema.
In this study, macular oedema will be deﬁned as an optical coherence tomography retinal thickness of
300 µm or greater (relative to Zeiss Stratus measurements) in any map region within one disc diameter
radius of the centre of the fovea (i.e. in any of the ﬁve central Early Treatment Diabetic Retinopathy Study
map regions).8. Project timetableYear 1
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
Year 2
Annotation software development
Improvements to individual lesion detection
Development of techniques for multiscale
lesion cluster analysis and classification
Lesion cluster feature evaluation and training
for macula oedema prediction
Accreditation of OCT operators
Patient recruitment
Training of graders and collection of 
training images
Collect data and grade photographs
Economic costing survey
Cost effectiveness model development
Cost effectiveness analysis
Data analysis and write-up
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DOI: 10.3310/hta17510 HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 51Appendix A: Speciﬁc Optical Coherence Tomography scanner instructions(a) Zeiss Stratus Optical Coherence Tomography
Data acquisition
For each eye, use the fast macular map protocol to obtain six intersecting radial lines with a length of
6mm. Total acquisition time is approximately two seconds.
Scans will be considered acceptable if: (1) the standard deviation of the central foveal measurements from
the six cross-sections is less than 10% of the mean central measurement, and (2) the recorded signal
strength is at least 4, and (3) there are no warnings about low analysis conﬁdence, missing data or high
variance, and (4) there are no visible boundary tracking errors.Data export
Two pieces of evidence are required to conﬁrm the presence of macular oedema: (1) the thickness map
giving the Early Treatment Diabetic Retinopathy Study region thicknesses in microns and (2) a
cross-sectional image showing the thickening is due to dark, ﬂuid-ﬁlled spaces.
Thickness maps: Generate thickness maps by selecting the best scans for the left and right eyes and
clicking on the “analysis” tab and selecting “Retinal Thickness/Volume (OU)”. Export the result as a PDF
document using the “Print to PDF ﬁle” option. An example is shown in ﬁgure Stratus 1.
Does the horizontal cross-section image included on the thickness map (a) pass through the region of
greatest thickening and (b) clearly show the thickening? If not, export an additional cross-sectional image
for one or both eyes as below:
Cross-sectional image(s): The PDF report includes a low-resolution/low-quality image of the horizontal
cross-section for each eye. If one or both images either does not pass through the region of thickening, or
is insufﬁcient quality to show the oedema, a higher quality image of the cross-section which best shows
the thickening should be exported. Select one eye at a time. Click on the analysis tab and click on the
“Scan Selection” button at the bottom of the analysis section. The six cross-sections are shown on the left
of the screen (see ﬁgure Stratus 2). Select the one which best shows the thickening and click on the
“Export JPEG” button to save the cross-section as a JPEG image (see ﬁgure Stratus 3). Repeat for the other
eye if necessary.
(b) Zeiss Cirrus Optical Coherence TomographyData acquisition
The Cirrus has two macular mapping protocols. The ﬁrst (512 × 128) acquires 128 horizontal cross-sections,
each containing 512 A-scans. The second (200 × 200) acquires 200 horizontal cross-sections, each
containing 200 A-scans. We recommend use of the 200 × 200 protocol as it produces equally high-quality
maps in a slightly shorter time; less time for patient movement, increasing the probability of obtaining
a successful scan. High-resolution orthogonal cross-sections are also acquired automatically during
the scan.
Scans will be considered acceptable if: (1) the signal strength is at least 5/10, and (2) there are no obvious
signs of movement, and (3) there are no visible boundary tracing errors, and (4) the ﬁxation point is within
250 microns of the centre of the foveal pit (where visible).Data export
Two pieces of evidence are required to conﬁrm the presence of macular oedema: (1) the thickness map
values and (2) dark ﬂuid-ﬁlled spaces on the cross-sectional image(s). If the orthogonal cross-sections do133
© Queen's Printer and Controller of HMSO 2013. This work was produced by Olson et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
IGURE Stratus 1 – example thickness map (PDF file).
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IGURE Stratus 2 – Cross-section selection for export.
IGURE Stratus 3 – Exported cross-section (JPEG file).
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Fnot intersect the region of thickening then a second image is required with the cross hairs moved to pass
through the thickened region.
To export the data select print and choose the option to save the printout as a TIFF image (note the quality
of the PDF image is too poor for the study).
Upload the optical coherence tomography images and colour photographs using the web-upload system
at: http://www.abdn.ac.uk/ismo/135
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136(c) Topcon OCT-1000 Mark I
The Topcon OCT-1000 is essentially a non-mydriatic fundus camera with an optical coherence tomography
spectrometer attached. As well as the spectral domain optical coherence tomography data it also acquires
3MP colour photographs which are ideal for use in this study.Important note about volume scaling
The OCT-1000 has an option to change the relative horizontal and vertical scale of the B-mode slice
display. Topcon call this the “volume scale”, and it has options of 1 : 1, 1 : 2 or 1 : 3. You do not need to
change this setting for the study but you should inform Aberdeen of your preferred local setting. The value
may be viewed/changed by selecting Tools from the main menu bar, Options => Volume scale.Data capture
Use the “3D scan” acquisition mode.
Select the 6 × 6mm rectangular scan area and 512 × 128 lines (128 lines of 512 A-scans per line).
Use the camera macular-centred (M) ﬁxation point.
Once an acceptable scan has been acquired save the data.NIHR Journals Library www.journalslibrary.nihr.ac.uk
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The colour photograph is exported by selecting “Export” from the main menu bar and selecting “Fullsize
fundus”. Select PNG ﬁletype (the jpeg quality is too poor for the study) and choose a ﬁlename, ideally
including the anonymous patient ID (e.g. for Aberdeen A0123_photo_left.png).Optical Coherence Tomography data export
Three pieces of information are required for the study:
The nine region Early Treatment Diabetic Retinopathy Study thickness map.
The central horizontal B-mode section (slice 64).
The horizontal B-mode section which best includes the severest thickening within the Early Treatment
Diabetic Retinopathy Study region, if different from (b) above.
These are obtained from the captured data as follows:
Analyse data: Make sure the raw study data has been analysed (this estimates the region boundaries on
the 128 B-mode sections).
The default view shows B-mode slice 64 on the left hand side and the colour photograph on the right.
Display Early Treatment Diabetic Retinopathy Study grid: Click on the Early Treatment Diabetic
Retinopathy Study icon by the colour photograph to overlay thickness values on the colour photograph
(see ﬁgure Topcon example 1).
Optional reposition: In images where the foveal pit is obvious, place a cursor on the deepest part of the
pit and check that this corresponds to the centre of the Early Treatment Diabetic Retinopathy Study grid. If
the difference is more than approximately 200 microns (for reference the central Early Treatment Diabetic
Retinopathy Study region is 1000 microns diameter) reposition the Early Treatment Diabetic Retinopathy
Study grid using the “reposition” option in the grid menu to the left of the colour photograph. This is
done by dragging the grid while holding down the left mouse button. Note that moving the grid will
mean part of one or more of the outer regions will be outside the captured data (indicated by the
green box). If the ﬁxation error is too large and the grid is moved too far then N/A will appear in place of a
thickness measurement. This will be counted as a technical failure and should be repeated. However, the
N/A designation appears too conservative. For example, ﬁgure Topcon example 1 shows a small corrective
shift of approximately 130 microns. Figure Topcon example 2 shows a much larger correction shift of
approximately 1000 microns, where 55% of the area of the outer inferior region is outside the collected
optical coherence tomography image. This is not acceptable and consequently images requiring a
corrective shift of more than 500 microns will be considered a technical failure and should be repeated.
Central section screen-shot: take a screenshot showing the central horizontal section (slice 64) and the
colour photograph with the Early Treatment Diabetic Retinopathy Study grid overlaid. Select Export from
the main menu bar followed by “Screenshot”. Save the screenshot as a PNG format image, ideally using a
ﬁlename convention which includes the patient anonymous ID. Figure Topcon 1 shows an
example screenshot.
Maximum thickness screen-shot: if the central slice does not include the area of thickening, change the
displayed section by scrolling the mouse wheel until the section with the thickening is displayed and repeat
the screenshot as above. If the central section adequately shows the thickening then this image
is not required.137
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IGURE Topcon example 1 showing B-mode section 60 on the left hand side and the colour photograph with Early
reatment Diabetic Retinopathy Study region thicknesses on the right.
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TFIGURE Topcon example 2 showing an excessive reposition of the Early Treatment Diabetic Retinopathy Study grid.
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to upload using the web-based system at http://www.abdn.ac.uk/ismo/
(d) Heidelberg Spectralis
The Heidelberg Spectralis is currently the fastest optical coherence tomography scanner on the market,
acquiring 40,000 A-scan lines per second. It has two features not found on any other optical coherence
tomography scanner: eye tracking and multiple lines acquisition to reduce noise (ART). It also has more
user adjustable parameters than any other scanner.
The default macular thickness protocol acquires 19 horizontal sections with horizontal and vertical ﬁeld of
views of 20 and 15 degrees respectively. By default each line is acquired multiple times (with ART
enabled). Note: This default protocol is not suitable for the study, as it does not cover the required 6 mm
diameter region about the centre of the macula.Data acquisition
The ﬁeld of view should be centred on the macula.
Change the horizontal ﬁeld of view (using the right cursor key) from 20 degrees to 30 degrees. The
current ﬁeld of view and number of sections is displayed at the bottom of the screen in acquisition mode.
Change the vertical ﬁeld of view (using the UP cursor key) from 15 degrees to 25 degrees (which also
increases the number of slides from 19 to 31).
The number of ART repeat scans can be set between 2 and 100. A setting of 3 is adequate for this study.
When the correct ﬁeld of view is obtained lock the position using the large black circular button on the
touch pad.
Signal strength should be greater than 15/40 (image quality bar blue rather than red).Data analysis and export
Three pieces of information are required for the study:
The nine region Early Treatment Diabetic Retinopathy Study thickness map.
The horizontal B-mode section through the centre of the macula.
The horizontal B-mode section which includes the severest thickening within the Early Treatment Diabetic
Retinopathy Study region. If this is the same slice as (b) above another image is not required.(a) Nine region thickness map
For the nine region thickness map select concentric circle diameters of “1, 3, 6 mm Early Treatment
Diabetic Retinopathy Study” (see ﬁgure Spectralis 2).
If the foveal pit is visible and there is an obvious ﬁxation error the Early Treatment Diabetic Retinopathy
Study grid may be moved using the mouse so as to be centred on the foveal pit. If the require shift is too
large one or more of the outer regions will go outside the ﬁeld of view and the thickness value will be
blank. These are considered a technical failure and should be repeated.
Export the screenshot image in PNG format (Please do not use JPEG. Even using the highest quality setting
the images are saved with the colour information at half the resolution of the brightness information,
which blurs coloured features with sharp edges, such as the text.)139
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IGURE Spectralis 2 Example screen print showing macular thickness map.
IGURE Spectralis 1 Example screen print of horizontal section.
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Produce a screenshot of the horizontal slice centred on the macula (see ﬁgure Spectralis 1) and save in
PNG format.
Optionally, if the region of greatest thickening is not visible on the central slice, select the slice which
shows the greatest thickening and produce a screenshot as above.
Upload the data using the web-based system at: http://www.abdn.ac.uk/ismo/
For each eye there will be one colour photograph and two or three (where the thickening is not visible on
the central section) optical coherence tomography images to upload.141
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